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ABSTRACT 
Liver failure remains a disease with a high mortality and with the exception of 
transplantation therapeutic options are limited.  The liver however has 
regenerative potential, and strategies based not only at supporting the failing 
liver, but promoting its recovery would be a significant evolution.  Plasma from 
patients with liver failure contains toxic molecules that have many effects on the 
liver including loss of cell viability. These factors represent a significant barrier 
to stem cell transplantation, bioreactor function and autologous liver recovery, 
suggesting removal or antagonism of these factors may be appropriate 
therapeutic strategies.  Since apoptosis has been implicated in the pathogenesis 
of a number of liver diseases including liver failure we proposed that it may be 
one of the mechanisms by which plasma is toxic to hepatocytes.  We developed 
and validated a model using primary human hepatocytes to investigate if plasma 
from patients with acute and acute-on-chronic liver disease was pro-apoptotic.   
Compared with normal plasma, acute liver failure plasma induced apoptosis 
whereas plasma from patients with acutely-decompensated chronic liver disease 
did not.   
Having identified that acute-liver failure plasma was pro-apoptotic we 
investigated the pathway via which the apoptosis was mediated by using specific 
inhibitors of caspases, key components of the death receptor and mitochondrial 
pathways.  We found that apoptosis was induced via a pathway involving 
caspase 8 and caspase 3, suggesting involvement of the death-receptor pathway.  
We investigated the effects of Caspase inhibition as a therapeutic option in acute 
liver failure by using an established animal model but did not find an improved 
outcome in treated animals. 
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We also investigated the effects of treatment with molecular adsorbent dialysis 
(MARS) on the pro-apoptotic effects of plasma and found MARS dialysis 
improved biochemical parameters, indicating effective removal of albumin-
bound molecules, but the apoptotic effects of the patients‘ plasma were 
unchanged. 
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SYNOPSIS 
This project has developed from the need to identify techniques to provide 
artificial liver support to patients with liver failure, a condition in which the 
pathogenesis is poorly understood and mortality remains high.  The ultimate aim 
of the liver group is to develop a bio-artificial liver which can maintain life until 
recovery of the native liver or availability of a donor organ.  There are multiple 
problems which must be overcome to develop such a device, particularly 
identifying cells that are available in sufficient numbers at short notice; that are 
safe; and can provide all the essential and complex functions that endogenous 
hepatocytes and cholangiocytes perform.  These functions must continue in an 
efficient manner when the cells are exposed to the patient‘s plasma, an 
environment that may be substantially hostile both as consequence and cause of 
the patient‘s original pathology.  The starting point for the project was therefore 
to investigate the observation that plasma from patients with acute liver failure 
was deleterious to the function and viability of hepatocytes derived from tumour 
cell lines. 
The first chapter is a general introduction and describes the clinical features and 
pathophysiology of liver failure.  It summarises the evidence that liver failure 
plasma is toxic to multiple organ systems and cell types, describes the two 
mechanisms of cell death, apoptosis and necrosis, and their role in liver disease 
and identifies some candidate molecules which have been identified as 
hepatotoxic.  Finally it sets out the aims and objectives of the project which were 
to develop a model by which the cytopathic effect of liver failure plasma could 
be studied, to attempt to isolate and identify molecules within plasma that are 
 26 
toxic, to elucidate their mechanism of action and to find a method of removing 
or antagonising this toxicity.   
There follows preliminary work using a model developed previously within the 
department, and utilised plasma samples for which large volumes were available 
(samples taken from patients with Acute Liver Failure collected at the onset of 
plasmapheresis).  It identified that there was variability in toxicity in acute liver 
failure plasma but that not all samples were cytotoxic.  Using the plasma sample 
that induced the greatest loss in cell viability (using MTT activity in HepG2 
cells as a marker of cell number) a number of experiments were performed to 
identify some of the physico-chemical properties of the toxic molecule/s within 
Acute Liver Failure Plasma.  By doing this we hoped to find a method to purify 
the substances so that they could subsequently be identified using high pressure 
liquid chromatography or magnetic resonance spectroscopy.   
We identified a toxic component of acute liver failure plasma that passed 
through a centrifugation device with a molecular weight cut off of 100kDa, but 
was excluded by a 30kDa device, suggesting the substance/s had a molecular 
weight of between 30kDa and 100kDa or was bound to a substance in that 
molecular weight range for example albumin.  The substance was water soluble 
and heat labile.  The removal of the toxic substance by removal of albumin from 
the plasma suggested that the toxic substance was albumin bound and the 
molecule itself was not dialyzable across a 10kDa cut off membrane with either 
phosphate buffered saline solution or 20% bovine serum albumin solution, nor 
was it removed by adsorption with activated charcoal, inferring that therapeutic 
devices using charcoal haemadsorption, or dialysis would not be beneficial in 
removing the toxin, and would be unlikely to show benefit in clinical studies.  
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During these experiments we found that some hepatocytes lost adhesion when 
exposed to acute liver failure plasma and further study revealed this effect 
occurred over a time course of 6-24 hours.  Reviewing the original earlier 
studies of cytopathic effects we noted the experimental methods used for 
quantifying cell death relied on an assumption that cells were only lost by cell 
death, i.e. did not account for cell loss by loss of adhesion (even though changes 
in cell morphology and adhesion were noted in one study) .  The time course of 
these earlier experiments exposed cells to liver failure plasma at concentrations 
from 10% to 25% vol:vol, for time periods ranging from overnight to 48 hours, 
and would therefore have been subject to this loss of adhesion effect. 
At the end of this preliminary work we concluded that the toxic molecule/s that 
had been physically characterised and others had previously described, was 
responsible for loss of cellular adhesion and not cell death.  Having eliminated 
this adhesion effect, there was little toxicity that could be identified with the 
current model and certainly not enough of a toxic effect to be traced through 
separation and purification.  
The second chapter therefore focused on the development of a robust in-vitro 
model in which to investigate the effects of liver failure plasma on hepatocytes.  
We defined the ideal characteristics of such a system and using primary human 
hepatocytes established a quantitative system for assessment of the effects of 
substances on the process of apoptosis, a key biological process in the 
pathogenesis of a number of liver diseases including acute liver failure.  By the 
end of the chapter we had identified a positive control, established two reliable 
techniques for the measurement of apoptosis and then validated the model by 
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investigating the protective effects of the growth factors EGF and HGF against 
Fas-Ligand induced apoptosis.   
Chapter 3 then used the model to investigate the effects of liver failure plasma 
on apoptosis.  We established that plasma from patients with acute liver failure 
induced increased apoptosis in primary human hepatocytes, but that plasma from 
patients with acutely-decompensated chronic liver disease did not.  There were 
no clinic-pathological correlates between a sample‘s pro-apoptotic tendency and 
other markers of liver function or renal function.  We used specific Caspase 
inhibitors to investigate the mechanism by which acute liver failure plasma was 
inducing apoptosis and established that the effects were inhibited by Caspase 3 
(a general effector caspase) and caspase 8 a caspase through which death 
receptors execute apoptosis.  We concluded that acute liver failure plasma 
increased apoptosis via a death receptor pathway.  Further studies suggested that 
the factor inducing apoptosis via a death receptor pathway was heat labile. 
In chapter 3 we used the Thioacetamide toxic liver injury in the rat as a model to 
investigate if caspase inhibitors could be of therapeutic value.  We demonstrated 
that apoptosis was implicated in the patho-physiology of liver injury in this 
model but could not demonstrate any therapeutic benefit in our primary 
endpoint, which was decreased mortality.  This may have been in-part to a lower 
than expected mortality in the control population, which was significantly lower 
than described previously in this model. 
In chapter 5 we discussed the development of bio-artificial liver support devices 
and in particular the mechanism of action of the Molecular Adsorbents 
recirculating system, we proposed that the removal of albumin bound toxins 
could remove the pro-apoptotic factor/s and therefore post treatment plasma 
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would be less pro-apoptotic than pre-treatment.  We described the clinical 
application and outcomes of MARS treatment in our unit.  We showed 
improvement in several clinical parameters but treatment did not have a 
significant effect on the pro-apoptotic effect of liver failure plasma. 
We summarise our findings, critique our work and describe future experiments 
to further this area of research in the final chapter.  
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CHAPTER 1: INTRODUCTION 
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1.0   BACKGROUND 
The liver is one of the largest organs in the body and plays a crucial role in 
metabolism, it consists of several cell types, 60% of which are hepatocytes 
(parenchymal cells); non-parenchymal cells include endothelial cells, Kupffer 
cells, Stellate cells, pit cells and biliary epithelial cells (Cholangiocytes).  The 
major synthetic, metabolic and detoxifying functions of the liver reside in 
hepatocytes, and although it has huge functional reserve and regenerative 
capacity, allowing transplantation and resection of large volumes of liver and 
complete recovery from severe liver insults, a minimum amount of hepatocyte 
function must always be retained or death will inevitably follow. 
 
1.1 LIVER FAILURE – CLINICAL FEATURES 
Hepatic Failure (HF) is the clinical syndrome which results from loss of liver 
function usually due to sudden hepatocyte cell death, which despite advances in 
critical care medicine and transplant medicine, remains a condition with a high 
mortality (Auzinger et al., 2008, Craig et al., 2010, O'Grady, 2007). 
 It can be caused by a wide variety of insults including drugs, toxins, viruses, 
alcohol, ischeamia, metabolic disorder, septic shock, massive malignant 
infiltration and autoimmune conditions (Lee et al, 2008).  Globally the 
commonest cause remains viral hepatitis but the commonest cause in the western 
world is drug induced liver injury with the vast majority being as a result of 
Paracetamol ingestion (Lee, 2004, Lee & Lee, 2008b, Polson & Lee, 2007, 
Williams, 2003).  This continues to be the case in the United Kingdom; despite 
changes in packaging and sales of over the counter Paracetamol (Bateman & 
Bateman, 2009), Paracetamol poisoning still accounts for 50-60% of admissions 
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to specialist liver units (Marudanayagam et al., 2009) (O'Grady, 1997).  Despite 
the diverse nature of the aetiologies of this disease a fundamental end point of 
them all is death of hepatoctytes and loss of the minimum requirement of 
functioning hepatocytes to maintain normal function, this loss of liver cell mass 
can only occur by two basic mechanisms, apoptosis or necrosis (Alison & 
Sarraf, 1994, Malhi et al., 2006).  
The original definition of Fulminant Liver failure by Trey & Davidson was that 
of a potentially reversible failure of liver function resulting in encephalopathy 
within 8 weeks of the first appearance of any signs or symptoms of liver disease 
(Trey et al., 1970).  However more recent definitions further classify liver 
failure depending on the time from onset of jaundice to encephalopathy into 
hyperacute (onset of encephalopathy within seven days of the onset of jaundice), 
acute (time from jaundice to encephalopathy eight to twenty-eight days) and 
sub-acute (time from jaundice to encephalopathy between four and twelve 
weeks).   
These definitions have been particularly useful in the management of patients 
enabling risk stratification of patients in terms of prognosis, with patients with 
hyperacute liver failure having the best prognosis (36% survival)  compared to 
those with sub-acute liver failure (14% survival) (O'Grady et al., 1993, O'Grady, 
2007) 
The syndrome of liver failure is characterised by a number of symptoms and 
signs. 
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Jaundice   
Jaundice occurs due to the inability of the liver to conjugate and excrete 
bilirubin.  There is also a small contribution from increased production of 
bilirubin due to increased destruction of red blood cells (Brunner G & Mito M, 
1992). 
 
Neurological Features  
Neurological disturbance is a common manifestation of liver failure which is 
categorized by the West Haven criteria as grades I-IV (Ferenci et al., 2002). It 
actually represents a continuous spectrum of abnormalities from subclinical 
electrophysiological changes, through subtle changes in personality, changes in 
sleep wake pattern and fine motor disturbance, to changes in conscious level and 
flapping tremor through to coma.   
The exact cause of hepatic encephalopathy is unknown; but increased ammonia, 
the presence of products of bacterial metabolism, increased quantities of 
aromatic amino-acids and other toxins are all postulated mechanisms which 
contribute to disturbances in several neurotransmitter systems including 
glutamate, GABA, Dopamine, and Serotonin systems (Ash, 1991, Butterworth, 
2003, Haussinger et al., 2008, Lemberg et al., 2009). 
As well as hepatic encephalopathy, patients with acute liver failure develop 
cerebral oedema and intra-cranial hypertension (Vaquero et al., 2003). 
Mechanisms suggested for the development of this phenomenon include the 
cytotoxic hypothesis which suggests that the accumulation of osmolytes 
(osmotically active substances) result in glial cell swelling and the vasogenic 
hypothesis which suggests that changes in blood flow and permeability of the 
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blood-brain barrier are responsible.  It appears that proinflammatory cytokines 
derived from microglial cells and oxidative/nitrosative stress are key 
components in the generation and perpetuation of astrocyte swelling and 
changes to the permeability of the blood brain barrier (Jiang et al., 2009).  
 Raised intra-cranial pressure can result in brainstem herniation and death 
(Larsen & Wendon, 2002).   
 
Coagulopathy 
With the exception of factor VIII all clotting factors, as well as components of 
the fibrinolytic system and inhibitors of coagulation are produced by the liver. 
Failure of hepatocyte protein synthesis results in decreased production of these 
factors and prolongation of the prothrombin time.  Disseminated vascular 
coagulation is also common further disturbing clotting and consuming platelets.  
Life threatening bleeding is thus a frequent complication of liver failure. 
 
Renal failure 
Renal failure is a common complication of acute liver failure affecting 55% of 
patients referred to specialist liver units.  It is often due to Acute Tubular 
Necrosis which results from factors such as sepsis, hypotension, hypoxia and 
changes in renal perfusion or due to direct toxicity in the case of paracetamol 
toxicity.   
Liver failure itself can also directly give rise to renal failure, the so-called 
hepatorenal syndrome (HRS).   The pathogenesis of HRS is a consequence of 
circulatory changes which result in a hyperdynamic circulation, decreased renal 
perfusion pressures, activation of the sympathetic nervous system and release of 
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vaso-active mediators, which result in renal vasoconstriction and direct changes 
in the glomerular ultrafiltration coefficient resulting in a decrease in glomerular 
filtration rate beyond that caused by changes in renal perfusion alone.  HRS is 
reversible with the recovery of the native liver or liver transplantation (Moore, 
1999) 
 
Metabolic changes 
There are multiple metabolic derangements in liver failure.  Decreased insulin 
uptake and decreased gluconeogenesis by the liver results in hypoglycaemia.   
Failure of conversion of ammonia to urea, changes in amino-acid metabolism 
resulting in increased aromatic and decreased branch chain amino acids all result 
from the liver‘s failure of nitrogen metabolism and may contribute to hepatic 
encephalopathy.  Decreased synthetic function results in decreased albumin 
synthesis and a consequent fall in serum albumin concentration, contributing to 
the production of oedema and ascites. 
Hyponatraemia, hypokalaemia, hypomagnesaemia, hypocalcaemia, 
hypophasphataemia, respiratory alkalosis and metabolic acidosis are all 
consequences of liver failure (Bernal & Wendon, 1999). 
 
Haemodynamic changes 
Changes in systemic vascular resistance cause peripheral vasodilatation and 
result in an increase in cardiac output, by increasing both heart rate and stroke 
volume.  Despite this high cardiac output state patients remain hypotensive.  On 
examination they may be found to be peripherally warm with a bounding pulse, 
tachycardic, prominent apex beat and ejection systolic flow murmur.  This 
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hypotension results in decreased perfusion of organs such as kidneys and the 
liver, resulting in renal failure and further liver injury.  Renal hypoperfusion 
results in activation of the renin-angiotensin system and consequently retention 
of salt and water contributing to oedema and ascites formation. 
The aetiology of this systemic vasodilation is currently unknown, and is most 
likely multifactorial.  Some vasoactive substances may be produced by ‗sick‘ 
cells within the liver, other factors may be due to the presence of vasoactive 
substances from the bowel (which may have increased permeability) which are 
usually inactivated/removed by hepatocytes, appearing in the circulation or 
being shunted through intra- or extra-hepatic shunts by-passing the liver (Ellis & 
Wendon, 1996).  
 
Systemic Inflammatory Response and Sepsis 
Septicaemia is a frequent terminal complication of liver failure.  Impaired 
function of cells of the immune system such as Kupffer cells and polymorphs, 
impaired production of opsonins and factors of the complement cascade 
decrease resistance to infection.  With increased bacterial translocation through 
the bowel and instrumentation of patients by cannulae and catheters possible 
sources of infection are increased.  Diagnosis can be difficult with many patients 
being apyrexial in the presence of sepsis.  A generalised systemic inflammatory 
response can occur in the absence of infection due to increased cytokines such as 
TNF-alpha resulting in a low grade temperature, acute lung injury and other end-
organ damage. 
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Non-specific symptoms and signs 
Lethargy, malaise and poor appetite are common non-specific features of liver 
failure, often associated with generalised weakness and muscle wasting due to a 
combination of malnutrition, poor protein synthetic function and a generalised 
catabolic state. 
 
1.2   PATHOPHYSIOLOGY OF FULMINANT HEPATIC FAILURE 
The clinical syndrome of acute liver failure is thought to be accounted for by 
three major pathophysiological processes. 
 The first is the failure of normal hepatocyte metabolic function to reach 
the critical minimum threshold required to meet the basic metabolic 
needs of the body.  This failure results in other organs becoming 
damaged; examples of this are coagulopathy due to lack of production of 
clotting factors and hypoglycaemia.  This theory is called ‗the metabolic 
mass theory‘ (Atillasoy et al., 1995). 
 The second process of major importance is the detoxifying ability of the 
liver. All blood from the portal circulation passes directly to the liver; 
here a variety of toxins are normally processed by the healthy liver being 
completely removed or inactivated before they reach the systemic 
circulation and thus other organs.  The ‗toxin hypothesis‘ proposes that 
failure of this detoxification function results in elevated levels of toxins 
such as ammonia, phenols, mercaptans, aromatic amino acids, fatty 
acids, benzodiazepine like substances, endotoxin, nitric oxide and 
cytokines in the systemic circulation thus allowing them to damage other 
organs e.g. causing encephalopathy. 
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 A third factor in the development of the clinical syndrome of acute liver 
failure is the contribution of the liver itself.  The liver consists of several 
different cell types in addition to hepatocytes, including Kupffer cells, 
vascular endothelial cells, and stellate cells; these cells as well as 
hepatocytes may be partly responsible for the perpetuation of liver injury 
by producing substances that may cause end-organ damage.  Thus the 
injured hepatocyte may itself aggravate and exacerbate liver injury 
ultimately leading to hepatocyte loss by a variety of mechanisms. These 
include loss of plasma membrane integrity, loss of intracellular 
homeostasis, oxidative stress, mitochondrial dysfunction, ATP depletion 
and activation of degradative hydrolysis ultimately resulting in cell death 
by apoptosis or necrosis (Rosser & Gores, 1995).  The suggestion that 
the liver is itself responsible for end organ damage rather than simply 
lack of metabolic or detoxifying functions is supported by the short-term 
clinical improvement in patients with acute liver failure when the failing 
liver is removed, temporarily rendering the patient anhepatic 
(Butterworth, 2003).  Many of these substances released from the liver 
result in a marked systemic inflammatory immune response (SIRS) 
which is a dominant feature of acute liver failure.  
 
Whilst these three mechanisms are suggested as possible alternative mechanisms 
in the pathogenesis of acute liver failure it is likely that all three are involved to 
a greater or lesser degree in the development and perpetuation of liver injury 
after the initial insult.  A complex interplay between these mechanisms with the 
liver releasing substances, or allowing substances it normally removes to build 
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up to such a degree that hepatocyte death occurs, may result in further 
hepatocyte death and decreased functional liver cell mass, which results in the 
release of further toxins thus resulting in a vicious circle that ultimately results 
in the patient‘s demise.   
Countering this effect is the ability of the liver to regenerate and thus the balance 
between the rate of hepatocyte death and hepatocyte regeneration will ultimately 
determine the patient‘s survival.  
 
1.3   TOXIC MOLECULES IN LIVER FAILURE PLASMA 
Early studies in which cross circulation between baboons and men with hepatic 
coma occurred, improved the condition of the patient but led to a deterioration in 
the health of the baboon (Abouna, 1968).  This suggested that toxins 
accumulating within the blood were responsible for other end-organs being 
damaged.  Some of these factors may be due to changes in the cellular 
component of blood, but many of these deleterious effects are due to changes in 
the humoral component of circulating blood.  These toxins may arise either as a 
consequence of a failure of normal hepatic clearance, or because those 
substances are generated within the liver or elsewhere in the body as a 
consequence of severe liver disease (Bradham et al., 1998, Cain & Freathy, 
2001, Spengler et al., 1996). These toxic factors in the blood affect the function 
of many organ systems, such as the systemic and portal vasculature and the 
brain, as well as the liver itself.  The exact nature of these toxins is unknown and 
may be different and multiple for each organ system damaged.  Ammonia, 
aromatic amino-acids, tryptophan, indoles, mercaptans and endogenous 
benzodiazepines are implicated in the development of hepatic encephalopathy.  
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Whereas, prostanoids, inflammatory cytokines, nitric oxide and oxidative stress, 
are all considered to be important factors in the development of the 
haemodynamic and renal changes seen in liver failure.  It is, however, the 
substances that are directly hepatotoxic that are particularly important in terms 
of recovery, as they may perpetuate liver injury invoking a downward spiral 
with further reduction in functional liver mass and increased toxin load, 
persisting long after the withdrawal of the original insult precipitating liver 
failure (Williams et al., 1977).  It is notable that many of the suggested toxins 
are insoluble in water and exist in the circulation bound to albumin.   
Since Abouna‘s original experiment it has been demonstrated that liver failure 
plasma contains increased levels of a vast array of substances, for example bile 
salts, which in-vitro are toxic to hepatocytes.  More significantly direct evidence 
for cytotoxicity has been shown by the application of plasma from patients with 
acute liver failure to both primary rabbit hepatocytes (Hughes et al., 1976) and 
immortalised cell lines (Anderson et al., 1999, McCloskey et al., 2002) both of 
which suffered from increased cell death compared to exposure to normal 
control plasma.  The measurement of cell death has usually been by 
demonstrating decreased viable cells after exposure to liver failure plasma, 
although few studies have labelled dead cells using substances necrotic cells are 
permeable to, for example, propidium iodide and trypan blue and thus the 
mechanism of cytotoxicity remains unidentified.  Whilst these results provide 
interesting data, problems with using immortalised cell lines, which by 
definition have dysregulated cell death and proliferation pathways and the use of 
primary non-human hepatocytes in experimental models has lead to concerns 
over the applicability of these results to human disease processes.  
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The previously described toxic effects are not limited to simply inducing cell 
death but also have inhibitory effects on metabolic function, adhesion and 
hepatocyte proliferation.  These effects on regeneration have been demonstrated 
in-vitro using radiolabelled thymidine incorporation as a measure of DNA 
synthesis in hepatocyte cell lines (Williams, Hughes, Cochrane, Ellis, & 
Murray-Lyon, 1977) and in primary rodent hepatocytes (Yamada et al., 1994) 
and in-vivo using either human plasma injected into partially hepatectomised 
rats (Hughes et al., 1991) or plasma from a rodent model of acute liver failure 
exchanged with plasma from normal control rats (Anilkumar et al., 1997).  In 
addition to cytotoxicity these inhibitory effects on regeneration are particularly 
important since it is the balance between cell death and proliferation which 
determines final recovery.  
In addition to inducing endogenous hepatocyte injury these effects remain a 
significant barrier to hepatocyte/stem cell transplantation and maintenance of 
function of bioartificial liver support devices when exposed to patient plasma.  
Although many candidate molecules, particularly cytokines, with the above 
effects have already been identified at increased levels in acute liver failure 
plasma their exact roles have yet to fully elucidated in human disease, 
particularly in the presence of increased levels of other protective factors found 
in acute liver failure. 
Also there are likely to be many factors as yet unidentified which may have a 
role to play.  It remains a huge challenge to identify which factors are of key 
importance in the pathophysiology of acute live failure.    
The problem can either be approached by trying to identify the physico-chemical 
properties of these substances, purify them and identify them using mass 
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spectrometry or by identifying the molecular mechanisms of liver injury, 
identifying ligands and identifying their role in acute liver failure.  Both methods 
have their proponents but a significant barrier to them both is the lack of a good 
model to test the effects of proposed toxins on model systems applicable to 
human liver disease.     
 
1.4   MECHANISMS OF HEPATOCYTE INJURY 
Liver cell death is the fundamental cause of the clinical syndrome of liver 
failure.  Liver cells can only die by two distinct pathways, necrosis or apoptosis. 
Apoptosis or programmed cell death, first defined by Kerr et al in 1965 ―a 
process in which cells die in a controlled manner in response to specific stimuli, 
following an intrinsic program‖ (Kerr JF & Wyllie AH, 1972, Kerr JF, 1965). 
Distinct from necrosis, cells which execute their apoptotic programme undergo a 
variety of characteristic morphological and biochemical changes which result in 
the formation of small packages of eosinophillic intracellular material called 
―apoptotic bodies‖ or ―Councilman bodies‖ which can be removed by 
phagocytosis.  The controlled manor in which the cell dies, and the lack of 
spillage of potentially noxious intracellular substances into the surrounding 
microenvironment, allows removal of a single cell in the absence of 
inflammation or disturbance to its neighbours. 
However, in the majority of diseases causing acute liver failure, inflammation 
and hepatocyte necrosis are prominent.  Cellular swelling is the predominant 
feature of necrosis, associated with small protrusions of the cell wall called 
blebs.  Lysosomal breakdown, mitochondrial depolarisation and anionic ion flux 
add to cell swelling which ultimately results in rupture of one of the blebs 
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resulting in leakage of intracellular contents.  Distinct from apoptosis, necrosis is 
often seen in contiguous cells.   
Since necrotic cells vastly outnumber apoptotic ones it has only been with 
advances in our understanding of the mechanisms of apoptosis and molecular 
biology that adequate sensitive and specific techniques for identifying apoptotic 
cells have been identified.  These have shown that there are increased numbers 
of apoptotic hepatocytes in a number of human liver diseases compared to being 
exceedingly rare in normal liver tissue. Although the total numbers at first 
glance seem inconsequentially small, the apoptotic process is very quick being 
complete in 4-6 hours and therefore apoptosis alone could account for 
substantial hepatocyte loss.  Schulte-Hermann et al have suggested that a 4% 
rate of apoptosis would result in a 25% loss in liver cell mass in 72 hours 
(Schulte-Hermann et al., 1999).  In addition a number of animal models of liver 
failure have shown apoptotic cells appear very early in the course of liver 
damage, prior to the appearance of necrosis or significant symptoms, since most 
of the human tissue examined for apoptosis has occurred after the onset of liver 
failure it may be that this underestimates the degree of apoptosis earlier in the 
disease process.  Finally, and most surprisingly, the inhibition of apoptosis in 
some animal models of acute liver failure by specific apoptosis inhibitors results 
in the absence of both apoptosis and necrosis on liver histology as well as the 
attenuation of liver failure and mortality (Bajt et al., 2001, Hoglen et al., 2001, 
Rouquet et al., 1996).  It may therefore be that apoptosis is an essential early 
event in the initiation of liver damage and that by overwhelming the processes 
that remove apoptotic bodies and protect surrounding cells secondary necrosis 
occurs.   
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The polarised view of cell death occurring by either apoptosis or necrosis with 
discrete initiating factors is however being replaced by an emerging view that 
both types of cell death can be initiated by common factors and that both 
represent extremes on a continuum of cell death.  Fundamental to the type of cell 
death that occurs is the fact that apoptosis is an energy requiring process 
requiring ATP. Thus the key feature that differentiates the choice of cell death is 
the ability of that cell to generate enough ATP via its mitochondria to execute 
the apoptotic pathway.   
Cytochrome c release from mitochondria represents the point of no return for 
initiation of cellular apoptosis, but it also is noteworthy that it is the point of 
destruction for the mitochondria and thus the cessation of ATP production and 
commitment of the cell to death via necrosis. 
Noxious insults, ligand-receptor pairs and signalling pathways may thus be 
common to both types of cell death; it is therefore not surprising that both types 
of cell death are seen concomitantly in the same disease processes.  It is likely 
that different types of liver injury have a predilection for inducing different types 
of liver cell death and that different cell types and differing energy status within 
same cell types have differing predilections for the manner of cell death.  For 
example the early phase of ischaemia/reperfusion injury induces predominantly 
necrosis with hepatocytes in the pericentral (perilobular) areas most vulnerable, 
with apoptotic cells being scarce (only about 2% of cells), and caspase inhibitors 
offering no protection.  The later phase of ischaemic injury results from 
activation of innate cellular immunity triggered by ischaemia of Kupffer cells 
inducing them to release reactive oxygen species, cytokines, chemokines and 
other factors  which lead to infiltration by neutrophils and CD4+ lymphocytes.  
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These cells may induce apoptosis, and therefore both types of cell death co-exist 
in the same disease, the balance of which type of cell death is determined by the 
severity of the original injury.  Inhibition of apoptosis by various mechanisms 
has been shown to attenuate this later phase of liver injury.   
It could be argued that necrosis is the default pathway by which cells undergo 
cell death in the absence of adequate ATP; the contrary can also be argued, in 
that cellular damage may be insufficient to induce necrosis but sufficient to 
induce apoptosis ensuring removal of damaged cells.  It is however fascinating 
that evolution has devised a ―belt and braces‖ approach to so many fundament 
cellular mechanisms including cell death. 
In the long-term the production of apoptotic bodies leads to fibrosis (Murphy et 
al., 2002).  Stellate cells are activated by engulfment of apoptotic bodies in 
culture.  Activated stellate cells produce collagen, inhibition of hepatocyte 
apoptosis decreases fibrosis in murine models of liver injury (Canbay et al., 
2003). 
 
1.5   APOPTOSIS BASIC SCIENCE 
The current widely accepted model is that apoptosis can be initiated by two 
basic converging pathways - receptor mediated apoptosis and the mitochondrial 
pathway.  In addition there are several minor pathways, but these are less well 
characterised.  Receptor mediated apoptosis is initiated by the binding of ligand 
to a cell surface receptor.  There are a number of these so called ―death 
receptors‖ including TNF-alpha, TGF-beta, and Fas (CD95).  These are 
transmembrane proteins with three domains, an extra-cellular ligand binding 
domain, a transmembrane domain and an intracellular death domain.  Death 
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receptors of importance in liver disease include Fas (CD95/Apo-1),  tumour 
necrosis factor receptor 1 (TNFR-1), tumour necrosis factor related apoptosis 
inducing ligand (TRAIL) receptors 1&2, death receptor (DR) 5 & 6, and various 
other death receptors and combinations of receptors.  Fas is extensively 
distributed through a wide range of tissues including cholangiocytes, sinusoidal 
endothelial cells, stellate and Kupffer cells, and is constitutively expressed by 
hepatocytes. It is the best characterised of the death receptors and is thought to 
play a central role in initiating apoptosis within the liver.  Binding of ligand, 
Fas-Ligand, to its receptor results in trimerisation of the receptor and brings their 
intracellular N-terminal domains into close proximity; these bind to other 
intracellular proteins and form an active ―death domain‖.   In the example of 
Fas, this is the fas associated death domain or FADD.  In hepatocytes Fas 
localises predominantly to the Golgi complex and trans-Golgi network with only 
small amounts expressed in the plasma membrane.  This allows rapid 
translocation of receptors to the plasma membrane in response to noxious 
stimuli (Feldmann et al., 1998).  Fas activation classically occurs by ligand 
binding, but if the density of Fas receptors becomes sufficiently dense 
trimerisation occurs spontaneously and thus activation of receptors can occur in 
the absence of ligand binding representing a second means of activation.  Fas-L 
itself increases localisation of Fas to the cell membrane.    
TNFR1 is distinct from other death receptors in that it also activates survival 
pathways.  Proteins which form components of its death receptor domain 
(TRADD) include RIP (receptor-interacting protein) and TRAF-2 (TNF 
associated factor 2).  TRAF-2 first activates NFkB and c-jun N terminal kinase 
(JNK) before internalisation of the ligand disassociated complex forming the 
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death inducing signal complex (DISC) which recruits FADD via interactions 
between conserved death domains. 
These death effector domains (DED) activate pro-caspase 8, a member of the 
caspase family.  Caspase 8 cleaves BID (BCL-2 Interacting Domain, a pro-
apoptotic member of the Bcl-2 family of proteins) to tBID and with sufficient 
stimulation directly activates Caspase 3.   
 
 
Figure 1.  Schematic of pathways utilised by death receptors in induction of 
apoptosis (courtesy of S.Sun) 
 
Cells can be classified into discrete subtypes; Type 1 cells which utilise the 
pathway of Caspase 8 directly activating Caspase 3 and type 2 cells which rely 
on Caspase 8 cleaving BID to tBID.  This tBID translocates to mitochondria 
resulting in mitochondrial permeablisation and release of cytochrome c.  
Hepatocytes are type 2 cells dependent on this pathway to execute apoptosis.  
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This is demonstrated by the fact that the BID knockout mouse is significantly 
protected against Fas-L induced liver injury. (El Hassan et al., 2003).  In type 2 
cells cytochrome c released from mitochondria associates with Apaf-1 to form 
haptomeric apoptosomes which proteolytically activate Caspase 9 which in turn 
activates Caspase 3.    
Caspases are a family of cysteine-aspartate proteases which characteristically 
possess an active site cysteine and cleave substrates after Aspartic acid residues. 
The specificity of each Caspase is determined by the four amino acid residues to 
the amino-terminal side of the cleavage site.  They exist in the cytoplasm in an 
inactive pro-caspase form and limited proteolysis causes conversion to their 
active form.  All pro-caspases are activated by cleavage of their prodomain after 
an Aspartic acid residue.  This makes them candidates for autocatalytic 
activation.  In this way activation of caspases lower down the cascade can 
catalyse those upstream, as well as themselves, resulting in a positive feedback 
loop allowing rapid activation and massive amplification of this signal. There 
are currently 13 caspase members some of which are involved in initiating the 
cascade - ―so called initiator caspases‖ - e.g. Caspase 8 and 9 which seem to 
have more limited substrates and be responsible for propagation of the apoptotic 
signal, and some more abundant ―effector caspases‖ which are considered the 
workhorses of the caspase family.  These have a wide variety of substrates 
including endonucleases, cytoskeletal proteins and transcription factors which 
are largely responsible for the controlled dismantling of intracellular machinery 
and the development of the morphological changes characteristic of apoptosis 
culminating in the formation of an apoptotic body (Cohen, 1997).  For example, 
Caspase 3 causes activation of transcription factors that modulate the expression 
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of various pro- and anti-apoptotic factors among which are the Bcl-2 family of 
mitochondrial proteins, cytochrome c, and various tumour suppressor genes, as 
well as endonucleases.  Caspase 3 also cleaves anti-apoptotic proteins e.g. Bcl-2 
and Bcl-xl that normally protect the mitochondrial membrane from 
permeablisation.  Activation of specific serine/threonine phosphatases results in 
changes in phosphorylation status and activation of pro-apoptotic factors e.g. 
BAX, BAD, BID and BIK in addition to caspases cleaving them to more potent 
pro-apoptotic forms.  It should also be noted that some caspases (1,4 & 5) are 
involved in the mediation of the inflammatory response (Martinon & Tschopp, 
2004). 
Changes such as these to the protein composition of the mitochondrial 
membrane and the state of various ion channels and receptors within it result in 
a sudden change in its permeability,  so called  mitochondrial membrane 
permeablisation (MMP) and this causes rapid release of cytochrome c (the 
electron transfer protein) from the mitochondrial inner membrane into the 
cytoplasm.   
The exact mechanism by which cytochrome c release occurs remains 
controversial and multiple mechanisms may exist.  Mechanisms suggested 
include the formation of specific channels by pro-apoptotic members of the Bcl-
2 family proteins (e.g. tBID, BAX, BAD) in the mitochondrial outer membrane, 
the opening of non-specific solute conducting channels called Mitochondrial 
Permeability Transition Pores  in  the mitochondrial inner membrane which 
cause mitochondrial swelling and outer membrane rupture, and the formation of 
pores by aggregation of misfolded membrane proteins associated with high 
mitochondrial Ca
2+
 levels and a lack of chaperoning proteins which normally 
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bind and close pores.  Whatever the mechanism, the sudden release of 
cytochrome c represents the point of no return for the cell.  The released 
cytoplasmic cytochrome c (associated with Caspase 9 and Apaf 1) forms 
apoptosome, this further activates Caspase 3 which in turn activates further 
release of cytochrome c and thus a positive feedback loop is created (Li et al., 
1998).   In addition there is activation of CAD, a caspase activated DNAse, an 
endonuclease which is responsible for the fragmentation of genomic DNA into 
50kb fragments one of the hallmarks of apoptotic cell death.  Other 
mitochondrial membrane proteins e.g. Apoptosis inducing factor are transported 
to the nucleus where they induce the characteristic morphological changes of 
apoptosis as seen on light microscopy (see table 1.).  With the use of special 
stains differences in membrane expression (e.g.Annexin V), DNA fragmentation 
(e.g.TUNEL) and caspase activation (e.g. Caspatag) can be utilised to 
differentiate between apoptotic and necrotic cells. 
Table 1. Morphological changes in Apoptosis and Necrosis 
 
APOPTOSIS 
 
 
NECROSIS 
Deletion of single cells 
 
Death of groups of cells 
Membrane blebbing, but no loss of 
integrity 
Loss of membrane integrity 
Cells shrink, ultimately forming 
apoptotic bodies 
Cells swell and lyse 
No inflammatory response 
 
Significant inflammatory response 
Phagocytosis by adjacent normal cells 
and some macrophages 
Phagocytosis by macrophages 
Lysosomes intact 
 
Lysosomal leakage 
Compaction of chromatin into 
uniformly dense masses 
Clumpy, ill-defined aggregation  of 
chromatin 
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The mitochondrial pathway is less well characterised, it does not require 
activation of cell surface receptors or Caspase 8, is mediated by Caspase 9, and 
can be instigated by a number of physical events particularly those that generate 
oxidative stress, typically by DNA damage, p53 activation and PUMA 
expression.  It still relies on changes in MMP, cytochrome c release and Caspase 
3 as the final common pathway of cell death. 
Much is still to be learnt about the control of apoptosis and its pathways and the 
current model is an oversimplification.  Alternative pathways must exist as the 
Caspase3 knockout mouse still undergoes Fas-L binding mediated liver injury 
and death, albeit delayed (Woo et al., 1999).  However there is at least an outline 
which provides a framework in which to develop strategies to inhibit apoptosis. 
 
1.6   APOPTOSIS IN LIVER DISEASE 
 The following is a brief résumé of evidence suggesting mechanisms by which 
apoptosis is implicated in various forms of liver disease:  
Cholestatic liver disease 
There are increased numbers of hepatocytes undergoing apoptosis in some 
cholestatic liver diseases including Primary Biliary Cirrhosis (Papakyriakou et 
al., 2002).   
This may be due to direct toxicity by accumulated bile salts since it has been 
demonstrated in cell culture that toxic hydrophobic bile acids can initiate 
apoptosis both via Fas translocation and Fas-ligation (Guicciardi & Gores, 2000) 
and via activation of TRAIL (Kahraman et al., 2008).  Bile acid levels in 
cholestatic patients are increased to sufficient levels to activate death receptor 
pathways  and Fas deficient lpr mice are protected against hepatocyte apoptosis 
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and subsequent liver fibrosis seen in normal mice induced by bile duct ligation 
(Canbay et al., 2002), demonstrating a mechanistic link between cholestasis and 
fibrosis.   Acute cholestasis also induces oxidative stress via activation of 
NADPH oxidase, which increases superoxide which, increases translocation of 
Fas to the plasma membrane and also activates TRAIL-R2. 
However not all bile salts are harmful to hepatocytes; some delay apoptosis by 
induction and translocation of Bax, a pro-apoptotic protein to mitochondria, and 
Ursodeoxycholic acid protects against bile salt induced apoptosis by preventing 
mitochondrial membrane permeability as well as decreasing stellate cell 
activation and fibrosis (Paumgartner & Beuers, 2004).   
Apoptosis in cholangiocytes may also be involved in the pathogenesis of 
conditions such as Primary Sclerosing Cholangitis as demonstrated by the 
induction of apoptosis and a similar liver injury by an agonistic Death Receptor 
5 antibody (Takeda et al., 2008). 
  
Viral hepatitis 
Cytotoxic T lymphocytes and natural killer cells secrete Fas-L and it is thought 
to be one of the mechanism that virally infected hepatocytes are killed (Kagi et 
al., 1994).  Increased numbers of Hepatocytes undergoing apoptosis have been 
demonstrated via TUNEL in chronic viral liver disease (Papakyriakou et al., 
2002b)  Hepatitis B (Mochizuki et al., 1996) and C virus (Hiramatsu et al., 
1994) increase both soluble Fas (Iio et al., 1998) and Fas expression whose 
levels correlate with histological disease activity (not biochemical) and response 
to therapy (Lee et al., 2004, Luo et al., 1997, Mita et al., 1994).  In the case of 
Hepatitis C an increase in activated Caspase 3 and 7 is in liver tissue which 
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correlates with inflammatory activity (Bantel et al., 2001) TRAIL is also 
increased in the serum of patients with viral hepatitis (Mundt et al., 2003). 
When HCV specific CD8+ lymphocytes are transplanted into mice expressing 
HCV proteins liver damage and increase in ALT occurs (suggesting necrosis).  
This effect is also seen when lymphocytes are transplanted into transgenic mice 
expressing HBsAg and the flare in hepatitis is antagonised by soluble Fas which 
acts as a decoy receptor (Kondo et al., 1997) , suggesting that the necrosis is 
secondary to apoptosis.  
 
Alcoholic Liver Disease 
In liver biopsies of patients with Alcoholic Hepatitis there is increased 
hepatocyte apoptosis measured both by TUNEL (Zhao et al., 1997) and 
increased activation of Caspase 3 (Ziol et al., 2001).  In Ziol‘s study there was 
correlation between apoptotic index and Maddrey‘s discriminant function, 
bilirubin levels and the presence of ascites, whilst Natori‘s study showed a 
correlation to Bilirubin and histological severity (Natori et al., 2001). Also liver 
biopsies of heavy drinkers show apoptotic cells in an identical distribution to 
hepatocytes containing intracellular Mallory bodies suggesting hepatocytes 
damaged by alcohol might be eliminated by apoptosis (Kawahara et al., 1994). 
Soluble Fas, hepatic Fas and Fas-L expression are increased in Acute Alcoholic 
Hepatitis compared with those with alcoholic liver disease with no hepatitis 
(Tagami et al., 2003) and levels correlate with liver injury, and in patients with 
alcoholic hepatitis TNFalpha and TNFR1 levels are elevated and correlate with 
mortality.  These data suggest that apoptosis induced by the death receptor 
pathway is a key factor in the pathogenesis of Alcoholic Hepatitis.  For this 
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reason there was hope that neutralising anti-TNF antibodies would be beneficial 
in the treatment of Alcoholic Hepatitis, unfortunately however this treatment did 
not result in a survival advantage (Blendis & Dotan, 2004), as there was an 
increase in death secondary to infection due to the immunosupressive effects of 
anti-TNF drugs.  
In animal models of chronic alcohol related liver damage hepatocyte apoptosis 
has been demonstrated from acinar zone 3 to zone 2 following ethanol feeding 
of rats (Benedetti et al., 1988, Rust et al., 2000) .  The exact mechanism by 
which alcohol has this effect is not fully elucidated but alcohol is known to 
induce oxidative stress which, in turn, can induce apoptosis both by direct and 
indirect mechanisms, thus oxidative stress has been implicated in both acute and 
chronic alcohol induced liver injury (Ishii et al., 1997, Kurose et al., 1997) 
(Higuchi et al., 2001, Minana et al., 2002).   Again it appears death receptor 
mediated pathways are important in chronic liver disease, particularly the 
TNFR1 receptor as studies in TNFR1 knockout mice show attenuated ethanol 
induced liver injury induced by chronic alcohol ingestion (Yin et al., 1999). 
   
 
Nonalcoholic Steatohepatitis (NASH) 
There are increased numbers of apoptotic cells demonstrated both by TUNEL 
and activation of Caspase 3 and 7 in liver biopsy specimens in patients with 
steato-hepatitis compared to both healthy controls and patients with steatosis 
only.  The quantity of apoptosis being associated with biochemical markers of 
liver injury and histological severity (Feldstein et al., 2003).  Both Fas & 
TNFR1 expression are increased in steatohepatitis again compared to normal 
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controls suggesting that death receptor pathways may be implicated in this 
process (Ribeiro et al., 2004).   
The role of steatosis may be to increase hepatocyte sensitivity to Fas induced 
apoptosis as demonstrated in a murine model of liver injury induced by Jo-2, a 
Fas binding antibody that induces oligerization and activation of Fas; there is 
increased apoptosis  in animals with diet-induced steatohepatitis compared to 
sham fed animals. 
This has led to the concept of the ―two hits‖ in the pathogenesis of NASH, the 
first being steatosis and the second being inflammation, apoptosis mediated by 
death receptor pathway activation being a key component of this second hit. 
 
 
Liver transplantation 
Apoptosis has been implicated in ischaemia-reperfusion injury post 
transplantation (Sasaki et al., 1997), as well as the Seventh Day Syndrome 
(Memon et al., 2001), and the long-term complication of Vanishing Bile Duct 
Syndrome (Nawaz et al., 1994).  The role of apoptosis in acute rejection may 
however only be a minor component (Tox et al., 2001)  In the immediate post 
transplant setting apoptosis is mediated at least in part by death receptor 
pathways as demonstrated by the attenuation of ischaemic induced apoptosis by 
silent interfering Fas RNA  (Li et al., 2007), silent interfering Caspase 8 and 3 
(Contreras et al., 2004) and by direct inhibition of Caspase 3 by direct Caspase 
inhibitors (Mueller et al., 2004),  Expression of soluble Fas but not soluble Fas 
Ligand is seen in serum post liver transplantation and may represent part of the 
immunological response post transplant (Seino et al., 1999).  TNFR1 knockout 
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mice have shown that graft TNFR1 deficiency increases graft injury whereas 
recipient TNFR1 deficiency results in decreased liver injury (Conzelmann et al., 
2002). 
Manipulation of apoptotic pathways may present opportunities to decrease graft 
rejection and may allow progress in isolated hepatocyte transplantation, for 
example TGF-α over expression protects against apoptosis and increases liver 
repopulation by hepatocytes (Kosone et al., 2008). 
This is however a complex area as many of the pathways by which apoptosis is 
mediated are also essential for liver regeneration.  TNFR1 expression is low in 
normal liver but is increased in a number of liver diseases suggesting a 
pathogenic role.  Partial hepatectomy has a protective effect against Fas-ligand 
induced apoptosis and this effect surprisingly appears to be mediated by TNF-α 
(Takehara et al., 1998).  Global inhibition of apoptotic pathways may therefore 
not always be advantageous.   
 
Acute Liver Failure 
Increased  hepatocyte apoptosis (Kasahara et al., 2000), Fas expression, 
infiltration with Fas-L expressing cytotoxic lymphocytes and increased soluble 
Fas occur in FHF due to various aetiologies (Ryo et al., 2000) Serum 
cytochrome c is elevated and correlates to serum ALT in ALF. 
Various animal models of acute liver failure induce injury via death receptor 
pathways and many of these models have been utilised to investigate ways of 
limiting liver injury and will be discussed in subsequent chapters. 
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Acetaminophen toxicity 
Acetominophen is metabolised to the toxic metabolite N-acetyl-p-benzoquinone 
imine (NAPQI) by the cytochrome p450 system.  NAPQI forms covalent 
adducts and initiates mitochondrial oxidative stress and mitichondrial 
permeability transition(MPT) (Cohen & Khairallah, 1997, Nelson, 1990). 
Cyclosporin A protects against acetaminophen toxicity both in vitro and vivo by 
blocking the MPT (Masubuchi et al., 2005). 
The role of apoptosis in acetominophen toxicity is controversial with some 
studies showing TUNEL cell positivity and DNA laddering in-vitro and in-vivo 
(Ray et al., 1996) in mouse hepatocytes, and some studies showing only 
minimal apoptosis (Gujral et al., 2002).  
This demonstrates the fact that apoptosis and necrosis can be initiated by the 
same pathways but the final outcome is determined by the ATP status of the cell.  
Necrosis occurs if Acetaminophen  causes mitochondrial dysfunction such that 
ATP is depleted; if this is prevented by fructose and glycine then apoptosis 
ensues (Kon et al., 2004). 
 
1.7 OPPORTUNITIES FOR DESIGN OF NOVEL THERAPEUTIC 
MODALITIES. 
Every step of the pathways culminating in apoptosis is amenable to 
manipulation and is therefore a potential therapeutic target:   For Example Bcl2 
proteins are a family of mitochondrial proteins, some of which are pro-(Bid, 
Bax, Bak) and some of which are anti-apoptotic (Bcl2, BclXL).  Manipulation of 
mitochondria to prevent MPT pore complex formation has been tried 
(Waldmeier et al., 2003) or blockage of pores, using non-immunosupressive 
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analogues of Cyclosporin A (Halestrap et al., 2004, Matsuki et al., 2002, 
Waldmeier et al., 2002).  Caspase 8 inhibition using siRNA prevents acute liver 
failure in mice (Zender et al., 2003), and ischaemia reperfusion injury in mice 
(Contreras, Vilatoba, Eckstein, Bilbao, Anthony, & Eckhoff, 2004).  Caspase 
inhibitors decrease liver injury in many models of liver disease, including the 
bile duct ligated mouse (Canbay et al., 2004), ischaemia reperfusion injury 
(Natori et al., 2003),  SiRNA targeting Fas protects mice against fulminant 
hepatitis (Song et al., 2003).  Fas siRNA protects transplanted hepatocytes in 
mouse spleen (Wang et al., 2003).  Soluble Fas gene therapy protects against 
Fas mediated apoptosis although does not prevent the lethal effects of Fas 
induced TNF-alpha production by kupffer cells.  
 
1.8   ARTIFICIAL LIVER 
Liver transplantation cures approximately 90% of patients with acute liver 
failure, however a shortage of donor organs combined with the fact that many 
patients will become too ill to undergo transplantation means mortality remains 
high. 
Unlike many other organs the liver has a tremendous capacity for regeneration 
and repair even in adulthood.  This ability is clearly demonstrated by the fact 
that after surgical resection the liver regenerates back to its original size and that 
some patients will make a complete recovery from fulminant hepatic failure with 
no long-term sequelae.  Strategies that allow temporary liver support buying 
time for transplantation or endogenous liver recovery are therefore required.  By 
performing the detoxifying function of the liver it is hoped an ―artificial liver‖ 
would not only prevent other end-organs from damage but would make the 
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general environment of the patient‘s own hepatocytes less toxic, thus decreasing 
liver cell death and promoting regeneration and repair, breaking the vicious 
circle described above.   
Early artificial liver support devices in acute and acute-on-chronic liver failure 
aimed at toxin removal such as whole blood exchange (Redeker et al., 1973), 
haemoperfusion (Bartels, 1978), charcoal haemoperfusion (O'Grady et al., 
1988), haemodiabsorption (BioLogic-DT) (Hughes et al., 1994) have failed to 
show any survival benefit.  More recent detoxifying systems such as 
Extracorporeal albumin dialysis (MARS) (Stange et al., 1999) have possibly 
been more successful, reducing mortality in a stratified meta-analysis in acutely 
decompensated chronic liver disease (Steiner & Mitzner, 2002).  MARS allows 
removes albumin bound molecules.  A special membrane allows transfer of 
water soluble and albumin bound toxins with molecular weight less than 50kDa 
from blood into a dialysate solution containing 20% human albumin.  This 
albumin solution is then ―cleaned‖ by passing it over a charcoal filter, resin 
adsorbents and a haemofilter before recirculation.  MARS has shown a survival 
advantage in small trials in acute-on-chronic liver failure (Heemann et al., 2002, 
Mitzner et al., 2000), but, despite improvement in several parameters, 
particularly encephalopathy, has yet to be shown to produce any survival benefit 
in acute liver failure. 
Plasmapheresis, another technique aimed at removing toxins in plasma has 
recently shown some improvement in survival in acute liver failure in case series 
(Larsen et al., 1994).  
Due to the complexities of liver function it is unlikely that any mechanical 
artificial liver will be able to reproduce the myriad of functions performed by the 
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liver.  Bio-artificial liver support systems containing hepatocytes in a bio-reactor 
have therefore been developed in an attempt to replicate normal liver function.  
Several systems have reached clinical trial.  The ‗Extra-corporeal Assist Device‘ 
(ELAD) utilises a hepotoblastoma cell line in its bioreactor (Ellis et al., 1996), 
whereas the Bio-artificial Liver (BAL), the ‗Berlin Extra-corporeal Liver 
Support System‘ (BELS) and the HepatAssist devices contain primary porcine 
hepatocytes (Demetriou et al., 2004).  Whilst biological systems perform more 
of the liver‘s endogenous functions no bio-artificial device has been shown to 
reduce mortality in acute liver failure although trials are small and therefore 
often underpowered.  There are also unique considerations with systems that 
contain live hepatocytes; animal sources of hepatocytes may contain 
transmissible infectious agents, cell lines whilst having the advantage of 
proliferative ability do not perform all the functions of primary hepatocytes and 
should any enter the patient circulation would have malignant potential, and 
primary human hepatocytes do not proliferate, are difficult to isolate with high 
viability and are in limited supply.  The maintenance of good cell viability and 
function in the presence of toxins in liver failure plasma also remains an issue of 
ongoing concern.  
Overall meta-analysis of all liver support devices compared with standard 
medical therapy has failed to show any significant reduction in mortality (RR 
0.86, 95% CI 0.65-1.12).  However stratified meta-analysis has shown that in 
acutely decompensated chronic liver disease mortality is reduced by 33%, 
whereas mortality in acute liver failure shows no reduction (Khuroo & Farahat, 
2004, Kjaergard et al., 2003, Liu et al., 2002). 
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1.9  HYPOTHESIS 
The core hypothesis of this project is that plasma from patients with liver failure 
contains substances that cause hepatocyte death.  
 
1.10   AIMS AND OBJECTIVES 
The initial aims of this project were: 
1.   To develop a model applicable to human disease by which the cytopathic 
effects of liver failure plasma could be studied. 
2.  To isolate and identify the toxic molecule/s present in liver failure plasma 
that are responsible for loss of viability and decreased function of hepatocytes.  
3.  To elucidate the mechanism of action of these toxins. 
4.  To investigate if cytotoxic substances are present in acutely decompensated 
chronic liver disease. 
5.  To determine if there are any clinico-pathological variables that correlate 
with acute liver failure plasma‘s cytopathic effect. 
6. To assess ways of removing/antagonising this toxicity. 
 
By doing so, we hope to be able to identify processes which can be applied to 
manipulate liver failure plasma, to make a more favourable environment for 
hepatocyte survival.  This ability would have multiple applications including 
improving function/recovery of the patients‘ endogenous liver cells,  improving 
the environment for transplanted cells e.g. stem cells and allowing  better 
function/survival of cells in a bio-artificial liver.  The ultimate aim of these 
strategies is to improve the survival of patients with liver failure. 
 
 62 
PRELIMINARY WORK: 
CONFIRMATION OF TOXICITY AND CHARACTERISATION OF 
PHYSICAL PROPERTIES OF TOXIC MOLECULES IN ACUTE LIVER 
FAILURE PLASMA.  
 
1.11   INTRODUCTION 
Previous work has suggested that plasma from patients with acute liver failure is 
toxic to hepatocytes affecting both their viability and function (McCloskey, 
Tootle, Selden, Larsen, Roberts, & Hodgson, 2002).   Native hepatocytes in 
patients with acute liver failure plasma are continuously exposed to plasma and 
therefore any toxic substances within it are likely to have a deleterious effect on 
the patient‘s clinical outcome.  In addition, hepatocytes are likely to be a key 
component of any bioartificial liver and they would also be exposed to possibly 
―toxic‖ plasma ultimately causing their demise or suboptimal function of the 
bioartificial liver.  An understanding of the ―toxic‖ nature of liver failure plasma 
is therefore essential in developing an effective bioartificial liver, and 
developing new therapies to optimise the patient‘s endogenous liver function 
and hepatocyte survival, thus improving the likelihood of liver recovery and 
ultimately patient survival. 
The initial aim of this project was to identify these toxic molecules, to 
understand their mechanism of action and to develop strategies for their removal 
or antagonism. 
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1.12 CONFIRMATION OF PLASMA TOXICITY AND 
IDENTIFICATION OF VARIABILITY IN TOXICITY FROM 
DIFFERENT INDIVIDUALS WITH ACUTE LIVER FAILURE.  
Measurement of toxicity of plasma was assessed by the effect of the addition of 
liver failure plasma to liver cells in-vitro.  Due to the lack of an unlimited source 
of primary human hepatocytes, and due to the fact that liver tumour cell lines are 
the source of hepatocytes in some current versions of the bioartificial liver, 
HepG2 cells were used to assess cell toxicity using the MTT assay. 
The MTT assay is a colorimetric assay used to estimate cell numbers.  It relies 
on cleavage of the yellow tetrazolium salt MTT (3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl tetrazolium bromide to give a purple coloured formazan product by 
the action of the mitochondrial enzyme succinate dehydrogenase, and is often 
considered to be proportional to the number of viable cells present (Mosmann, 
1983). 
Liver failure plasma (donated by Larsen et al, Coppenhagen) was taken at the 
onset of plasmapherisis treatment in patients with acute liver failure (as defined 
by O‘Grady et al 1993).    See table 1 for clinical details of liver failure plasma, 
see table 2 for biochemical details. 
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Table 2. Acute Liver Failure plasma donors clinical details. 
Sample 
ID 
Aetiology Age Gender Encephalopathy 
Grade 
Outcome 
LFP 1 Paracetamol 
toxicity 
32 Male IV Spontaneous 
Recovery 
LFP 2 Paracetamol 
toxicity 
51 Male IV Spontaneous 
Recovery 
LFP 3 NonA-E 
Hepatitis 
47 Female IV Spontaneous 
Recovery 
LFP 4 Paracetamol 
toxicity 
54 Female IV Spontaneous 
Recovery 
LFP 5 Paracetamol 
toxicity 
34 Male IV Died 
 
Method 
HepG2 cells from 90% confluent cell monolayers in tissue culture flasks were 
trypsinised (see general methods).  Cells had over 95% viability measured by 
trypan blue exclusion and were plated into plastic 96 well plates at a density of 
15 000 cells/well in 100uL of complete alpha-mem medium.  Cells were 
incubated for 24 hours to allow cellular adhesion and proliferation.  Cell 
monolayers at 40% confluence were washed twice with HBSS to remove dead 
cells and cellular debris.  100uL of plasma taken from patients with acute liver 
failure (see table 1 for clinical details), or normal controls was added to each 
well, each sample being repeated in triplicate.  After 16 hours the plasma was 
removed and the cells washed thrice with complete alpha-mem medium.  50uL 
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of MTT (0.75mg/ml in PBS) was added to each well and then the plates were 
incubated at 37ºC for 3 hours in the dark.  Excess MTT solution was then flicked 
off leaving the purple granules of formazan product in the bottom of the well.  
To solubilise the formazan product 100uL/well of 0.004M Hydrochloric acid in 
iso-propranol was added.  The 96 well plate was wrapped in clingfilm to prevent 
evaporation and was agitated on a platform shaker for 30 minutes to ensure 
complete dissolution of the formazan product.  The optical density at 550nm was 
then read by an automated plate reader.      
Toxicity in toxic samples was confirmed by exactly the above method but 
HepG2 cells were incubated with different percentages of liver failure plasma 
made up in complete alpha-mem forming a dose response curve. 
 
Results 
Viewing of HepG2cells under phase contrast microscopy after 16 hours 
exposure to 100% plasma from different individuals showed differences in cell 
density.  This suggested differences in rates of cell death, proliferation, adhesion 
or combinations of those processes induced by different samples of plasma. 
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Figure 2.  Phase contrast photographs, magnification x20 of HepG2 cells after 
16 hours exposure to different samples of liver failure plasma. A. Normal 
Plasma. B. Liver failure plasma sample 2.  C. Liver Failure Plasma Sample 3. 
A. Normal Plasma 
B. LFP 2 
 C.  LFP 3 
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Liver failure plasma sample 2 shows increased cell density, whereas liver failure 
sample 3 shows reduced cell density compared with plasma from normal 
control. 
This apparent difference in cell number was confirmed by the results of the 
MTT assay (Figure 2).  A statistically significant decrease in mean MTT activity 
was observed in cells incubated in liver failure plasma sample 3 (LFP3) 
compared to normal plasma (P<0.005).  Theses data were consistently 
reproducible on many occasions.  
 
 
 
 
 
 
 
 
 
 
Figure 3.  MTT activity, as an indirect measure of cell number, for HepG2 cells 
incubated in 100% plasma for 16 hours from patients with acute liver failure and 
normal control.  Mean values ± SD. n=3 *= P value ≤ 0.05 cf Normal control. 
 
Conclusion 
Plasma from patients with acute liver failure and from normal patients varies in 
its effect on cell number.  Liver failure plasma samples 1, 2 and 5 appear to 
L
FP
 1
L
FP
 2
L
FP
 3
L
FP
 4
L
FP
 5
N
or
m
al
0.0
0.5
1.0
1.5
Incubation Medium
A
b
so
rb
a
n
ce
@
5
5
0
n
m
 * 
 68 
confer a survival or proliferative benefit on HepG2 cells compared with normal 
plasma.  Liver failure plasma samples 4 and 6 appear to have no effect on 
HepG2 cell survival/proliferation compared to normal plasma.  Whereas liver 
failure plasma sample 3 has a marked deleterious effect on cell number.   
A large variation in effect of liver failure plasmas is not unexpected considering 
the plasmapheresis samples were taken from different patients possibly with 
different severities of liver failure at different stages of the disease process.  Due 
to the complex nature of plasma there may also be substances which offer a 
survival advantage e.g. growth factors as well as toxic molecules, and these may 
offer protection against some of the plasma‘s toxic effect as well as increasing 
cell proliferation.  This complex nature of plasma makes it difficult to identify 
toxic molecules as a deleterious effect may not be due to the presence of a toxic 
substance but may be due to the absence of beneficial factors.  However since it 
is the final outcome of the cells‘ fate that is of interest this assay does give an 
insight into the balance of toxins/beneficial factors in different plasma samples. 
Since liver failure plasma sample 3 shows the most striking toxicity it was 
decided to use liver failure plasma 3 to characterise possible toxic molecules. 
Using the above system as a biological assay we hoped by putting the plasma 
through a number of different processes each time reconstituting it back to its 
original volume and testing its toxic effect on HepG2cells, we could further 
characterise ―toxins‖ in liver failure plasma.   
 
 
 
 69 
1.13  CHARACTERISATION OF THE MOLECULAR WEIGHT OF 
PUTATIVE TOXIC MOLECULES IN ACUTE LIVER FAILURE 
PLASMA.  
 
In an attempt to narrow the field of search for the toxic molecules in liver failure 
plasma so as to make its/their purification and identification easier we 
fractionated whole plasma into different fractions using centrifugation across 
membranes with different molecular weight exclusions.   
 
Method 
HepG2 cells were trypsinised, plated at 15000/well in 100uL in a 96 well plate 
and incubated at 37C for 24 hours as described previously.   
Centricon ultrafiltration tubes with different molecular weight cut offs were 
sterilised with ethanol. 
10ml of liver failure plasma 3 was loaded into the upper chamber of a centricon 
tube with molecular weight cut off of 100 000kDa, normal plasma control was 
loaded in an identical way to a separate identical centrifuge tube.  Tubes were 
then centrifuged in a swinging bucket centrifuge at 3000g for 90 minutes.  1.5ml 
of centrifugate was retained, the remaining 3.5ml was loaded into a second 
sterile centricon tube with a molecular weight cut of off 30 000 kDa and 
centrifuged at 3000g for 90 mins.  1.5ml of centrifugate was retained and the 
remaining 2ml loaded into a third sterile centricon tube with a molecular weight 
cut off of 10 000 kDa, this was again centrifuged at 3000g for 90 minutes.  Each 
centrifugate was then made up to its starting volume with serum free complete 
alpha-MEM.  50uL of each sample was added to the HepG2 cells; after 
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incubating for 16 hours at 37ºC in 5% humidified CO2 the centrifugate was 
removed, cells washed in HBSS x3 and then the MTT test was performed as 
described previously. 
To confirm the molecular weights of the centrifugate, equal amounts of each 
sample were separated by SDS-PAGE.  Protein concentration of each sample 
was measured using the Bradford method (see general methods). A volume 
equivalent to 4ug of protein of centrifugate was mixed with an equal volume of 
SDS-PAGE loading buffer and heated to 100ºC for 5 minutes to denature the 
protein; samples with protein concentrations less than 0.4mg/ml were loaded in 
a maximum volume (20uL) onto a 12% Tris-glycine gradient gel in pairs of 
normal plasma and liver failure plasma 3.  A rainbow marker (RPN 800 
Amersham) with a molecular weight range of 10k-250kDa was also loaded.  The 
gel was run at 200V constant voltage for 50 minutes in MOPS running buffer.  
Gels were then thoroughly washed in PBS and stained using silver staining (see 
general methods). 
 
Results 
The MTT test showed that once liver failure plasma sample 3 had passed 
through the membrane with molecular weight cut off of 30kDa its toxicity was 
lost. 
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Figure 4.  MTT activity as an indirect measure of cell number for HepG2 cells 
incubated for 16 hours in different fractions of liver failure plasma sample 3, 
produced by serial centrifugation across membranes with different molecular 
weight exclusions. Mean values ± SD. n=3 **= P value ≤ 0.005 cf Normal 
control. 
 
The Bradford assay demonstrated that once the plasma had been passed through 
the 10 kDa molecular weight filter very little protein remained and this was 
confirmed by the absence of any silver staining on these samples.  A densely 
stained band of molecular weight between 50-75kDa was clearly seen on 
uncentrifuged, 100kDa centrifugate, and to a far lesser extent the 30 kDa 
centrifugate.  This band is likely to represent albumin (molecular weight 67 
kDa).  The reason for the appearance of a band with a molecular weight above 
that of the exclusion point of the membrane in the centrifuge device is that 
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molecules with molecular weights up to three times the molecular weight ―cut 
off‖ can pass through the membrane.  The manufacturer‘s recommendation is to 
select a molecular weight cut off at least three times smaller than the molecule to 
be retained.  The stated molecular weight cut off is based on the ability of the 
device to retain >90% of globular protein of the defined molecular weight.  
 
Conclusion 
The toxicity of liver failure plasma sample 3 is lost after the plasma has passed 
through the 30 kDa centrifugation device, but the toxic molecule/s pass through 
the 100kDa device.  This suggests that the ―toxin‖ is a molecule with a 
molecular weight greater than 30kDa and is therefore unlikely to be a small 
water soluble molecule e.g. Urea.  This suggests that the toxic molecule/s are 
either substances with larger molecular weight or that they are small molecular 
weight substances that are carried on larger molecular weight molecules e.g. 
Albumin.  This seems a likely hypothesis since many small molecules that could 
be toxic to hepatocytes are carried in plasma bound by albumin.  Centrifuging 
through a 100kDa selective centrifuge device could also be an initial step in 
purifying and thus identifying toxic molecules in liver failure plasma. 
 
 
1.14  LIPID SOLUBILITY  
Since one of the aims of this project was to identify toxic molecules in liver 
failure plasma an initial step in purifying it was to see if the toxic molecule/s in 
liver failure plasma were hydrophilic or hydrophobic using a technique 
originally described by Bligh and Dyer (Bligh et al, 1959).  
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Method 
Liver failure plasma sample 3 and normal control plasma were each treated in 
the following way.  A solution of 4 vols plasma: 5 vols chloroform: 10 vols 
methanol in a glass test tube was vortexed for 2 minutes in a fume hood.  
Additional chloroform (5vols) was added followed by further vortexing for 30 
seconds.  The mixture was chilled a 4ºC for 1 hour and then spun at 2000rpm for 
30mins at 4C.  The bottom yellow chloroform layer was drawn off and placed in 
a glass test-tube.  The top clear layer was drawn off and stored.  The protein 
precipitate was washed with a further 5 vols chloroform spun at 2000rpm at 4C 
the chloroform layer drawn off and pooled with the original chloroform layer.  
Samples were then frozen at -20ºC and lyophilised overnight. Samples of 
untreated plasma were also frozen and lyophilised to ensure the freezing and 
lyophilising process itself did not remove plasma toxicity.  All lyophilised 
samples and controls were diluted in 75uL of ethanol to allow solubilisation of 
the lipid component, the water soluble layers and the whole plasma were treated 
in an identical way to ensure ethanol was present in an equal amount in all 
samples and controls.  Samples were then made back up to there starting volume 
1.5ml in Hepes buffered serum free medium.  Having been filter sterilised 
100uL of sample or control was added to 40% confluent HepG2 monolayers 
which had been plated 24 hours prior in triplicate.  Cells were incubated for 16 
hours.  The sample was then removed and the cell monolayers washed twice 
with sterile medium, an MTT test was then performed as described previously. 
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Results 
The results show that the toxicity seen in the unseparated sample of liver failure 
plasma persists in the aqueous fraction, but is not present in the chloroform 
layer.  
Figure 5.  MTT activity as an indirect measure of cell number for HepG2 cells 
incubated for 16 hours in liver failure plasma sample 3, and normal plasma 
control separated into its lipid soluble and aqueous fractions using the technique 
described by Bligh and Dyer. Mean values ± SD. n=3 ***= P value ≤ 0.001 cf 
Normal control. 
Conclusion 
The toxicity in liver failure plasma sample 3 appears to be present in the sample 
from the aqueous phase produced by the treatment of plasma using the technique 
described by Bligh and Dyer but not in the lipid soluble phase; this suggests that 
it is a hydrophilic molecule.   
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1.15  HEAT LABILITY 
As part of the physical characterisation of possible toxic molecules in liver 
failure plasma we aimed to determine if these toxins were heat labile. 
Method 
400uL of either liver failure plasma of normal control plasma was placed in a 
sterile eppendorf and placed in a waterbath at 20ºC, 45ºC, 60ºC and 70ºC for 30 
minutes, then immediately removed and cooled on ice.  100uL/well of heat 
treated plasma sample was added to 40% confluent HepG2 monolayers in a 96 
well format in quadruplicate.  Cell monolayers were then incubated for 16 hours 
at 37ºC in 5%CO2 and the effect on cell viability assessed by the MTT test as 
previously described. 
Results 
Heat inactivation resulted in loss of toxicity of liver failure plasma. 
 
Figure 6.  MTT for HepG2 cells after cells incubated for 16 hours in liver 
failure Plasma and Normal Plasma control.  The Plasma was previously heat 
inactivated for 30 mins at different temperatures (x axis). 
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No data are available for normal plasma heat treated to 70ºC as due to the high 
albumin content the sample was denatured and solidified by heat treatment. 
Conclusion 
The toxicity of liver failure plasma sample 3 was decreased by heating to 60ºC 
for 30 minutes however the viability of cells treated with 60ºC heat inactivated 
normal plasma for 30 minutes was also increased suggesting that the 
improvement may not be specific to ―toxic liver failure plasma‖ but may be due 
to general inactivation of substances inhibitory to cell growth in all plasma.  
 
1.16  DIALYSIS 
Introduction 
Conventional dialysis allows the removal of small molecules from a sample by 
allowing them to diffuse down a concentration gradient across a selectively 
permeable membrane.   To determine if the toxic molecules in acute liver failure 
plasma sample 3 could be removed by dialysis we dialysed human liver failure 
plasma against a solution of PBS and against a solution of 20% bovine albumin 
across a snakeskin dialysis membrane with a molecular weight cut off of 10kDa. 
  
Method 
A tubular dialysis membrane was cut into four 20cm lengths, membranes were 
cleaned by boiling in10mM sodium bicarbonate for 10 minutes and then boiling 
for 5 minutes in 10mM Na2EDTA, repeated twice and then rinsed several times 
with sterile ddH2O.  The bottom was tied in a double knot, and, having tested 
the membrane for leaks, a 1.5ml sample of liver failure plasma sample 3 was 
loaded into the two dialysis tubes and the tops of the tubing clamped with sterile 
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clamps allowing plenty of room for expansion due to solvent movement in the 
opposite direction.  This tubing was then fully immersed in either 100ml PBS or 
100ml 20% bovine serum albumin solution in PBS, which was then 
continuously stirred with a magnetic stirrer.  The samples were left at 4ºC 
overnight to equilibrate with two changes of dialysis buffer every 6 hours.  Two 
samples of plasma from a normal individual were set up in an identical way as a 
control.  Untreated plasma was also kept at 4ºC overnight to control for any loss 
of toxicity due to time alone.  At the end of the dialysis period the samples were 
removed from the dialysis fluid and their volume accurately measured.  Each 
sample was then made up to the highest final volume of the sample, which was 
1.6ml to compensate for fluid shifts and ensures their other than dialyzable 
solutes other molecules do not become differentially diluted/concentrated by 
fluid shifts.  Untreated control plasma was also diluted to a final volume of 
1.6ml with sterile PBS. 
100ul of plasma from either LFP3 or normal plasma both undialysed, dialysed 
against PBS and dialysed against 20% BSA were added in triplicate to HepG2 
monolayers in 96 well plates that were 40% confluent having been seeded 28 
hours prior.  These cells were then incubated for a further 16 hours and then 
plasma was removed, cell layers washed twice with medium, and MTT test 
performed as a measure of cell viability as described previously. 
 
Results 
Dialysis of liver failure plasma against PBS or 20% albumin solution did not 
remove its toxicity. 
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Figure 7.  MTT assay for HepG2 incubated for 16 hours with toxic liver failure 
plasma (3).  The plasma was dialyzed against PBS or 20 % Bovine Serum 
Albumin in PBS for 24 hours at 4ºC.  Normal plasma control. Mean values ± 
SD. n=3 ***= P value ≤ 0.001 cf Normal control. 
 
Conclusion 
The toxicity of liver failure plasma sample 3 is retained despite dialysis against 
either PBS or 20% Bovine serum albumin solution.  There are several plausible 
explanations for this.  The first would be that the molecular weight of the toxic 
molecule itself is above the cut off of the dialysis membrane (10kDa) and is 
therefore not able to freely cross it and be dialysed.  The second explanation is 
that the molecule is small but bound with a high affinity to a carrier protein and 
thus only a tiny fraction is in the aqueous phase and thus available to be 
removed by dialysis.  If, for example, the toxin was bound to human albumin, 
this could be the case.  The results support the findings of the previous work 
which found that toxicity was excluded from the sample by centrifugation 
though the centricon tube with a 10kDa cut off.   
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To try and differentiate between whether the molecule was bound to albumin or 
was itself greater than 10kDa we dialysed against a 20% albumin solution.  We 
would have expected dialysis against albumin solution to remove some of the 
toxicity if the molecule was less than 10kDa but was bound to albumin.  In a 
similar way to the use of albumin dialysis, such as is used in the MARS in the 
treatment of liver failure. 
Dialysis against albumin did not however remove toxicity.  This could be 
because either the toxin is not albumin bound, or that the albumin in the dialysis 
buffer does not have as high a binding affinity as human albumin.  This may be 
the case as the processing of albumin often results in a large decrease in its 
binding capacity.  Higher grades of human albumin are available and these have 
higher albumin specific binding capacities but are prohibitively expensive.  Even 
the highest grade of human albumin in clinical use in MARS requires 20 
minutes of recirculation across the charcoal and anion-exchange resin columns 
to optimise its binding capacity and remove stabilisers within the product.  
MARS also uses a special dialysis membrane which is pre-impregnated with 
albumin to facilitate transfer of albumin bound substances, we did not have this 
refinement. The membrane used may therefore not be suitable for dialyis of 
albumin bound substances. 
Subsequent experiments will look at toxicity of plasma from patient‘s pre and 
post MARS treatment.  These dialysis results do however confirm the results of 
clinical trials which suggest that standard haemodialysis of water soluble 
products from patients with fulminant hepatic failure does not improve the 
patient‘s outcome.  
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1.17  ALBUMIN BINDING 
Since previous experiments to demonstrate the molecular weight of toxic 
molecules in liver failure plasma suggested that the toxicity co-localised to the 
range of molecular weight that albumin falls in, we hypothesised that the toxin/s 
may be albumin bound, and that the dialysis against albumin method was 
inadequate alone to disprove the theory that the toxin was albumin bound due to 
the limitations described above.  To further test this hypothesis we specifically 
removed albumin from plasma and subsequently tested it to see if it remained 
toxic. 
Method 
Sepharose blue which has an albumin binding capacity of 7mg/ml was hydrated 
and washed in Tris buffer.  0.75ml of liver failure plasma sample 3 or normal 
plasma was added to 6ml of sepharose blue beads in a 15ml conical tube.  The 
tubes were then turned end over end continuously for 16 hours at 4ºC.  The tubes 
were then centrifuged at 3000g for 30 minutes. The clear supernatant was then 
removed.  Albumin was removed from the blue sepharose beads by adding 
2.5ml of sodium chloride 2M and the tubes turned end over end for 2 hours; 
tubes were then centrifuged at 3000g for 30mins and the supernatant removed.  
This sample was then desalted through a PD10 Sephadex G25 desalting column 
using 0.1M ammonium acetate pH 7.4 as the exchange buffer.  3.5ml of elutant 
was collected in 0.5ml fractions and run through a spectrophotometer at 280nm 
to confirm the presence of protein.  Pooled fractions were then frozen and 
lyophilised (as was untreated control plasma and the albumin free plasma 
prepared earlier).  Lyophilised samples were then reconstituted in 0.75ml 
HEPES buffered serum free medium and added to 40% confluent HepG2 cell 
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monolayers which had been plated 24 hours earlier in quadruplicate.  
Monolayers were then incubated for 16 hours at 37ºC in 5% CO2 after which 
they were washed twice with sterile medium and an MTT test was performed.  
The removal of albumin from serum and the removal of albumin from the 
sepharose blue beads was confirmed by electropheresis of samples on 12% Tris-
glycine gel and subsequent silver staining as described earlier. 
 
Results 
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Figure 8.  MTT activity as a measure of cell number for HepG2 cells incubated 
for 16 hours in plasma which has been treated with blue sepharose beads to 
remove albumin.  The albumin was then removed from the sepharose blue.  
 
Conclusion 
The toxicity of liver failure plasma sample 3 is removed by removing albumin 
from the sample and seems to be present in the albumin recovered from the blue 
*** 
*** 
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sepharous beads.  This confirms that the toxin is albumin bound and suggests 
techniques which remove albumin bound toxins e.g. MARS could theoretically 
render patients plasma less toxic to hepatocytes.  Treatments that seek to ―clean 
patients albumin‖ such as MARS or plasmapheresis which have been 
demonstrated to improve outcome in some trials may do so by decreasing 
toxicity of plasma to hepatocytes.  Developing a detoxifying system using blue 
sepharose beads would not be efficient as blue sepharose does not have a high 
enough binding capacity to be used practically. 
 
1.18  ACTIVATED CHARCOAL 
Activated charcoal is known to remove a number of toxins by non-specific 
adsorption.  Charcoal haemoperfusion has been used to treat patients with acute 
liver failure in the past, and is no longer used as it failed to show a survival 
benefit.  A charcoal filter is also one of the two filters in the albumin 
regenerating circuit in the MARS machine.  We therefore hypothesised that 
treatment of liver failure plasma 3 with activated charcoal could be a means of 
removing its toxicity. 
 
Method 
Three 15ml nunc tubes were filled with 5g of activated charcoal (sigma C9157) 
each; the activated charcoal was hydrated by the addition of 5ml of 0.1M 
buffered ammonium acetate pH 7.4.  Excess buffer was removed and 0.5ml of 
liver failure plasma 3, normal plasma or water was added to separate tubes.  The 
tubes were briefly vortexed and then turned continuously end over end for 30 
minutes.  Tubes were then centrifuged at 2000g for 30 minutes at 4ºC.  The 
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supernatant was removed, and the charcoal washed by the addition of a further 
2ml of ammonium acetate buffer vortexing and then centrifuging at 2000g for 
30 minutes, the supernatant was again removed and pooled with the earlier 
supernatant.  A further two washes were performed in this way each time 
pooling the supernatant with earlier fractions.  Samples were filtered through a 
0.2µM filter to sterilise and remove any residual charcoal.  Samples were then 
frozen at -20ºC and lyophilised.  Samples were resuspended in 0.5ml of Hepes 
buffered serum free medium and 100µL was added to 40% confluent HepG2 
cells in monolayer in a well of a 96 well plate having been plated 24 hours 
earlier in quadruplicate.  Cells were incubated for 16 hours at 37ºC in humidified 
5%CO2 atmosphere.  Samples were then removed and the monolayers washed 
twice with sterile serum free medium.  A MTT test was performed as described 
earlier. 
 
 
Results 
There remained a persistent toxic effect of liver failure plasma despite treatment 
with activated charcoal. 
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Figure 9.  MTT activity for HepG2 cells that were incubated in medium or 
plasma (water control) that had been treated with activated charcoal. Mean 
values ± SD. n=3 *= P value ≤ 0.05 cf Normal control 
 
Conclusion 
These results suggest that activated charcoal does not remove the toxicity 
associated with liver failure plasma sample 3 and would not therefore be useful 
in detoxifying plasma prior to the plasma being exposed to hepatocytes in a 
bioartificial liver and confirms the clinical results that charcoal haemoperfusion 
is unlikely to improve clinical outcome in patients with fulminant liver failure. 
 
1.19  DISCUSSION 
The MTT test as an indirect measure of cell number has a number of possible 
flaws.  The assay relies on the activity of the mitochondrial/microsomal enzyme 
being constant.  Changes in enzyme quantity or activity which may occur as a 
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result of different experimental conditions could result in changes in the MTT 
test due to factors other than change in absolute cell number.   
The second possible source of error is that due to the amount of time the plasma 
is left in contact with the cells, changes in proliferation rates by different 
experimental conditions could result in significantly different cell numbers at the 
end of the experiment.  These would be misinterpreted as being due to 
differential effects of experimental conditions on cell death, when this may not 
be the case. Methods which directly measure cell death e.g. LDH release may 
therefore be better.  It would also be preferable to develop a model which was 
more informative regarding the exact mechanism of cell death. 
A third criticism is that the methodology means that cells not adhering to the 
bottom of the well at the end of the experiment are counted as dead, as they are 
washed away.  Factors which effect cellular adhesion may therefore be wrongly 
interpreted as directly affecting cell death.  Indeed this is a major flaw of the 
MTT model developed above, as the ensuing paragraphs demonstrate.  
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1.20  CELLULAR ADHESION 
Detailed visual inspection after incubation with liver failure plasma and after 
addition and incubation of MTT showed large numbers of non-adherent cells in 
liver failure plasma sample 3. These non-adherent cells contained large amounts 
of purple formazan product indicating their viability (Fig 7).  Tipping off the 
MTT prior to solubilisation results in loss of these cells and associated formazan 
product, and thus is an underestimate of cell number.   
 
 
   
 
 
 
 
 
 
 
 
 
 
 
Figure 10.  Photomicrographs of HepG2 cells having been incubated in MTT 
pre-solubilisation showing the presence of large quantities of purple formazan 
product in cells that  have been exposed to normal plasma (A) or liver failure 
plasma 3 (B), note the cells although viable are not adherent. 
A. 
B. 
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Subsequent to these experiments Acute liver failure plasma was confirmed to be 
able to decrease cellular adhesion via down regulating beta-1 integrin receptor 
expression and activation (Newsome et al., 2004).  This effect is rapid occurring 
within a few hours, and is one of the hurdles to hepatocyte/stem cell 
transplantation (Potocnik et al., 2000, Zvibel et al., 2002).  Although loss of 
cellular adhesion will ultimately result in cell death by apoptosis, a process 
termed anoikis, the MTT assay, or any assay that relies on cells remaining 
adherent cannot be used as a measure of cell toxicity.  
In an attempt to quantify how much of liver failure plasma sample 3 toxicity was 
due to effects on cellular adhesion the initial experiment to assess the effect of 
cell toxicity was repeated.  HepG2 cell adhesion was increased by pre-coating 
96 well plates with collagen (see general methods) prior to plating.  The method 
was adapted by decreasing the vigour of washing steps, replacing 
tipping/flicking off with gentle aspiration and inspecting washings at each step 
to ensure no cells were lost.  Using this method the MTT assay was repeated. 
 
Results 
Having minimised the effects of changes in cellular adhesion it can be seen that 
there no significant variation in toxicity between liver failure plasma and normal 
plasma. 
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Figure 11.  MTT activity as an indirect measure of cell number for HepG2 cells 
incubated in different plasma samples on collagen coated plastic. 
 
1.21  TIME COURSE OF LOSS OF ADHESION 
Method  
To investigate the time course over which loss of adhesion occurred, 
experiments using non-collagen coated plastic and vigorous washing as in the 
original method (see appendix for general methods) were performed using acute 
liver failure plasma 3, but exposing HepG2cells for different time period prior to 
the measurement of MTT activity.  Photomigrographs prior to washing under 
phase at each time point are also shown. 
Results   
Upto and including time of exposure 360 minutes there was no statistical 
difference between MTT activity (as a marker of cell number) between normal 
plasma and liver failure plasma (LFP3).  From the time point 10 hours onwards 
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and inclusive there was a reduction in MTT activity in HepG2 cells exposed to 
acute liver failure plasma and an increase in MTT activity in HepG2 cells 
exposed to normal plasma.  This resulted in a marked reduction in MTT activity 
in cell number in acute liver failure plasma compared to that of normal plasma 
for each time point ≥14 hours (P≤0.005). 
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Figure 12.  Time course of MTT activity (as a marker of cell number) against 
time of exposure for HepG2 cells exposed to LFP 3 and normal plasma (control) 
** P ≤ 0.005 
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Figure 13. Photomicrograph of Hep G3 cells under phase contrast microscopy 
prior to washing, after exposure to Acute Liver Failure Plasma (LFP 3) for 
various times. A=15min. B=90min, C=150min, D=210min, E=360min, 
F=14hrs, G=20hrs, H=26hrs 
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The increase in MTT activity (cell number) in HepG2cells exposed to normal 
plasma over time most likely results from on-going proliferation of HepG2 cells.   
The reduction in MTT activity in Acute Liver failure Plasma represents loss of 
cell number by loss of adhesion or viability.  Figure 10 shows that although 
unattached the cells remain viable, confirming the loss is due to cell detachment 
not death.  The time course of loss of adhesion by Acute liver Failure plasma 
appears to become significant after 6 and before 14 hours of exposure.  
 
1.22  CONCLUSION 
Through this preliminary work we have identified that exposure to some 
samples of liver failure plasma results in changes in cellular adhesion and these 
factors begin to cause detachment of cells after 6 hours. 
Having eliminated the problem of cellular adhesion it can be seen that there is 
little variation of toxicity using the MTT assay and that attempts to isolate or 
identify toxins in liver failure plasma would be futile as there is no liver failure 
sample with significant toxicity.  The earlier experiments to isolate/physically 
characterise the toxin in liver failure plasma sample 3 were most likely 
isolating/physically characterising substances in liver failure plasma which 
affect cellular adhesion. 
On examining the original literature from which the concept of toxic molecules 
in Acute Liver Failure was developed, it was apparent that the methodology 
used in these experiments and duration of exposure to the liver failure plasma 
means that they too where vulnerable to the effects on cellular adhesion induced 
by exposure to liver failure plasma.  Hughes at al exposed primary rabbit 
hepatocytes to 20% liver failure plasma overnight, Anderson et al exposed 
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HepG2 cells to 10% liver failure plasma for 24 hours, McCloskey et al exposed 
HHY41cells to 100% liver failure plasma for 20 hours and Shi et al exposed 
HepG2cells to 10% plasma for 4 days.  There experiments describe reductions in 
viability by 25-40% compared to normal plasma but all the methods used 
assume cells are lost by death only and loss by detachment, although Shi et al 
did comment that changes in morphology and adhesion were seen. 
It seems intuitively correct that such large reductions in cell number would not 
be due to cell death, as it seems improbable that a substance so toxic, that at 
20% concentration it can induce cell death in 40% of hepatocytes after overnight 
exposure, would be compatible with survival of the donor. 
The question therefore remains if plasma from patients with Acute Liver Failure 
Plasma is toxic to hepatocytes. 
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CHAPTER 2:  DEVELOPING AN IN-VITRO MODEL TO 
INVESTIGATE THE EFFECTS OF LIVER FAILURE PLASMA ON 
HEPATOCYTES. 
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2.0  INTRODUCTION 
As indicated in the preliminary work in cheaper 1 the MTT test and other 
measures of cell number are insensitive methods of assessing the effects of 
substances such as liver failure plasma on immortalised hepatocyte cell lines.  If 
differences between individual liver failure plasma samples, differences over 
time within individuals or differences before and after therapeutic manoeuvres 
wish to be undertaken, a more sensitive method would be required. 
However in-vivo and in-vitro studies have suggested that substances in liver 
failure plasma are deleterious to primary non-human hepatocytes and hepatocyte 
cell lines (Anderson, Thabrew, & Hughes, 1999, Anilkumar, Ryan, Aslam, 
Poulsom, & Alison, 1997, Hughes, Cochrane, Thomson, Murray-Lyon, & 
Williams, 1976, Shi et al., 1998).  A robust reproducible in-vitro system is 
required to further study this phenomenon.  
 
The ideal requirements of such a system would be for it to: 
 Use Primary Human Hepatocytes rather than cell lines which by 
definition have deregulated life cycle pathways. 
 Not be affected by anti- or pro- proliferative effects of substances i.e. 
non-dividing cells 
 Sensitive 
 Specific 
 Reproducible 
 Would investigate a single biological process. 
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As discussed in chapter 1 there is an increasing body of evidence that suggests 
apoptosis may be a major factor in the pathogenesis of a number of liver 
diseases including acute liver failure.  10% acute liver failure serum has been 
shown to increase apoptosis to 3.8% and 8.4% after 24 and 48 hours 
respectively, compared to negligible amounts in normal plasma.  There are 
certainly a number of substances in plasma which are increased in liver failure 
which can induce apoptosis in hepatocytes, for example bile salts and cytokines.  
The aim was therefore to develop a robust in-vitro system for the study of the 
effects of liver failure plasma and substances within and their effects on 
apoptosis.  
 
 
2.1  CONFIRMING ACUTE LIVER FAILURE CAUSES HEPATOCYTE 
APOPTOSIS AND CALCULATING TIME COURSE OF EXPOSURE 
Initial experiments to assess whether liver failure plasma did induce apoptosis 
and to determine the time course of apoptosis were performed.  Initially using 
HepG2 cells due to their abundance and fluorescence staining of the activated 
effector Caspase, Caspase 3 using Caspatag
tm
.  This test utilises a 
carboxyfluorescein labelled caspase inhibitor. The inhibitor binds irreversibly to 
active caspases and is specific to activated Caspase 3 and can be used in live 
cells. 
 
Method 
HepG2 cells were trypsinised and seeded at a density of 33000/well on a 
collagen coated glass 8 chamber slide in 0.5ml of  complete Williams E medium 
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and left to adhere and proliferate for 24 hours. Medium was aspirated and 
replaced by 0.5ml of 100% liver failure plasma sample 3 and incubated for 0 
mins, 90 mins, 150 mins, 210 mins, 360 mins, 14 hours, 20 hours and 26 hours.  
Plasma was then removed and replaced substituted with 300uL serum free 
medium.  Caspase 3 staining was performed on live unfixed cells according to 
the protocol described in general methods.  Identical fields were then viewed 
under phase and fluorescence microscopy. 
Results 
Although only semi-quantitative, liver failure plasma did induce apoptosis in 
HepG2 cells as measured by activation of Caspase 3.  The Caspase 3 activity 
seemed to peak after 210 mins exposure and appeared to decline thereafter due 
to loss of cells presumably due to changes in cellular adhesion described earlier. 
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T=0 minutes phase     T=0 minutes Caspase 3 (green) 
 
T=210 minutes phase x20     T=210 minutes Caspase 3 
(green) 
 
Figure 14.  Photomicrographs of the same fields of HepG2 cells under phase 
and fluorescent microscopy (magnification x20) showing increased caspase 3 
activation (green) after 210 minutes exposure exposure compared to control, 0 
minute. 
 
Conclusion 
Caspase 3 activation appeared to occur on exposure to liver failure plasma and 
this appeared to peak after approximately 210 minute exposure.  After this time 
particularly after 14 hours total cell numbers were decreased either due to loss of 
adhesion or due to cell death and subsequent detachment.  To avoid difficulties 
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with cell loss it was decided to use 210 minutes as the period of exposure of 
hepatocytes to possible pro-apoptotic stimuli. 
 
2.2  POSITIVE CONTROL 
To develop a robust reliable system for measuring the effects of liver failure 
plasma on apoptosis it is necessary to develop a robust positive control.  
Commonly available substances that have been cited in the literature as 
predictable inducers of apoptosis in hepatocytes were tested.  Staurosporine (a 
protein kinase c inhibitor (Sigma S5921)), TNF-alpha, TGF-beta and Ethanol 
were all tested as previous literature suggests that all can induce hepatocyte 
apoptosis.   
Method 
For an initial rapid screen of toxicity, dose response curves were made for each 
of the test substances by incubating 40% confluent HepG2 cells plated 24 hours 
earlier on a collagen coated 96 well plate in 100uL of the test dose for 16 hours.  
The test substance was then gently aspirated and washed gently twice with 
serum free alpha-MEM.  An MTT test was then performed as described 
previously.  Staurosporine 100ug was dissolved in 100ul of DMSO and stored as 
a stock solution at 4ºC; it was then dissolved in medium at an appropriate 
concentration fresh for each experiment.  
Substances that induced significant cell death were further tested on HepG2 cell 
monolayers to ensure that the mechanism of toxicity was via inducing apoptosis 
and that the time course of that reaction was similar to the proposed time of 
exposure of plasma samples, by the following method.  Glass 8-chamber slides 
were coated with collagen (see general methods) and then seeded at a density of 
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66000/well in 0.5ml complete alpha-mem and incubated for 24 hours.  Test 
substances were then added and incubated for 4 hours.  The test substance was 
gently aspirated and the cell monolayer and fresh serum free medium added.  
Live cells were then stained for Caspase 3 technique (see general methods). 
Results 
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Figure 15.  Graph showing MTT activity as an indirect measure of cell number, 
for HepG2 cells exposed to different apoptosis inducing factors for 16 hours. 
 
These results suggested that Staurosporine 1uM was toxic and could therefore be 
a good positive control, as it resulted in significant loss of viable cells after 16 
hours.  Further study to investigate whether that loss of cell number was due to 
apoptosis, and to ensure the loss of cell number was due to loss of viability and 
not changes in adhesion, and the time course of the apoptotic process were 
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undertaken and confirmed Staurospaurine 1uM induced significant apoptosis in 
HepG2 cells over a time period of 4 hours (Fig 13). 
 
 
 
 
 
   
 
 
 
A. 
 
 
 
 
 
 
 
 
B. 
 
Figure 16.  Photomicrographs showing increase in Caspase 3 (green) activation 
in Hep G2 cells after exposure to (B) Staurosporine 1uM for 4 hours compared 
to control (A).  Nuclei counterstained with Hoescht (Blue) (magnification x40). 
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Conclusion 
Staurosporine cause significant apoptosis over an appropriate time course and 
was therefore used as a positive control in this in-vitro model. 
 
2.3  PRIMARY HUMAN HEPATOCYTES 
Since the aim was to develop an in-vitro system that accurately reflects the in-
vivo situation the ideal choice of cells was primary human hepatocytes.   
 
Methods 
Primary human hepatocytes were isolated according to the method described 
above (see general methods – isolation of primary human hepatocytes).  Having 
been counted and viability assessed using trypan-blue cell preparations with 
viability >95% were suspended in complete Williams E medium and seeded at a 
density of 66000 /well in a volume of 0.5ml on collagen coated glass 8 chamber 
slides (see general methods for collagen coating).   Cells were then treated with 
Staurosporine 1uM to ensure apoptosis could be induced. 
 
Results 
The results show in figure 14 demonstrate the large healthy adherent cells with 
bright blue nuclei under Hoescht staining (A) compared with the shrunken 
spherical apoptotic cells with dark blue nuclei with Hoescht staining  These 
apoptotic human cells have significant activation of Caspase 3 shown in green 
(B). 
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A. 
 
 
 
 
 
 
B.  
 
 
 
 
 
 
 
Figure 17.  The same fields of Primary human hepatocytes under phase 
superimposed with fluorescence stained with Hoescht stain (A) and active 
Caspase 3 (B) having been exposed to Staurosporine 1uM for 4 hours. 
 
The approach was therefore to use this model to investigate apoptosis induced 
after a period of 4 hours exposure in primary human hepatocytes by substances 
known to effect apoptosis in animal hepatocytes. 
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2.4   VALIDATION OF THE IN-VITRO MODEL IN THE ASSESSMENT 
OF WHETHER EPIDERMAL GROWTH FACTOR (EGF) AND 
HEPATOCYTE GROWTH  FACTOR (HGF) CAN PROTECT PRIMARY 
HUMAN HEPATOCYTES AGAINST FAS-LIGAND BINDING 
INDUCED APOPTOSIS 
 
As discussed earlier apoptosis is implicated in the pathogenesis of a number of 
human liver diseases, including acute liver failure (ALF) (Kasahara, Saitoh, & 
Nakamura, 2000), alcoholic Hepatitis (Ziol, Tepper, Lohez, Arcangeli, Ganne, 
Christidis, Trinchet, Beaugrand, Guillet, & Guettier, 2001), viral hepatitis 
(Rivero et al., 2002),(Nasir et al., 2000), Autoimmune Hepatitis (Masuichi et al., 
1999), Wilsons Disease (Strand et al., 1998), post liver transplantation (Memon 
et al, 2001) and toxin related liver injury (Sakamoto et al., 1998).  Although the 
mechanisms by which hepatocyte apoptosis is controlled are not yet fully 
defined in these pathological states (Schuchmann & Galle, 2001), Fas, a death 
receptor of the TNF supereceptor family, is highly expressed in normal liver 
(Pinkoski et al., 2000).  Binding of Fas by Fas-Ligand causes activation of a 
cascade of Caspase enzymes resulting in apoptosis (Nagata, 1996).  Fas 
knockout mice have hyperplastic livers suggesting Fas may be a key part of the 
hepatocyte apoptosis mechanism (Adachi et al., 1995).  In acute liver failure in 
humans the levels of death receptors and their ligands rise – there is increased 
Fas on hepatocytes (Hayashi & Mita, 1999, Rivero et al, 2002, Tagami et al., 
2003, Taieb et al., 1998), increased  Fas-Ligand (Fas-L) on lymphocytes and 
hepatocytes, elevated serum Fas-L and hepatic tumour necrosis factor (TNF-α), 
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TRIAL, tumour necrosis factor receptor 1, and TNF-related apoptosis-inducing 
ligand receptor DR5 expression (Mundt et al, 2003) and increased soluble Fas.  
Since a significant role of the Fas receptor pathway is implicated in the 
pathophysiology of acute liver failure, it was decided it would be an appropriate 
molecule to induce apoptosis to validate our in-vitro model. 
Understanding which factors regulate apoptosis in hepatocytes may assist in the 
identification of agents with therapeutic potential. Epidermal growth factor 
(EGF) has been shown to be protective against Fas-Ligand binding induced 
apoptosis in primary murine hepatocytes (Musallam et al., 2001), in TGF-ß 
induced apoptosis in fetal primary hepatocytes (Fabregat et al., 1996), and in rat 
hepatocytes (Roberts et al., 2000).  
The role of hepatocyte growth factor (HGF) is less clear, since whilst it is 
essential for normal liver growth and hepatocyte survival (Schmidt et al., 1995),  
in some circumstances HGF can be pro-apoptotic (Gohda et al., 1998) (Arakaki 
et al., 1998) (Conner et al., 1999).  HGF has been shown in-vivo in animal 
models to prevent endotoxin induced hepatic failure (Kosai et al., 1999), Fas-
induced fulminant hepatic failure (Kosai et al, 1999) and carbon tetrachloride 
induced liver injury (Xue et al., 2002), at least in part by reducing hepatocyte 
apoptosis.  One of the mechanisms that growth factors,  such as HGF, may 
inhibit apoptosis is via binding of the activated growth factor to death receptors 
sequestering them to prevent their aggregation and thus activation (Wang et al., 
2002); other mechanisms include interaction with anti-apoptotic proteins 
(Bardelli et al., 1996).  The different effects may depend on dose, cell type and 
species.   
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To validate this model our aim was to use the in-vitro system developed for 
studying apoptosis in primary human hepatocytes to evaluate the effect of EGF 
and HGF, both alone and in combination, in the protection of primary human 
hepatocytes against Fas-Ligand binding induced apoptosis.  Two methods of 
measuring apoptosis were used, Caspase 3 activity and TUNEL staining. 
 
Methods 
Primary human hepatocytes were isolated by collagen perfusion of segments of 
resected normal human liver (see general methods).  After washing, cells were 
plated on collagen coated glass slides in complete Williams E medium and 
incubated for 12 hours at 37ºC in 5%CO2 to allow cell attachment. Cell layers 
were washed vigorously to remove unattached cells and cellular debris, and 
incubated for 2 hours with human EGF at a concentration of 25ng/ml, HGF at 
50ng/ml, and a combination of EGF at 25ng/ml and HGF at 50ng/ml, or in 
complete medium alone.  After 2 hours Fas-Ligand (20ng/ml) was added and 
incubated for a further 4 hours for Caspase activation and 6 hours for TUNEL 
staining.   For measurement of Caspase 3 activation cells were lysed in situ and 
lysate activity measured using a substrate yielding a luminescent product 
(Caspase-glo 3/7, Promega, Madison,WI, USA) see general methods. 
For TUNEL staining cells were fixed and stained using Rhodamine labelled 
TUNEL (Apotag R&D systems Abingdon, UK) and Hoechst nuclear stain (see 
general methods). Slides were visualised under fluorescent microscopy with 
appropriate filters and then counted. Results were recorded as TUNEL positive 
cells as a percentage of total cells. 
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Statistical analysis was performed with results tested for normality using 
Gaussian distribution; parametric data were analysed using paired Student‘s t-
test and non-parametric data using Wilcoxon matched pairs test. 
 
Results 
Preliminary experiments showed exposure to Fas-Ligand at 20ng/ml induced 
similar levels of apoptosis to Staurosporine 1micmol/L.  Treatment with Fas-
ligand induced more apoptosis than control (P<0.005) (Figure 15).  EGF 
(P<0.05), HGF (P<0.05, and EGF and HGF combined (P<0.05) significantly 
reduced apoptosis compared to Fas-L alone as measured by both Caspase 3 
activation (Figure 16.) and TUNEL staining (Figure 17) graphs show means 
with standard error bars. 
 
Figure 18.  Photomicrograph showing increase in  apoptosis in primary human 
hepatocytes measured by TUNEL staining (pink) with Hoescht nuclear 
counterstain (blue) induced by Fas-Ligand 20ng/ml (B) compared with control 
(A).   
 
A. 
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Figure 19.  Protective effect of HGF, EGF and EGF and HGF in combination 
against Fas-L induced apoptosis as measured by Caspase 3 activity (Control= no 
pro-apoptotic stimulus, Fas-L= Fas-Ligand, LU luminescence units). 
 
 
Figure 20.  Protective effect of HGF, EGF and EGF and HGF in combination 
against Fas-L induced apoptosis as measured by TUNEL cell positivity 
(Control= no pro-apoptotic stimulus, Fas-L= Fas-Ligand). 
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Conclusion These results validated our model of apoptosis in primary human 
hepatocytes, which we have used in subsequent chapters.  In the next chapter we 
explored the effect of liver failure plasma on apoptosis using this model.  
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CHAPTER 3.  LIVER FAILURE PLASMA AND ITS EFFECTS ON 
APOPTOSIS AND CELL DEATH IN PRIMARY HUMAN 
HEPATOCYTES.  
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3.0  INTRODUCTION 
As discussed in chapter 1 Acute liver failure is associated with the accumulation 
of a wide range of potentially toxic substances within the circulation as a result 
both of failure of normal hepatic metabolism and generation from the inflamed 
liver itself.  As well as affecting other organs in the body giving rise to some of 
the clinical manifestations of this syndrome these toxins may themselves further 
damage the liver and inhibit liver regeneration, The processes involved in the 
pathophysiology of ongoing liver damage and regeneration are now being 
elucidated and this increased knowledge is leading to the generation of new 
therapies, and a better understanding of the mechanism of action of old ones.  
The aim of these therapies is to decrease hepatocyte loss and promote liver 
regeneration tipping the balance in favour of recovery (Fausto, 2000).  
Apoptosis appears to be a key process in the pathogenesis of some liver diseases 
and may in itself result in substantial hepatocyte loss.  In addition it may also be 
a key step in the generation of necrosis and fibrosis.  A number of animal 
models of liver failure have shown apoptotic cells appear very early in the 
course of liver damage, prior to the appearance of necrosis or significant 
symptoms, since most of the human tissue examined for apoptosis has occurred 
after the onset of liver failure it may be that the degree of apoptosis earlier in the 
disease process is underestimated (Ledda-Columbano et al., 1991).  Furthermore 
and somewhat surprisingly, the inhibition of apoptosis in some animal models of 
acute liver failure by specific apoptosis inhibitors results in the absence of both 
apoptosis and necrosis on liver histology as well as the attenuation of symptoms 
of liver failure and mortality (Cursio et al., 2000, Hoglen, Hirakawa, Fisher, 
Weeks, Srinivasan, Wong, Valentino, Tomaselli, Bai, Karanewsky, & Contreras, 
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2001, Jaeschke et al., 1998, Kim et al., 2000, Kunstle et al., 1997, Rodriguez et 
al., 1996).  This challenges traditional beliefs that apoptosis is a benign process 
leading to cell death without inflammation. Indeed phagocytosis of apoptotic 
bodies by kupffer cells and infiltrating neutrophils and macrophages results in 
release of cytokines including TNF-alpha, TGF-β, IL-6 and IL-1β which may 
result in further apoptosis, increased inflammatory infiltrate and liver fibrosis 
(Gressner et al., 2002).  Thus either by generating too much phagocytosis of 
apoptotic bodies or by overwhelming the processes that remove apoptotic bodies 
resulting in the accumulation of extracellular debris, secondary necrosis will 
occur.  Apoptosis may therefore be an essential event in the initiation and 
perpetuation of liver failure and a target for therapeutic manipulation. 
Previous in-vitro studies using hepatocyte derived cell lines (Anderson, 
Thabrew, & Hughes, 1999, McCloskey, Tootle, Selden, Larsen, Roberts, & 
Hodgson, 2002, Shi et al, 1998), primary non-human hepatocytes (Hughes, 
Cochrane, Thomson, Murray-Lyon, & Williams, 1976)) and foetal hepatocytes 
have shown that plasma/serum from patients with Acute Liver Failure is toxic, 
resulting in decreased synthetic function, excretory capacity, cell proliferation, 
cellular adhesion and viability compared to normal plasma/serum.  A recently 
published study adding 20% vol/vol serum to primary human hepatocytes 
suggested that whilst fulminant hepatic failure serum can induce apoptosis it 
does not do so until after at least 24 hours exposure and these effects may be 
secondary to changes in adhesion mediated by the β1-integrin pathway.   
Since plasma represents the internal milieu in which the hepatocytes are situated 
we hypothesised that substances within liver failure plasma may induce 
apoptosis in hepatocytes and may represent a mechanism of perpetuation of liver 
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damage in acute liver failure.  Apoptosis induced by exposure to acute liver 
failure plasma also represents a significant hurdle to hepatocyte transplantation 
and bioartificial liver function. 
Previously demonstrated effects of Acute Liver Failure Plasma have relied on 
the use of either tumour cell lines or non-human primary human hepatocytes.  
Whilst these studies have been informative, the use of cell lines derived from 
malignant cells, which by definition have dysregulation of apoptosis, is 
inappropriate for the study of apoptosis in ―benign‖ disease, and the use of non-
human primary hepatocytes again raises difficulties regarding cross-species 
effects.  Having established a robust reliable in-vitro system for demonstrating 
and quantifying apoptotic effects we examined the effects of exposure of 
primary human hepatocytes to 100% vol/vol plasma from patients with acute 
liver failure (ALFP) on apoptosis.  We aimed to establish if Acute Liver Failure 
Plasma (ALFP) induces apoptosis to a greater extent than plasma from normal 
controls as an early event independent of cellular adhesion. 
The effect of plasma from patients with acutely-decompensated chronic liver 
disease on hepatocytes has not previously been established.  Similarly to Acute 
Liver Failure there are increased quantities of a number of substances known to 
be capable of inducing hepatocyte apoptosis in the plasma of patients with 
chronic liver disease including cytokines, lipopolysacharide, and bile salts.  The 
nature of these compounds may differ from that of acute liver failure in that the 
picture of liver dysfunction may be much more cholestatic, therefore some of the 
accumulated compounds have undergone metabolism by hepatocytes and as a 
consequence be less toxic or conversely substances such as bile salts may 
accumulate to much higher levels.  Our second aim was therefore to investigate 
 113 
if plasma from patients with acutely-decompensated chronic liver disease 
induces apoptosis in primary human hepatocytes.     
Our third aim was to investigate if there was any correlation between other 
markers of liver injury/function and quantity of apoptosis induced for a given 
sample of plasma.  For example if the apoptosis inducing agent accumulated as a 
failure of excretion then other markers of cholestasis, Bilirubin, Alkaline 
Phosphatase, or gamma GT may correlate with apoptosis inducing ability.  If 
apoptosis is the major initiator of liver injury then apoptosis inducing ability 
should correlate with markers of hepatocyte injury such as ALT, AST or if 
apoptosis was induced by an albumin bound toxin then serum albumin may 
negatively correlate with apoptosis inducing ability as it is only unbound 
substances that are biologically active.  Identifying such correlations may be 
important in developing new therapeutic strategies for the treatment of liver 
failure e.g. MARS removes albumin bound toxins that accumulate in liver 
failure, IV albumin will increase binding of unbound substances, a bioartificial 
liver would increase metabolism of possible toxic substances and produce 
substances which inhibit apoptosis, and Caspase inhibitors may decrease liver 
injury. 
Our final aim was to investigate via which pathways Liver Failure Plasma 
induces apoptosis in hepatocytes.  As discussed in Chapter 1 apoptosis can be 
initiated and executed through a number of different pathways (e.g. extrinsic 
(death receptor) pathway and intrinsic (mitochondrial) pathway, involving 
distinct though overlapping intracellular enzymes and proteases notably 
caspases (Fig.18).  Inhibition of the enzyme activity of individual Caspases by 
small selective peptides (caspase inhibitors) provide tools to investigate the 
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intracellular pathways that lead to apoptosis, giving information on the possible 
substances in the plasma involved in the initiation of apoptosis as well as 
offering therapeutic potential. 
 
 
 
Figure 21..   Diagram outlining Caspase pathways in Apoptosis. 
Picture courtesy of R&D Systems 
 
 
Using our in-vitro system and inhibitors of Caspase3 (common terminal effector 
in both pathways), Caspase8 (initiator in death receptor pathway) and Caspase9 
(activated in mitochondrial pathway) the pathway by which apoptosis is initiated 
by liver failure plasma was determined.   
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3.1  MATERIALS & METHODS 
Primary human hepatocytes from normal liver resections were isolated by 
Collagenase perfusion (See appendix * for detailed method & suppliers) and 
plated in complete Williams E medium (See appendix for recipe & suppliers) at 
a density of 50 000/well in 100uL of medium on collagen coated sterile 96-well 
tissue culture plates; white sided plates were used for luminescence based 
Caspase 3 assay and standard clear sided for measurement of cell viability by 
MTT activity (See appendix for recipe & suppliers).  Cells were plated on sterile 
Collagen-coated glass eight-chamber slides at a density of 250000/well in 0.5ml 
of complete Williams E medium.  Cells were incubated at 37ºC in 
5%CO2/95%Air overnight to allow attachment and were then thoroughly washed 
three times with medium to remove unattached cells and cell debris.  Cells were 
exposed either to 100% Liver Failure Plasma (LFP) or 100% normal plasma; 
complete Williams E medium was used as a negative control; and both Fas-
Ligand 20ng/ml in complete Williams E medium and Staurosporine 1uM in 
complete medium were used as a positive controls.    
Measurement of Caspase 3 activation.  For measurement of Caspase 3 
activation 50uL of test substance was added/well of a white sided 96-well plate 
in triplicate and incubated for 4 hours in 5%CO2/95%Air at 37ºC.  A 4 hour 
exposure period was chosen as previous experiments with HepG2 cells (see 
chapter 3) had shown that this represented adequate time for initiation of 
Caspase activity and preceded any effects on cellular adhesion.  After exposure 
test plasma was removed and cell monolayers gently washed before the addition 
of 25uL of sterile PBS. Caspase 3 activity was measured enzymatically using a 
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substrate that produces a luminescent product (Fig) (Caspase-glo 3/7, Promega) 
(Figure 18).   
 
                    
Figure  22.  Schematic of luminescent reaction in Caspase glo3/7. 
 
Addition of an equal volume of reagent (25uL/well) results in in-situ cell lysis 
and also contains a substrate for Caspase 3, the cleavage of DEVD (Aspartic 
acid -Glutamic acid – Valine – Aspartic acid) from this substrate produces a 
product that is a substrate for Luciferase (also in the reagent) resulting in the 
generation of luminescence, thus luminescent activity is directly proportional to 
Caspase 3 activity.  Appropriate blanks of PBS (no cells) were subtracted from 
readings to eliminate any effects due to background luminescence.  After 
addition of the reagent the 96-well plates were incubated and gently agitated for 
1 hour at room temperature.  Light emission per well was recorded over 1 
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second.  Luminescence readings in light units (LU) are directly proportional to 
Caspase 3 activity per well.  Since the method is performed in-situ and 
hepatocytes were plated at identical densities luminescence readings within each 
experiment are directly comparable. 
TUNEL staining.  Cells on collagen-coated 8-chamber glass slides were 
exposed to test plasma/medium/control for 4 hours.  Plasma was gently removed 
and cell monolayers were gently washed with PBS three times.  Cells were then 
fixed and stained using Rhodamine labelled TUNEL and Hoechst nuclear 
counterstain (Apotag R&D Systems) (see appendix).  Cells were visualised 
under high power (magnification x40) fluorescent microscopy with appropriate 
filters and counted.  A minimum of 1000 cells/well were counted.  Results were 
recorded as TUNEL positive cells as a % of total cells. 
MTT activity.  MTT activity was used as a measure of cell viability.  Cells in 
96-well plates were exposed to test plasma for 16 hours following which cells 
were washed three times, 50μL of the tetrazolium salt, MTT (0.75mg/ml in 
PBS), was added to each well and the plates incubated at 37
o
C for 3 hours in the 
dark.  Excess MTT solution was then flicked off leaving the purple granules of 
formazan product within the cells attached to the bottom of the well.  To 
solubilise the formazan product 100μL/well of 0.004M Hydrochloric acid in iso-
propranol was added.  The 96-well plate, wrapped in clingfilm to prevent 
evaporation, was agitated on a platform shaker for 30 minutes to ensure 
complete dissolution of the formazan product.  The optical density at 550nm was 
read by an automated plate reader.  Optical density is therefore proportional to 
live cell number.   
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Each experiment was repeated on at least three separate occasions each time 
using hepatocytes prepared from a different liver resection in an attempt to 
eliminate individual variation in hepatocyte susceptibility.  Results shown are 
representative of all experiments.   
Plasma Samples 
Heparinised plasma from 15 individuals with acute liver failure due to various 
aetiologies and severity (Table 1), 31 patients with acutely-decompensated 
chronic liver disease of various aetiology and severity (Table 2), and 4 normal 
controls, was acquired and stored at -20
o
C.  In patients with acute liver failure 
due to paracetamol overdose samples were taken after a minimum of 48 hours 
after ingestion by which time Paracetamol was undetectable in the plasma.   
Subjects (or if unable their advocates) gave informed consent for the acquisition 
and experimental use of tissue samples in accordance with local ethics 
committee guidelines.  Liver function tests were measured using standard 
laboratory based methods by the clinical biochemistry department. 
Having confirmed data had a Gaussian distribution, data was subsequently 
analysed for statistical significance using a Student‘s t-test.  To investigate the 
relationship between clinical parameters and apoptosis/cell viability, linear 
regression and correlation analyses were performed. 
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Table 3- Acute Liver Failure plasma. 
ID Age S
e
x 
Aetiology Liver & Renal Function 
    Ur 
 
Cr B 
I 
L 
A 
L 
P 
A 
S 
T 
A 
L 
T 
G 
G 
T 
T 
P 
R 
A 
L 
B 
 
1 
 
32 
 
M 
 
POD 
 
5.3 
 
525 
 
77 
 
69 
 
99 
 
411 
 
44 
 
44 
 
28 
 
2 
 
51 
 
M 
 
POD 
 
16.1 
 
150 
 
188 
 
94 
 
357 
 
668 
 
281 
 
34 
 
24 
 
3 
 
47 
 
F 
 
Hepatitis Non A-E 
 
 
12.2 
 
213 
 
29 
 
60 
 
2427 
 
3058 
 
32 
 
38 
 
34 
 
4 
 
45 
 
F 
 
POD 
 
3.8 
 
252 
 
248 
 
61 
 
329 
 
66 
 
11 
 
37 
 
27 
 
5 
 
34 
 
M 
 
POD 
 
2.8 
 
117 
 
206 
 
34 
 
5.0 
 
6.0 
 
48 
 
48 
 
26 
 
12 
 
27 
 
M 
 
Alcoholic Hepatitis 
 
27.6 
 
278 
 
487 
 
252 
 
51 
 
91 
 
390 
 
43 
 
26 
 
14 
 
34 
 
M 
 
Hepatitis Non A-E 
 
5.2 
 
87 
 
162 
 
172 
 
248 
 
274 
 
426 
 
 
72 
 
37 
 
22 
 
51 
 
M 
 
POD 
 
26.4 
 
633 
 
544 
 
123 
 
42 
 
62 
 
107 
 
54 
 
31 
 
25 
 
72 
 
M 
 
Hepatitis Non A-E 
 
11.3 
 
171 
 
256 
 
374 
 
308 
 
194 
 
126 
 
65 
 
25 
 
38 
 
25 
 
M 
 
POD 
 
6.2 
 
97 
 
52 
 
98 
 
9441 
 
3930 
 
186 
 
 
45 
 
20 
 
39 
 
48 
 
F 
 
POD 
 
11.2 
 
206 
 
40 
 
89 
 
687 
 
2362 
 
154 
 
30 
 
12 
 
87 
 
38 
 
F 
 
 
Hepatitis Non A-E 
 
 
4.2 
 
 
157 
 
439 
 
263 
 
405 
 
 
229 
 
141 
 
 
64 
 
23 
 
 
92 
 
28 
 
F 
 
Hepatitis Non A-E 
 
 
3 
 
167 
 
484 
 
314 
 
358 
 
188 
 
133 
 
45 
 
20 
 
99 
 
22 
 
M 
 
POD 
 
8.3 
 
167 
 
141 
 
41 
 
142 
 
163 
 
193 
 
49 
 
21 
 
52 
 
42 
 
F 
 
 
Wilsons Disease 
 
23.7 
 
237 
 
825 
 
26 
 
109 
 
52 
 
31 
 
57 
 
29 
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Table 4-Chronic liver disease patients. 
ID Age S
e
x 
Aetiology Liver & Renal Function 
 
 
 
 
 
 
 Ur 
 
Cr B 
I 
L 
A 
L 
P 
A 
S 
T 
A 
L 
T 
G 
G 
T 
T 
P 
R 
A 
L 
B 
 
7 
 
59 
 
M 
Acutely 
decompensated 
alcoholic Cirrhosis 
 
14.1 
 
173 
 
441 
 
196 
 
173 
 
129 
 
61 
 
52 
 
28 
 
9 
 
42 
 
M 
 
 
Alcoholic Hepatitis 
 
12.1 
 
173 
 
569 
 
147 
 
81 
 
32 
 
104 
 
41 
 
24 
 
10 
 
45 
 
F 
 
Decompensated PBC 
 
16.8 
 
428 
 
207 
 
763 
 
96 
 
69 
 
248 
 
58 
 
27 
 
11 
 
44 
 
F 
Decompensated 
Autoimmune  
Hepatitis 
 
4.0 
 
141 
 
517 
 
87 
 
249 
 
181 
 
294 
 
50 
 
33 
 
12 
 
27 
 
F 
 
Alcoholic Hepatitis 
 
27.6 
 
278 
 
487 
 
252 
 
51 
 
91 
 
390 
 
43 
 
26 
 
15 
 
58 
 
M 
Acutely 
decompensated 
alcoholic Cirrhosis 
 
7.1 
 
132 
 
351 
 
158 
 
51 
 
46 
 
16 
 
60 
 
30 
 
16 
 
50 
 
M 
Acutely 
decompensated 
alcoholic Cirrhosis 
 
8.5 
 
155 
 
358 
 
91 
 
117 
 
42 
 
106 
 
 
51 
 
25 
 
18 
 
61 
 
M 
Acutely 
decompensated 
alcoholic Cirrhosis 
 
7.8 
 
136 
 
118 
 
267 
 
69 
 
34 
 
628 
 
59 
 
29 
 
19 
 
58 
 
M 
Acutely 
decompensated 
alcoholic Cirrhosis 
 
4.8 
 
115 
 
354 
 
431 
 
176 
 
107 
 
164 
 
58 
 
22 
 
21 
 
52 
 
F 
Acutely 
decompensated 
alcoholic Cirrhosis 
 
23 
 
245 
 
135 
 
901 
 
39 
 
55 
 
758 
 
48 
 
25 
 
23 
 
44 
 
M 
Acutely 
decompensated 
alcoholic Cirrhosis 
 
3.2 
 
132 
 
400 
 
212 
 
158 
 
83 
 
288 
 
45 
 
22 
 
24 
 
48 
 
F 
 
Decompensated PBC 
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3.2  RESULTS 
Acute Liver Failure Plasma 
Primary human hepatocytes showed increased numbers of apoptotic cells (as 
demonstrated by TUNEL staining (Fig 3) after exposure to Acute Liver Failure 
Plasma (LFP) compared to normal plasma.   
 
This was confirmed by the demonstration of significantly increased Caspase 3 
activity in primary human hepatocytes exposed to liver failure plasma compared 
to normal plasma (Fig. 20). 
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Figure 23.  Caspase 3 activation in primary human hepatocytes exposed to 
samples of acute liver failure plasma (green n=15) and normal plasma (red n=4). 
 
 
 
 
 
 
 
 
 
 
 
Figure 24.  Mean (%) total primary human hepatocytes TUNEL +ve after 
exposure to samples of acute liver failure plasma (green n=15) and normal 
plasma (red n=4). 
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There was significant variation in quantity of apoptosis between individual 
samples of acute liver failure plasma with nine of the fifteen samples exhibiting 
significantly more apoptosis, two of the samples significantly less and four of 
the samples no difference in the amount of apoptosis as measured by Caspase 3 
activation compared to the mean for normal controls. 
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Figure 25.   Percentage cells TUNEL +ve after exposure to samples of acute 
liver failure plasma (green) and normal plasma (red) 
LF
P 
1
LF
P 
2
LF
P 
3
LF
P 
4
LF
P 
5
LF
P1
2
LF
P1
4
LF
P2
2
LF
P2
5
LF
P3
8
LF
P3
9
LF
P8
7
LF
P9
2
LF
P9
9
LF
P 
52
N
P1
N
P2
N
P3
N
P4
0
1000
2000
3000
4000
5000
6000
7000
8000
*
** **
*
* * *
*
* *
* Sig. > mean for normal plasma p<0.05
** Sig. < mean for normal plasma p<0.05
*
C
a
sp
a
se
 3
 a
ct
iv
a
ti
o
n
 (
L
U
)
 Figure 26.  Caspase 3 activation in primary human hepatocytes exposed to 
samples of acute liver failure plasma (green) and normal plasma (red). 
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Quantification of apoptosis by TUNEL staining and by measurement of Caspase 
3 activity showed a good correlation Pearsons r = 0.6150, p=0.0051.  This 
confirms that both methods are reliable in the detection of apoptosis. 
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Figure 27.  Correlation between TUNEL cell positivity and Caspase 3 activity 
in primary human hepatocytes exposed to liver failure plasma. 
 
 
Clinico-Pathological correlates - Acute Liver Failure Plasma 
There was no correlation between amount of apoptosis induced in hepatocytes 
by exposure to acute liver failure plasma measured either by Caspase 3 
activation or TUNEL staining and markers of cholestasis (Bilirubin, ALP, 
GGT), hepatocellular injury (AST, ALT) or serum albumin.  
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Caspase 3 activation Vs ALP
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Figure 28.  Clinico-Pathological correlates - Acute Liver Failure Plasma 
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Chronic Liver Disease Plasma 
Unlike Acute liver failure plasma, plasma from patients with chronic liver 
disease did not induce significantly more apoptosis than normal plasma as 
measured by TUNEL cell positivity or Caspase 3 activity.  However both liver 
failure plasma and normal plasma showed significantly reduced apoptosis 
compared to medium.  Positive controls Fas-Ligand and Staurosporine showed 
significant increases in apoptosis demonstrating that the failure to demonstrate 
any difference between normal plasma and chronic liver disease plasma was not 
due to technical failure. 
Again there was large variability in apoptotic responses between individual 
chronic liver failure plasma samples and some samples did induce increased 
apoptosis whilst others decreased apoptosis (Figure 28.).  
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Figure 29.  Mean TUNEL cell positivity in primary human hepatocytes exposed 
to chronic liver failure plasma n=31 (purple),normal plasma n=4 (red) and 
controls (yellow). 
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Figure 30.  Mean Caspase 3 activation in primary human hepatocytes exposed 
to chronic liver failure plasma n=31 (purple),normal plasma n=4 (red) and 
controls (yellow). 
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Figure 31.  TUNEL cell positivity for primary human hepatocytes exposed to 
samples of acute liver failure plasma (green) and normal plasma (red) 
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Figure 32.  Caspase 3 activation in primary human hepatocytes exposed to 
samples of acute liver failure plasma (green) and normal plasma (red) 
 
As with previous experiments there was good correlation between apoptosis as 
measured with TUNEL and Caspase 3 activity.   
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Figure 33.  Correlation between Caspase 3 activation and percentage cells 
TUNEL positive for chronic liver failure plasma. 
 
 
 
Clinico-pathological correlates for chronic liver failure plasma 
There was no correlation with markers of liver injury, cholestasis, renal function 
or synthetic function and apoptosis induced by plasma from patients with 
chronic liver disease. 
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Figure 34. Clinico-pathological correlates for chronic liver failure plasma. 
 
 
As with acute liver failure plasma chronic liver disease plasma showed no 
association of cell viability with markers of liver injury, cholestasis, renal 
function or synthetic function.  
 
 
 
3.3  CASPASE INHIBITORS 
Acute Liver Failure plasma samples that had been shown to increase hepatocyte 
apoptosis were used to assess the effect of Caspase inhibitors. 
 
Materials & Methods  
Caspase inhibitors were purchased from R&D Systems and stored at -20C until 
use.  Having been solubilised in DMSO according to manufacturers‘ instructions 
a solution of 100-fold the final required strength in Williams E medium (no 
additives) was prepared.  DMSO at the same concentration in Williams E was 
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used as control (no inhibitor) to eliminate the effects of DMSO on apoptosis. 
Caspase inhibitors or control were diluted 1:100 with plasma, mixed thoroughly 
and applied to cell layers for 4 hours before TUNEL analysis as before. A 
Caspase 3 inhibitor Z-VAD-FMK (z-Valine – Alanine – Aspartic Acid- 
fluoromethylketone) (C3I) (20μMol), a Caspase 8 inhibitor Z-IETD-FMK (z-
Isoleucine - Glutamic Acid - Threonine – Aspartic Acid – flouromethylketone) 
(C8I) (20μMol), and a Caspase 9 inhibitor Z-LEHD-FMK (z-Leucine – 
Glutamic Acid – Histidine – Aspartic Acid) (C9I) (20 μMol) were all used at 
final concentrations specified.  For experiments with Caspase inhibitors Caspase 
3 activity analysis of cell layers was performed after removal of plasma and 
washing thrice with sterile PBS to remove any Caspase inhibitor which may 
interfere with the assay.  Data were tested for statistical significance using a 
paired student t-test.  
Results 
The increase in apoptosis induced by Acute liver failure plasma (n=9) measured 
by both % cells TUNEL positive and increased Caspase 3 activity was 
significantly inhibited by the presence Caspase 3, and Caspase 8 inhibitors but 
not by a Caspase 9 inhibitor.  
 
Table 5.  Apoptisis induced by Acute Liver Failure Plasma in the presence of 
Caspase 3, Caspase 8 and Caspase 9 inhibitors. 
 
 
Normal 
Plasma 
LFP LFP+Casp 3 
inhibitor 
LFP+Casp 8 
inhibitor 
LFP+Casp 
9 inhibitor 
Caspase3 
activity(LU) 
3426 
+/-520 
p<0.05 
6145 
+/-494 
4140 
+/-228 
p<0.01 
5187 
+/-516 
p<0.01 
5332 
+/-223 
p=0.10 
TUNEL+ve 
Cells % 
3.9 
+/-0.44 
p<0.05 
9.4 
+/-0.49 
4.9 
+/-0.25 
p<0.01 
5.8 
+/-0.43 
p<0.01 
7.0 
+/-0.88 
p=0.07 
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Figure 35.  Percentage cells TUNEL positive for primary human hepatocytes 
incubated in Acute Liver Failure Plasma +/-Caspase inhibitors 
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Figure 36.  Caspase 3 activity (LU) for primary human hepatocytes incubated in 
Acute Liver Failure Plasma +/-Caspase inhibitors 
 
Discussion 
The presence of Caspase 3 inhibitors significantly inhibited apoptosis.  Caspase 
3 is an effector caspase utilised by both intrinsic and extrinsic pathways.  
Caspase 8 is the major caspase in the propagation of signals from cell surface 
death receptors to effector caspases; the protective effect of Caspase 8 inhibitors 
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suggests that the toxic substances in liver failure plasma that induce apoptosis in 
hepatocytes do so by activation of cell surface death receptors.  Caspase 3 and 8 
inhibitors may therefore have therapeutic potential in acute liver failure.  
Caspase 9 inhibition did not significantly inhibit apoptosis although there was a 
trend towards a reduction.  This is may be due to the inhibition of Caspase 9 
activation downstream of Caspase 3 activation and cytochrome c release.  
Caspase 9 is activated by cytochrome c release and forms part of the amplifying 
signal after initiation of apoptosis. 
In summary there are substances in acute liver failure plasma (but not in chronic 
liver failure plasma which induce apoptosis in primary human hepatocytes via a 
Caspase 8 dependent pathway.  Further experiments were undertaken to define 
the physico-chemical properties of the molecule. 
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3.4  DOSE RESPONSE CURVES  
Dose response curves of normal and acute liver failure plasma mix were 
constructed having diluted plasma vol/vol with complete Williams E medium.  
Heat inactivated fetal calf serum was used as a control.  Paradoxically both liver 
failure plasma and normal plasma significantly decrease the Caspase 3 activity 
they induce as they become more concentrated i.e. the exact opposite of the 
expected curve for a toxic substance.  This interesting finding is consistent with 
the previous work in HepG2 cells (chapter 2) which showed that human plasma 
from either normal controls or liver failure patients resulted in improved cell 
viability compared with medium.  Also at 100% vol/vol plasma the liver failure 
plasma induces more caspase activity than normal plasma as in previous 
experiments.   
Why human plasma is more effective at promoting hepatocyte survival is 
unknown, but the presence of either heat labile (inactivated in FCS) or species 
specific protective factors are a possibility. 
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Figure 37.  Caspase 3 activity in primary human hepatocytes after exposure to 
plasmas diluted with complete medium (red=normal plasma, green=liver failure 
plasma). 
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3.5  HEAT INACTIVATION OF ACUTE LIVER FAILURE PLASMA 
Earlier experiments demonstrated that Acute Liver Failure plasma increased 
apoptosis in hepatocytes compared to normal plasma. This is consistent with 
experimental work from other groups using rat hepatocytes and cell lines, and 
has been the main evidence for suggesting that there are toxic substances within 
acute liver failure plasma.  However both normal plasma and liver failure 
plasma were better for cells than Complete Williams E medium or 100% FCS 
(heat inactivated).  An alternative suggestion could therefore be that there are 
substances within human plasma that are protective for hepatocyte cell death and 
that Acute Liver Failure contains less of these substances than normal plasma.  
All previous published work used normal plasma as control rather than 
medium/FCS.  If there was a heat labile toxic substance within liver failure 
plasma we would expect that heat activating would result in decreased Caspase 
3 activation, whereas if plasma contained heat labile protective factors then we 
would expect that heat inactivation would result in increased Caspase 3 
activation.  This section explores these two alternatives. 
Materials & Methods 
Human plasma was heat inactivated by warming to 56ºC in a water bath for 30 
mins.  Heat inactivated plasma and normal plasma was then applied to 
hepatocytes in 96 well plates and after 4 hours Caspase 3 activity measured as 
previously described. 
Results 
Heat inactivation of plasma resulted in a significant increase in Caspase 3 
activity in hepatocytes compared with untreated control plasma in 3 of the 4 
samples of acute liver failure plasma and in all the samples of normal plasma.  It 
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can be seen that the increase in apoptosis induced by heat inactivation was far 
greater for normal plasma than liver failure plasma.  Interestingly once heat 
inactivated apoptosis induced by 100% vol/vol human plasma was not 
significantly different from apoptosis induced by 100% vol/vol heat inactivated 
FCS.  Suggesting that once heat inactivated there is no cross species effects. 
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Figure 38.  Heat inactivation of Acute Liver Failure Plasma (LFP1, LFP 5, 
LFP99) and Normal Plasma (CS, Ali) 
 
Discussion 
These results suggest that there may be a heat labile protective factor in human 
plasma and that this protective factor is diminished in acute liver failure.  So we 
investigated this possibility in the following section. 
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3.6  PROTECTIVE EFFECTS OF HUMAN PLASMA 
To demonstrate if there are protective factors in human plasma we investigated 
whether human plasma attenuated apoptosis induced by Fas-Ligand or 
Staurosporine; and in addition if normal plasma attenuated the apoptosis to a 
greater extent than acute liver failure plasma. 
Material & Methods  
Fas-Ligand stocks of 400ng/ml, 200ng/ml, 100ng/ml, 20ng/ml, and 2ng/ml in 
Complete Williams E were made and 20uL added to 380uL of plasma resulting 
in a 1:20 dilution; 20uL of Complete Williams E was added to plasma for 
control ―No-Fas-Ligand‖.  Staurosporine stocks of 20uM, 10uM, 5uM, 1uM and 
0.1uM were made in Complete Williams E and 20uL was added to 380uL of 
plasma resulting in a 1:20 dilution, 20uL of Complete Williams E was added to 
plasma for control (no staurosporine). After thorough mixing Fas-Ligand or 
Staurosporine in plasma was applied to hepatocytes for 4 hours and Caspase 3 
activity measured as described previously  
Results 
Neither acute liver failure plasma, normal plasma nor FCS attenuated apoptosis 
induced by Fas-ligand as evidenced by the similar slope of the curves; the 
different position of the curves is due to the different starting point of the curves 
due to the differences in plasmas as demonstrated in previous experiments.  Both 
liver failure plasma and normal plasma seem to attenuate apoptosis induced by 
Staurosporine with normal plasma exerting a greater protective effect than acute 
liver failure plasma.   
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Figure 39.  Caspase 3 activity in primary human hepatocytes exposed to 
increasing concentrations of Fas-L diluted in either medium (pink), FCS 
(yellow), normal plasma (red), or liver failure plasma (green). 
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Figure 40.  Dose response curves for Staurosporine diluted in acute liver failure 
plasma, normal plasma, FCS and Complete Williams E medium 
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3.7  DISCUSSION 
Many substances which are potentially toxic are increased in the circulation of 
patients with acute liver failure plasma and other possibly protective factors are 
reduced.   
These substances are of importance as in theory they may perpetuate cell loss in 
liver failure, affect transplanted liver cells (both in organ transplantation, and 
stem cell transplantation and they may affect the function of a bioartificial 
device.  As a result there has been much research aiming to identify toxic 
substances in-vivo and to identify methods of reducing these toxic effects. 
Theoretically fractionation and purification of plasma could identify the 
molecules involved in liver failure plasma toxicity, but due to the complex 
nature of plasma, the possible interplay of perhaps more than one toxic 
substance, the decrease in possible protective factors and the use of a biological 
assay as an end-point requiring proteins not to be denatured and not to be 
contaminated with toxic substances arising from contamination during 
processing, this is a formidable task.  An alternative is to test the substances 
known to be increased in acute liver failure independently dissolving them in 
plasma and observing their effects (Hughes, Cochrane, Thomson, Murray-Lyon, 
& Williams, 1976); again this is difficult as plasma contains a vast array of 
substances many of which are unidentified and these substances may have 
additive or diminutive effects when used in combination.  Thus to test all known 
substances in all combinations again becomes an impossible task.   
A more pragmatic approach is not to try to identify these toxins but to 
investigate their effects and to attempt to identify the mechanism of action of 
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toxicity and thus therapeutic strategies.  The design of such studies is however 
fraught with difficulties and compromises. 
Previously used models have shown that plasma/serum from patients with acute 
liver plasma is toxic to cell lines and primary non-human hepatocytes.  These 
vitro studies are limited by several factors.  The first is that the demonstration of 
in-vitro toxicity of a purified substance applied in tissue culture medium does 
not necessarily translate to in-vivo toxicity as the presence of other factors in 
plasma (many of which are unidentified) may negate such toxicity.   
The second is the choice of cells used in any in-vitro system.   Tumour cell lines 
whilst readily available have by definition dysregulated apoptosis and are 
therefore not suitable as a model of apoptosis in non-neoplastic disease.  An 
alternative is to use primary non-human hepatocytes, however, even human 
plasma from normal individuals has been shown to have deleterious effects on 
non-human cell viability, possibly due to cross species effects.  In addition there 
are large variations in activity of specific hepatic metabolic pathways, 
particularly via the cytochrome p450 system between species again making 
applicability of results to human disease difficult.   
A further difficulty is whether to use serum or plasma.  Previous studies have 
mainly used serum, this contains many substances released from components of 
blood by activation of the coagulation cascade and therefore does not represent 
the internal milieu of the patients‘ hepatocytes.  Plasma would therefore appear 
to be a better choice particularly since hepatocytes in a bioartificial liver would 
be exposed to this.  The plasma used was not heat inactivated as this would 
destroy many of the substances of interest but as a consequence it contains 
proteins from the complement cascade that can directly lyse cells in the absence 
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of any cellular immune component.  For this reason the ideal choice of cell is 
human hepatocytes from a blood group O donor.  This reduces effects due to 
major incompatibility of blood group however minor effects due to antibodies in 
plasma activating complement cascade due to individual cross-reactions between 
plasma and hepatocytes cannot be entirely eliminated.  A final difficulty noted 
by ourselves (unpublished) and others (Shi, Gaylor, Cousins, Plevris, Hayes, & 
Grant, 1998) is that acute liver failure plasma may have effects on cellular 
adhesion resulting in cell detachment after prolonged exposure.  Studies should 
ideally either express results standardised for cell number or expose cells for 
shorter durations, otherwise over-estimates of toxic effects due to loss of cells by 
detachment may occur.   
We have developed a robust in-vitro model for the study of apoptosis in primary 
adult human hepatocytes using two different methods for quantifying apoptosis, 
TUNEL staining and Caspase 3. The two methods showed a good correlation 
suggesting that both methods are accurate and reproducible measures of 
apoptosis.  We have used this model to investigate the effects of liver failure 
plasma on hepatocyte apoptosis. 
 
Acute Liver Failure Plasma 
We have demonstrated that exposure to acute liver failure plasma induced 
increased apoptosis in adult primary human hepatocytes compared to exposure 
to normal plasma.  This suggests that there are toxic substances within liver 
failure plasma which cause hepatocyte loss by apoptosis.  Since apoptosis has 
been shown in animal studies to be an important step in the pathophysiology of 
acute liver failure these results confirm that apoptosis induced by substances 
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within acute liver failure plasma may be important in the perpetuation of acute 
liver failure in humans. 
It was noted that there was a wide variation in degree of apoptosis induced by 
acute liver failure plasma and not all samples were toxic; indeed two individuals 
plasma showed significantly less apoptosis than control normal plasma.  This is 
not surprising considering the diversity of the patients‘ clinical conditions both 
between individuals and within individuals over time.   
Dose response curves of Caspase 3 activity for hepatocytes diluting plasma with 
complete Williams E were generated to demonstrate this toxic effect, 
paradoxically the cells incubated with more concentrated plasma demonstrated 
less apoptosis than at lower concentrations.  This is consistent with the 
observation that apoptosis is always greater and cell viability less in hepatocytes 
incubated in complete Williams E medium compared to all plasma samples.  It 
suggests that complete Williams E is not the perfect milieu for primary human 
hepatocytes and as a consequence there is a background rate of cell loss by 
apoptosis which is greater than that seen in plasma.  Thus to construct a dose 
response curve is impossible unless we can identify a medium which is more 
favourable than plasma and generates minimal apoptosis to dilute the plasma 
with.   
This demonstration of both normal and liver failure plasma inducing less 
apoptosis than medium suggests a possible alternative explanation for the 
differences in toxicity seen with normal and acute liver failure plasma. Instead 
of an increase in apoptosis due to an increase in toxic substances within liver 
failure plasma compared to normal plasma, there maybe a general background 
level of apoptosis in-vitro and normal plasma protects against this to greater 
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extent than acute liver failure plasma.  In summary the increased toxicity 
observed in liver failure plasma compared to normal plasma maybe due to 
decreased factors that protect against apoptosis in acute liver failure plasma 
compared to normal plasma rather than an increase in toxic factors in acute liver 
failure plasma.  This is consistent with previous papers in which the differences 
between normal and acute liver failure plasma are demonstrated but amounts of 
apoptosis in medium alone are not shown. 
 
Clinico-Pathological correlates – Acute Liver Failure Plasma 
There was no correlation between apoptosis induced by the patients‘ plasma, or 
cell viability and the patients‘ renal or liver function tests measured. We had 
hypothesised that if apoptosis was a cause of hepatocyte injury leading to 
secondary necrosis that other markers of hepatocellular damage, e.g. AST, ALT, 
may positively correlate with apoptosis inducing ability of plasma.  No such 
correlation could be demonstrated. Although this may be taken as evidence to 
reject this hypothesis results have to be interpreted with caution as no correlation 
may be due to differences in the time course of release of these markers.    
We also hypothesised that if apoptosis was induced by toxins that had 
accumulated in the plasma as a result of failure of liver excretion that markers of 
excretion/cholestasis bilirubin, ALP, GGT would positively correlate with 
apoptosis inducing capacity of plasma; again no such correlation could be 
demonstrated, suggesting that the toxic nature of plasma was not related to 
failure of hepatic excretion of hepatotoxins.   
Finally, we hypothesised that if albumin binds to lipid soluble hepatotoxins and 
that it is unbound toxins that induce hepatocyte apoptosis that serum albumin 
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would negatively correlate with apoptosis inducing ability of plasma.  Whilst 
this correlation failed to reach statistical significance there was a trend in this 
direction.  This may have been due to the direct effect of unbound toxins, due to 
albumin itself having protective effects against apoptosis or be an indirect 
association as patients with lowest serum albumin represent the ―sickest‖ 
patients.  Greater patient numbers may be required to confirm this correlation.  
Some of these hypotheses could be tested by measuring apoptosis inducing 
ability of plasma from non-liver critically ill patients as these also have low 
serum albumin and increased inflammatory cytokines and patients with chronic 
liver disease who also have low albumin. 
Chronic Liver Disease Plasma 
Plasma from patients with acutely-decompensated chronic liver disease did not 
significantly increase apoptosis, measured by both TUNEL staining and Caspase 
3 activation, compared with plasma from normal individuals.  However both 
normal and liver failure plasma were associated with less apoptotic hepatocytes 
than complete Williams E medium.  As with acute liver failure plasma there was 
a wide variation in quantity of apoptosis associated with each sample, with some 
samples increasing apoptosis and some decreasing it compared with normal 
plasma.  Again cell viability measured by MTT activity did not correlate with 
apoptosis and the possible explanations for this are the same as for acute liver 
failure plasma.   
Apoptosis, measured by Caspase 3 activation, positively correlated with serum 
creatinine P<0.05); apoptosis, measured by TUNEL cell positivity, also showed 
a trend toward a positive correlation, although this did not reach statistical 
significance (p=0.07).  It is known that renal failure is a significant cause of 
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mortality in chronic liver disease with the onset of impaired renal function often 
heralding the terminal stages of this disease.  Serum creatinine is therefore 
considered a good prognostic indicator and is used to calculate the MELD score 
and the creatinine corrected Childs-Turcott-Pugh Score, both of which have 
been shown to be of greater prognostic value compared to Childs-Turcott-Pugh 
Score alone which does not consider renal function.  The correlation of 
apoptosis with creatinine therefore suggests a possible mechanism for this is 
association.  The onset of renal impairment may result in the accumulation of 
substances normally excreted renally that are capable of inducing apoptosis in 
hepatocytes, thus decreasing the likelihood of recovery.  From this it could be 
theorised that removal of these substances by haemofiltration/dialysis could 
decrease plasma toxicity and improve outcome in acutely decompensated 
chronic liver disease.  Since haemofiltration is an integral part of MARS therapy 
this hypothesis will be investigated in the following chapter.   
Apoptosis, measured by TUNEL cell positivity, is negatively associated with 
GGT activity (p<0.05), there is also a trend towards this association when 
apoptosis is measured by Caspase 3 activation although this does not reach 
statistical significance (p=0.07).  The explanation for this is unclear but both 
methods of measuring apoptosis indicate a similar result, making a type II error 
unlikely.  Gamma-GT is induced by a number of liver diseases, the function and 
mechanism of this induction is unclear.  Apoptosis was not associated with other 
markers of cholestasis and the correlation is negative suggesting accumulation 
of toxins is not an explanation.  It may be that the induction of GGT represents 
some form of protective mechanism in liver disease and this induction may be 
associated with activation of other protective mechanisms, for example those 
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that protect against hepatocyte apoptosis such as NFκβ activation and increased 
expression of proteins of the Bcl-2 family.  However until more is known about 
the role of GGT in liver disease no further comment can be made. 
 
Caspase Inhibitors 
Having shown that acute liver failure plasma is associated with an increase in 
apoptosis in hepatocytes when compared to normal plasma, we investigated by 
which pathway apoptosis was mediated by using specific caspase inhibitors.   
Inhibition of Caspase 3 resulted in a significant (and the greatest) decrease in 
apoptosis, Caspase 3 is the major effector caspase and is utilized by both 
intrinsic and extrinsic pathways, it would therefore be expected that inhibition of 
Caspase 3 would result in maximal inhibition of apoptosis.    
Caspase 8 inhibition also resulted in a significant inhibition of apoptosis, 
Caspase 8 is the major caspase activated by binding of cell surface ―death 
receptors‖ to their ligands, including Fas and TNF-α receptors.   
This result suggests that the increase in apoptosis seen in hepatocytes incubated 
in acute liver failure plasma is induced by substances which act on cell surface 
death receptors.  It also suggests that Caspase 8 inhibitors may have therapeutic 
potential in Acute Liver Failure.   Caspase 9 inhibition did reduce apoptosis 
marginally but this effect did not reach statistical significance.  This is not 
entirely unexpected as the caspase cascade in the intrinsic and extrinsic 
pathways are not exclusive and there is cross activation of pathways.  In the case 
of Caspase 9 release of cytochrome c from the mitochondria (the defining point 
of apoptosis for cells, common to all pathways), results in oligomerisation of the 
protein apoptotic protease activating factor-1 and this combines with 
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cytochrome c and Caspase 9 resulting in the formation of the apoptosome which 
processes Caspase 9 to its active form.  This activated Caspase 9 further 
activates Caspase 3 thus acting as a positive feedback loop amplifying the 
apoptotic signal.  Thus inhibition of Caspase 9 may result in some diminution of 
apoptotic response whichever pathway it is triggered by as a result of knocking 
out its downstream amplificatory function. 
Inhibition of apoptosis by Caspase inhibitors 3 & 8 indicate possible pathways 
by which apoptosis is induced by liver failure plasma and could have therapeutic 
potential in the treatment of acute liver failure.  The role of caspase inhibition as 
a therapeutic modality for Acute Liver Failure will be investigated further in 
chapter 7. 
 
Heat inactivation of Acute Liver Failure Plasma 
Heat inactivation resulted in an increase in Caspase 3 activity induced by 
exposure to both normal plasma and to two of the three samples of acute liver 
failure plasma compared to each‘s non-heat inactivated control.  This suggests 
that heat inactivation of plasma results in inactivation a substances(s) within it 
which are protective against apoptosis.  Having been heat inactivated there was 
no significant difference between the amounts of apoptosis induced by normal, 
acute liver failure plasma, 100%FCS and Complete Williams E medium 
suggesting there are no cross-species differences after heat inactivation. 
Protective effects of Acute Liver Failure Plasma  
Previous results suggested that the differences in plasmas` apoptosis inducing 
effect was due to differences in their content of factors which protect against 
apoptosis, rather than differences in their content of ―toxic molecules‖.  To test 
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this hypothesis we diluted substances which are known to induce apoptosis in 
hepatocytes (Fas-L and Staurosporine) in plasma from patients with Acute Liver 
Failure and normal controls to see if there were differences in response to these 
apoptosis-inducing substances in the different substrates.  
Neither acute liver failure plasma, normal plasma, nor FCS attenuated apoptosis 
induced by Fas-ligand; whereas both liver failure plasma and normal plasma 
attenuated apoptosis induced by Staurosporine with normal plasma exerting a 
greater protective effect than acute liver failure plasma.   
The reason for the differences in protective effects against the  two apoptosis 
inducing agents is unclear but may be due the different pathways by which 
apoptosis is induced (Staurosporine is a protein kinase c inhibitor whereas Fas-L 
activates cell surface death receptors), or may be due to differences in the 
physical properties of the substances once dissolved in different agents.  For 
example if Staurosporine becomes albumin bound its toxic effect may become 
attenuated due to decreased unbound compound.  In this case substances with 
greater albumin concentration or greater albumin binding capacity may exert a 
greater protective effect against apoptosis induced by Staurosporine.   
Summary 
We have demonstrated that acute liver failure plasma is toxic to hepatocytes by 
inducing apoptosis, but that plasma from patients with acutely decompensated 
chronic liver disease does not.  These patients may have equally deranged failure 
of excretion of hepatotoxins (using bilirubin as a marker of toxin load) as in 
acute liver failure.  These data challenges the simple theory that liver failure 
plasma is toxic due to accumulation of toxins not excreted by the liver.  What, 
therefore could explain the differences between acute and chronic liver failure? 
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One possibility is the release of toxic substances, such as cytokines, from the 
inflamed liver may be responsible for acute liver failure plasma toxicity.  This 
has radical implications in the development of therapeutic modalities for liver 
failure and may be at least in part be responsible for the fact that detoxicatory 
therapies have never shown any survival benefit in acute liver failure (Novelli et 
al., 2002a).  It suggests that therapies aimed at decreasing inflammatory 
cytokines or preventing their effect may be more rewarding in acute liver failure, 
or that any detoxifying treatments must have metabolic capability to conjugate 
toxins prior to excretion.  Although MARS and other detoxicatory therapy can 
potentially remove cytokines, which are albumin bound substances, their 
capacity to do so is relatively small, studies to show reduction of inflammatory 
cytokines before and after treatment have not been consistent and indeed 
initially cytokine production may be increased due to exposure of plasma to 
artificial membranes with the device. 
These results do not suggest that detoxifying treatments are of no benefit to all 
liver disease patients, indeed they may be a necessary part of any bioartificial 
device that would have no excretory system, but we suggest that the theory of 
detoxifying plasma to directly promote hepatocyte viability is flawed.  MARS 
therapy has shown improvement in liver function in-vivo, and we suggest that 
removal of vasoactive mediators e.g. nitric oxide and the resultant increase in 
blood pressure and regional perfusion is responsible for this improvement rather 
than removal of direct hepato-cellular toxins.  Removal of toxins may still be of 
benefit to the patient‘s clinical condition by improving encephalopathy where 
evidence for a direct effect for toxic molecules is greater.  We suggest that liver 
support devices should be thought of in two distinct categories:  Devices such as 
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MARS therapy, plasmapheresis and adsorption columns which promote 
excretion of liver toxins, and detoxifying treatments which have metabolic 
capability i.e. bioartificial livers or extracorporeal liver perfusion.  The former 
may be of greatest value to patients in whom cholestasis is predominant.  Bile 
salts are known to be cholestatogenic and removal of these compounds may thus 
break the vicious cycle that appears in these patients.  The latter would be able to 
metabolise unconjugated substances and would be perhaps of greatest benefit to 
non-cholestatic patients with acute liver failure. 
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CHAPTER 4:  ANIMAL MODELS OF ACUTE LIVER FAILURE AND 
INHIBITORS OF APOPTOSIS IN THIOACETAMIDE INDUCED LIVER 
INJURY 
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4.1   APOPTOSIS AND ACUTE LIVER FAILURE 
Apoptosis is thought to be an important process in the pathophysiology of a 
number of liver diseases with an enhanced rate of apoptosis above the 
background rate of 1-5 cells per 10,000 hepatocytes having been reported in 
many forms of human liver disease.  Particularly striking is the increase in rate 
of hepatocyte apoptosis in acute liver failure (Kasahara, Saitoh, & Nakamura, 
2000).  The aetiologies of acute liver failure in which increased (Ryo, 
Kamogawa, Ikeda, Yamauchi, Yonehara, Nagata, & Hayashi, 2000) hepatocyte 
apoptosis has been demonstrated have previously been described in the first 
chapter.  The association between liver failure and apoptotic hepatocytes has 
been firmly established in human tissue through conventional histological 
analysis and detailed nuclear morphology demonstrating chromatin fracturing 
using the TUNEL technique (Kasahara, Saitoh, & Nakamura, 2000, Ryo, 
Kamogawa, Ikeda, Yamauchi, Yonehara, Nagata, & Hayashi, 2000); 
Apoptosis leads directly to significant hepatocyte loss and although only a small 
percentage of total hepatocytes may be seen to be apoptotic on histological 
specimens at any given time, the speed of the apoptotic process and lack of 
accumulation of apoptotic debris means that even low rates of apoptosis can be 
directly responsible for loss of large amounts of liver cell mass over short 
periods of time.   
In addition apoptosis is known to be capable of inducing the development of 
secondary necrosis with inflammatory cell infiltrates, activation of kupffer cells, 
lymphocytes and macrophages, release of cytokines, and activation of hepatic 
stellate cells stimulating fibrogenesis all of which further contribute to liver 
damage.  Inhibition of apoptosis may therefore be beneficial in the treatment of 
acute liver failure both by preventing loss of liver cell mass and reducing the 
liver‘s inflammatory response.  
There are several key targets which could be harnessed to therapeutically inhibit 
apoptosis including manipulation of death receptors and their ligands, Caspase 
inhibitors, inhibitors of apoptosis proteins (IAPs), Bcl-2 family proteins and 
mitochondrial membrane transition potentials. 
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Interventions that reduce quantity or activity of ligands known to stimulate 
apoptosis have already been used with success in several non-malignant human 
diseases (see table 7).   
Table 6. Summary of clinical trials using anti-death receptor antagonism. 
Target Reagent Principle Experimental 
Effects/Disease 
Trial 
status 
Manufactur
er 
& 
References 
TRAIL 
recepto
rs 
  Hepatitis C   
CD95/
Fas 
CD95-Fc Humanised 
CD95  
Fc-decoy 
construct 
Inhibition of CD95 
signalling in spinal 
cord injury. 
Preclini
cal 
Apogenix 
(Demjen et 
al., 2004) 
TNF & 
Fas-
Ligand 
Anti-TNF 
& Anti-
FasLigand 
 
Soluble anti-
Fas ligand 
antibody 
antibody 
Mouse stoke 
model, decreased 
infarct volume & 
Mortality 
Animal 
Models 
(Martin-
Villalba et 
al., 2001) 
TNF Infliximab Mouse/huma
n anti-TNF 
antibody 
Inhibition TNF-α 
& Apoptosis of 
surface TNF 
expressing cells 
e.g. Macrophages 
IBD, RA, 
beneficial 
Alcoholic Hepatitis 
(increased 
mortality) 
Routine 
clinical 
use 
Centercor/S
chering-
plough 
(Targan et 
al., 1997) 
(Naveau et 
al., 2004) 
CD95/
Fas-
Ligand 
Anti-Fas 
ligand 
antibodies 
Intra-thecal 
Soluble anti-
Fas ligand 
antibody 
antibody 
Decreased 
inflammation in 
experimentally 
induced mouse 
encephalomyeilitis. 
An animal model 
of Multiple 
Sclerosis 
Animal 
model 
(Okuda et 
al., 2000) 
CD95/
Fas-
Ligand 
& TNF 
Anti-Fas 
ligand & 
anti-
TNFantibod
ies 
Systemic 
administratio
n of soluble 
neutralising 
antibody 
Amelioration of 
mouse model of 
graft versus host 
disease  
Animal 
model 
(Hattori et 
al., 1998),  
CD95/
Fas-
Ligand 
Pooled 
human 
immunoglo
bulin 
Interference 
with Fas-
Ligand 
binding 
Toxic epidermal 
necrosis  
Clinical 
trial 
(Viard et al., 
1998) 
TNF Adalimuma
b 
Recombinant 
human anti-
Inhibition of TNF-
α  
Routine 
clinical 
CAT/Abbott 
(Hanauer et 
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TNF 
antibody 
IBD, RA, Psoriasis, 
Ankylosing 
Spondylitis 
use al., 2006, 
Sandborn et 
al., 2004) 
TNF Etanercept Recombinant 
TNFR2/IgG 
fusion protein 
Anti-inflammatory  
RA, IBD. 
Small case series in 
Alcoholic Hepatitis 
Routine 
clinical 
use 
Amgen/Wye
th 
(Menon et 
al., 2004) 
 
TNF ISIS 
104838 
2‘-O-
Methoxyethy
l antisense 
construct 
against TNF-
α 
Anti-inflammatory  
RA, IBD, psoriasis. 
Phase 
II 
Trials 
for RA, 
Crohns, 
Psoriasi
s 
 
 
 
 
TNF Pentoxyfylli
ne 
Reduces TNF 
secretion, + 
Downstream 
effects on 
CPP32-like 
protease. 
Anti-inflammatory 
and renal protective 
effects, in 
Alcoholic 
Hepatitis.  
Phase 
III 
Trials 
 
(Okamoto, 
1999) 
(Akriviadis 
et al., 2000) 
 
IBD = Inflammatory bowel disease RA = Rheumatoid arthritis 
 
 
Since death receptor activation is known to induce liver failure, 
inhibition/antagonism of these pathways should improve outcome in liver 
disease.  TNF-neutralising antibodies, anti-Fas ligand antibodies, TNF decoy 
receptors (Kondo, Suda, Fukuyama, Adachi, & Nagata, 1997), pentoxyfylline 
(Okamoto, 1999), and physical removal of toxins such as bile salts have all been 
shown to reduce apoptosis and have/are undergoing clinical trials in liver 
disease.  Inhibition of the CD95 receptor/ligand system using CD95 neutralising 
antibodies have shown benefit in-animal models decreasing disability after 
spinal cord injury (Demjen et al, 2004). 
The targets of these therapies, often cytokines, do however serve multiple 
functions some of which may be beneficial.  For example TNF-alpha although 
capable of inducing hepatocyte apoptosis is also implicated in hepatocyte 
proliferation and survival and thus its removal/antagonism may worsen liver 
regeneration and clinical outcome.  In addition the antagonism of TNF is highly 
immunosupressing increasing the risk of septic complications, particularly 
tuberculosis.  Complications already described after the use of Infliximab 
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include lymphoma, infections, congestive cardiac failure, demyelinating disease 
and lupus-like syndrome (Bratcher & Korelitz, 2006).   
More specific inhibition of apoptosis would avoid these effects and could be 
enabled by inhibiting the downstream intracellular machinery leading to 
apoptosis.  A further advantage of manipulating apoptosis downstream is the 
avoidance of the administration of these large recombinant proteins which are 
expensive, unstable, require systemic administration and may provoke 
immunogenicity resulting in hypersenstitivity reactions and loss of efficacy.  
 
 
4.2  CASPASE INHIBITION  
The molecular mechanisms/pathways involved in the execution of apoptosis are 
described in detail in the introductory chapter, however in brief activation of 
apoptosis via surface cell death receptors or mitochondrial permeablisation 
results in activation of a series of serine proteases called Caspases.  These 
enzymes not only result in transmission of the apoptotic trigger to effector 
substances e.g. other caspases and endonucleases which result in  cellular 
dismantling but also amplify the apoptotic signal resulting in a rapid all or 
nothing response.  Caspases are therefore ideal targets for antagonism in specific 
prevention of apoptosis and have been studied in various animal models and 
human diseases.  Caspases may be classified according to their function.  
Caspases 1, 4 & 5 are predominantly involved in the maturation of pro-
inflammatory cytokines e.g. Interleukin-1(Thornberry et al., 1992).  Caspases 8, 
9 & 10 are initiator caspases, whereas others (e.g. 3,6 & 7) are executioner 
caspases.  Studies of transgenic and caspase knockout mice have shown that 
diseases such as stroke, myocardial infarction, neurodegenerative disease and 
liver injury are all attenuated by caspase inhibition and synthetic caspase 
inhibitors have already been successfully used in several animal models 
including  spinal cord injury, arthritis, sepsis, stroke, renal and mesenteric 
ischaemia and liver disease (see table below).  
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Table 7. Summary of clinical trials using Caspase inhibition. 
Target Reagent Model Experimental 
Effects/Disease 
Trial 
status 
 References 
 Caspase 
inhibitor 
 Mice Acute 
Spinal cord 
injury 
Decreased cell 
death, Improved 
hind leg activity 
 (Li et al., 
2000, 
Springer et 
al., 1999) 
Broad 
spectrum 
Caspase 
z-VAD-
fmk 
Mouse Acute 
liver failure 
induced by Jo-2 
(activating anti-
Fas antibody 
antibody 
Attenuated liver 
injury 
 (Rodriguez 
et al, 1996) 
 
Broad 
spectrum 
Caspase 
z-VAD-
fmk 
Mouse Acute 
liver failure 
induced by Jo-2 
(activating anti-
Fas antibody 
antibody) to 
TNF-alpha 
Attenuated liver 
injury 
 (Kumgstle et 
al, 1997) 
Caspase 
1 
inhibitio
n 
 Mouse Arthritis 
models 
Decreased 
disease severity 
 (Miller et 
al., 1995) 
Broad 
spectrum 
Caspase 
z-VAD-
fmk 
Mouse sepsis Decreased 
severity 
&Mortality 
 (Hotchkiss 
et al., 1999) 
Caspase 
1 
inhibitio
n 
  Rat model of 
cardiac 
ischaemia 
reperfusion 
injury. 
 (Yaoita et 
al., 1998) 
Pan-caspase 
inhibitor, 
boc-
aspartyl(OMe)-
fluoromethylket
one 
Rat stroke model Reduced 
neuronal death 
and infarct size 
 (Cheng et 
al., 1998) 
 IGF-1 and 
ZVAD-
fmk 
Rat renal 
ischaemia 
reperfusion 
injury 
Decrease 
apoptosis and 
necrosis 
  
(Daemen et 
al., 1999) 
 
 
Pan-case 
inhibitor 
ZVAD 
(N-
benzyloxy
carbonyl 
Val-Ala-
Asp-Ome-
fluoromet
hylketone) 
 
Mouse small 
intestine 
ischaemia 
reperfusion 
injury 
Decreased 
apoptosis and 
inflammation. 
 (Farber et 
al., 1999) 
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Irreversi
ble pan-
caspase 
inhibitor 
IDN-6556  Anti-apoptotic, 
Anti-
inflammatory, 
Ant-i-fibrotic 
effects in liver 
damage 
Decreased 
serum 
transaminases in 
healthy 
volunteers 
Preservation of 
livers during 
transplantation 
Phase 2 
trials 
HepC, 
open 
label 
trials 
Hep B 
and 
ischae
mia 
reperfu
sion 
post 
liver 
transpla
ntation 
IDUN 
(Canbay et 
al,2004, 
Hoglen et al, 
2001) 
(Valentino 
et al., 2003) 
Caspase 
inhibitor 
IDN-6734  Decreases heart 
muscle damage 
in animal 
models 
Phase 1 
studies 
acute 
MI 
IDUN 
VX-799 Small 
molecule 
Caspase 
inhibitor 
 Effective in 
sepsis and 
neuronal death 
models 
Phase 
II trials 
for 
septic 
multior
gan 
failure 
started 
2003 
Vertex/Sero
no 
MX-
1013 
Dipeptide 
pancaspas
e inhibitor 
 Prevents 
apoptosis in 
animal models 
MI, Stroke, 
Acute Liver 
Failure 
Preclini
cal  
Maxim 
(Jaeschke et 
al., 2000, 
Yang et al., 
2003) 
M-920 Broad 
spectrum 
Caspase 
Inhibitor 
 Mouse model 
septic shock 
Preclini
cal 
Merck Frost 
(Hotchkiss 
et al., 2000) 
IDN-
11104 
ICE-
inhibitor 
  Preclini
cal 
IDUN 
VX-740 ICE-
inhibitor 
 Anti-
inflammatory 
effects in 
Rheumatoid and 
OA studies 
Phase 
II 
Rheum
atoid 
arthritis 
Vertex/Aven
tis 
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M-826 Reversible 
Caspase 3 
inhibitor 
 Reduces 
neuronal loss in 
mouse model of 
Huntington‘s 
disease and 
stroke 
Preclini
cal 
Merck 
Frosst 
(Han et al., 
2002, 
Toulmond et 
al., 2004) 
M-791 Caspase-3 
inhibitor 
 Effective in 
mouse model of 
septic shock 
Preclini
cal 
Merck 
Frosst 
(Hotchkiss 
et al, 2000) 
Xyz 033 Broad 
spectrum 
Caspase 
inhibitor 
 Concavalin A in 
mice 
 (Kim et al , 
2000) 
 
 
Animal models of liver disease in which caspase inhibitors have been utilized 
include the warm ischaemia reperfusion rat model, in which a broad spectrum 
Caspase inhibitor decreased apoptosis, necrosis and mortality (day 7 Caspase 
inhibitor group 5%, Control 30%) (Cursio, Gugenheim, Ricci, Crenesse, 
Rostagno, Maulon, Saint-Paul, Ferrua, Mouiel, & Auberger, 2000); a rat model 
of haemorrhagic shock in which a broad spectrum Caspase inhibitors did not 
prevent hepatocellular injury (Mauriz et al., 2003); the Endotoxin & D-
galactosamine mouse model (a TNF-alpha mediated model) in which caspase 
inhibition decreased apoptosis, necrosis and mortality (at 24 hours 0% mortality 
in pancaspase inhibitor group, 100% in controls) (Jaeschke, Farhood, Cai, 
Tseng, & Bajt, 2000) and in the same model a specific Caspase 8 inhibitor also 
attenuated liver injury (Bajt, Vonderfecht, & Jaeschke, 2001, Kunstle et al, 
1997, Rouquet, Pages, Molina, Briand, & Joulin, 1996); Mice treated with Jo-2 
antibody (a Fas activating antibody) to induce apoptosis, showed apoptosis, 
necrosis and mortality were decreased both by a specific Caspase 8 inhibitor 
(Bajt et al., 2000) and a broad spectrum caspase inhibitor (Rodriguez et al, 1996, 
Yang et al, 2003); A cold ischemia warm reperfusion  rat liver transplant model 
showed a pancaspase inhibitor added to the preservation solution reduced SEC 
apoptosis in explants by 55% and Caspase 3 activity by 94%  (Natori, Higuchi, 
Contreras, & Gores, 2003). Decreased acute and chronic injury was seen in the 
bile duct ligated mouse model using a pancaspase inhibitors (Canbay, Feldstein, 
Baskin-Bey, Bronk, & Gores, 2004); Concavalin A in a murine model of T-cell 
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mediated apoptosis via the Fas receptor pathway akin to autoimmine hepatitis 
showed reduced apoptosis, necrosis and mortality using a specific Caspase 3 
inhibitor and a broad-spectrum Caspase inhibitor (Kim, Kim, Park, Park, Chang, 
Park, Chung, & Kang, 2000); in contrast in a mouse model of acetaminophen 
toxicity Capsase 3 activity was not increased and Caspase inhibitors did not 
attenuate injury (Lawson et al., 1999). 
Caspase inhibitors, although showing mixed results depending on the 
mechanism of liver injury, do show considerable promise as therapies both for 
endogenous hepatocytes in acute liver failure and also provide a method by 
which apoptosis can be inhibited in exogenous hepatocytes during 
transplantation and use in a bioartificial device.   
Since the commonest causes of acute liver failure in the U.K. are toxin mediated 
(i.e. paracetamol toxicity and alcoholic hepatitis) and we have demonstrated in 
earlier chapters that there are toxic substances within acute liver failure plasma 
which may perpetuate liver failure which are inhibited in-vitro by Caspase 
inhibitors we wished to study the effect of Caspase inhibition in-vivo on a toxin 
induced animal model of acute liver failure, the thioacetamide (TAA) model of 
AHF.  
 
4.3  THIOACETAMIDE MODEL 
In this experimental model Thioacetamide is metabolised to toxic metabolites 
thioacetamide sulfine (sulphoxide) and sulfene (sulfone) (Hunter et al., 1977, 
Ramaiah et al., 2001).  Hepatocyte damage involves generation of free radicals 
and superoxide anions causing lipid peroxidation  (Diez-Fernandez et al., 
1996a).  Cellular consequences include interruption of cellular calcium 
homeostasis (Diez-Fernandez et al., 1996b), disruption of membranes of the 
endoplasmic reticulum and failure of amino acid incorporation into liver 
proteins with resultant hepatic necrosis (Ramaiah, Apte, & Mehendale, 2001) 
and apoptosis (Ledda-Columbano, Coni, Curto, Giacomini, Faa, Oliverio, 
Piacentini, & Columbano, 1991) associated with activation of Caspase 3 
(Hayami et al., 1999). 
Thioacetamide causes hepatic failure in rats, the severity of which varies 
according to intra-species variation, age, diet, and also concomitant supportive 
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therapy (Caballero et al., 2001, Diez-Fernandez et al., 1998, Zimmermann et al., 
1989).  Previous work of this group characterised the clinical, biochemical, 
metabolic and histological pattern of thioacetamide-induced hepatic failure in 
the Wistar rat, to create a model of substantial severity (~70% mortality), which 
fulfils the criteria of reproducibility, reversibility and provision of a therapeutic 
window, suggested by Terblanche et al.(Terblanche & Hickman, 1991) for 
animal models of AHF(Rahman & Hodgson, 2003).  This model induces 
lethargy within 6 hours of the first injection of Thioacetamide, and by 12 hours 
70% of the animals demonstrated Grade 1 encephalopathy lasting 4-12 hours 
and then developed Grade II-III encephalopathy by 48 hours.  The model had a 
50% mortality by 48 hours with a 70% mortality by 96 hours (Rahman & 
Hodgson, 2003).  
Using this model the ability of a broad spectrum caspase inhibitor VE-453, and a 
selective Caspase 3 inhibitor Z-VAD, to attenuate liver injury was assessed. 
 
4.4   EXPERIMENT TO DEMONSTRATE IF THERE IS INCREASED 
APOPTOSIS IN THIOACETAMIDE INDUCED LIVER FAILURE. 
A preliminary experiment to confirm the presence of apoptosis of hepatocytes 
and delineate its time course was performed. 
Method 
Animals and treatments. Male Wistar rats weighing 250-300 grams were fed 
with standard rat chow diet ad libitum, allowed free access to water and housed 
in standard facilities with a 12-hour day/night cycle at a room temperature of 
25
o
C.   Animals were handled and the method licensed according to home office 
criteria (see appendix for licence).  Rats were rested for 2 weeks after 
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transportation.  All the animals used in these experiments were cared for in this 
way. 
Thioacetamide at a concentration of 62.5mg/ml was dissolved in sterile Normal 
saline.  A dose of 500mg/kg was injected intraperitoneally, twice 6 hours apart 
in eight rats.  Vehicle only was injected in four rats as controls.  Rats (two 
thioacetamide and one vehicle control) were sacrificed in accordance with home 
office regulations at 6, 12, 24 and 36 hours.  Liver tissue was taken and samples 
were fixed in formalin and embedded in Paraffin blocks; also samples were 
placed in tissue mounting medium on cork tiles and snap frozen in Iso-pentane 
(for frozen cryostat section histology).  Liver tissue was snap frozen in liquid 
nitrogen and stored at -80ºC for subsequent analysis.  Paraffin embedded tissue 
sections were cut and placed on APES coated slides and allowed to dry.  
Sections were then stained with TUNEL according to the protocol in general 
methods. 
Numbers of apoptotic cells (TUNEL -Rhodamine positive nuclei) and normal 
nuclei (Hoescht – Blue) were counted under x40 magnification with 
immunofluorescence using appropriate filters.  
 
Results 
Increased numbers of TUNEL positive apoptotic cells were seen in 
Thioacetamide treated rats compared with vehicle only controls.  The TUNEL 
positive cells were particularly distributed in areas of increased cellularity 
around central veins.  The time course appeared to show increasing apoptosis up 
to 36 hours. 
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Fig. 41.  Photomicrographs showing sections of rodent liver treated with 
Thioacetamide at (B) 6 hours, (C) 12 hours, (D) 24 hours and (E) 36 hours 
compared to normal control (A) magnification x40.  TUNEL positive cells red, 
Hoescht nuclear counterstain blue. 
A B C 
D E 
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Figure 42.  Percentage of total hepatocytes TUNEL positive in rat liver after 
Thioacetamide administration at 0, 6, 12 and 24 hours. 
 
 
4.5 THE EFFECTS OF CASPASE INHIBITORS ON THE 
THIOACETMIDE INDUCED LIVER INJURY RAT MODEL. 
The effect of a broad spectrum caspase inhibitor VE-453 (Vertex 
Pharmaceuticals, Didcot), and a selective Caspase 3 inhibitor Z-VAD (Vertex 
Pharmaceuticals, Didcot) on morbidity and mortality of the Thioacetamide rat 
model was assessed. 
 
Method 
Animals and treatments. Male Wistar rats 250-300grams in weight, cared for as 
described, were weighed and labelled immediately prior to experimentation. 
Caspase inhibitors were made up in accordance with manufacturer‘s 
instructions.  Z-VAD and VE-453 (stored at -20ºC) powder was allowed to 
come to room temperature to allow water absorption prior to weighing (powders 
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being very hydroscopic).  30.25mg of Z-VAD powder and 90.75mg of VE-453 
powder were individually solubilised initially in 3 ml of 100% PEG300 and then 
diluted 1:10 vol/vol with PBS to a final volume of 33ml of vehicle 
(10%PEG300, 90%PBS).  A dose of 10mg/kg body weight of Z-VAD 
(approximately 3ml), 30mg/kg body weight of VE-453 (approximately 3ml) or 
vehicle alone (approximately 3ml)  was drawn up in labelled individual 5ml 
syringes, volumes drawn up were adjusted according to each animals weight.   
Thioacetamide 2.888g (Sigma) was dissolved in 35mls sterile normal saline and 
thoroughly vortexed.  A dose of 600mg/kg body weight (approximately 2ml) 
volume adjusted for individual animals weight, was drawn up in 2ml syringes. 
Three groups of five animals were randomly selected; Group 1 Z-VAD + 
Thioacetamide; Group 2 VE-453 + Thioacetamide; and Group 3 Vehicle alone + 
Thioacetamide.  At time=0 hours, and t=6 hours animals were injected 
intraperitoneally with TAA followed by either a Caspase inhibitor or vehicle 
alone with an orange needle.  Animals were examined for the presence of 
encephalopathy 6 hourly (table).  Animals with grade 3 encephalopathy were 
reviewed hourly and animals with Grade 4 encephalopathy were terminated in 
accordance with the home office animal licence.  Animals were weighed 24 
hourly as a marker of general well being.  Animals were given subcutaneous 
maintenance fluids of normal saline 70ml/kg/24 hours in four divided doses (six 
hourly).  A primary endpoint of mortality rate at 96 hours (the end of the study 
period) was selected.  Secondary end points were degree of grade of 
encephalopathy and weight loss. 
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Table 8.  Encephalopathy scoring system for rodents. 
Stage of HE Prominent  neurobehavioral  change Total Reflex Score  
(Maximum score=30) 
I Lethargy 20-25 
II Lethargy and Ataxia 15-20 
III Gradual loss of reflexes 10-15 
IV Coma 0-10 
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Results 
Table 9.  Data from Thioacetamide toxicity rodent model  
Anim
al 
Code 
Substa
nce 
Wgh
t 
T=0  
Enc 
T=0 
Enc 
T=6 
Enc 
T=1
2 
Enc  
T=1
8 
Wgh
t 
T=2
4 
Enc 
T=2
4 
Enc 
T=3
0 
Enc 
T=3
6 
Enc 
T=4
2 
C1 Contr
ol 
273 0 0 0.5 0.5 252 1 1 2 3 
C2 Contr
ol 
257 0 0 0.5 1 244 2 1 2 1.5 
C3 Contr
ol 
268 0 0 0.5 0.5 260 1 2 2 1.5 
C4 Contr
ol 
271 0 0 0.5 1 275 2 2 3 D 
C5 Contr
ol 
254 0 0 0.5 0.5 237 1 1 2 2 
C6 Contr
ol 
278 0 0 0.5 1 258 0.5 0 1 1 
C7 Contr
ol 
273 0 0 0.5 1 257 0.5 0 1 1 
C8 Contr
ol 
260 0 0 0.5 1 241 0.5 0 1 1 
V1 VE-
453 
254 0 0 0.5 1 248 0 3 D D 
V2 VE-
453 
262 0 0 0.5 0.5 251 1 2 1.5 0.5 
V3 VE-
453 
262 0 0 0.5 1 258 1 1 1.5 0.5 
V4 VE-
453 
271 0 0 0.5 0.5 262 0 1 1.5 0.5 
V5 VE-
453 
265 0 0 0.5 1 259 1 0.5 0.5 0.5 
Z1 Z-
VAD 
260 0 0 0.5 1 257 1 1 2 0.5 
Z2 Z-
VAD 
263 0 0 0.5 0.5 244 1 1 2 1.5 
Z3 Z-
VAD 
253 0 0 0.5 0.5 244 1 1 2 0.5 
Z4 Z-
VAD 
245 0 0 0.5 0.5 236 1 1 2 0.5 
Z5 Z-
VAD 
245 0 0 0 0 240 0 1 2 0.5 
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Anim
al 
Code 
Wgh
t 
T48 
Enc 
T4
8 
Enc 
T54 
Enc 
T60 
Enc 
T66 
Wg
t 
T7
2 
Enc 
T72 
Enc 
T78 
Enc 
T84 
Enc 
T90 
Wgh
t 
T=9
6 
En
c 
T9
6 
C1 247 0.5 1 0.5 1 240 0.5 1 1 1 240 0.5 
C2 241 0.5 1 0.5 1 228 1 1 1 1 228 0.5 
C3 246 0.5 1 0.5 1 246 0.5 1 1 1 246 0.5 
C4 D D D D D D D D D D D D 
C5 230 0.5 I 0.5 1 221 0.5 1 1 1 221 0.5 
C6 246 0.5 0 0 0 242 0 0 0 0 238 0 
C7 245 0.5 0 0 0 240 0 0 0 0 247 0 
C8 231 1 0.5 0.5 0.5 223 0 0.5 0.5 0 230 0 
V1 D D D D D D D D D D D D 
V2 237 0.5 1 0.5 0.5 236 0 0.5 0.5 0.5 244 0 
V3 225 0.5 0.5 0.5 0.5 239 0 0.5 0.5 0.5 252 0 
V4 245 0.5 1 0.5 0.5 237 0.5 0.5 0.5 0.5 240 0 
V5 216 0.5 1 0.5 0.5 232 0 0.5 0.5 0.5 230 0 
Z1 239 0.5 1 1 1 233 0 1 1 1 239 0.5 
Z2 226 0.5 0.5 1 0.5 229 0 1 1 1 230 0.5 
Z3 230 0.5 1 1 0.5 217 0 1 1 1 212 0.5 
Z4 219 0.5 2 1 0.5 210 0 D D D 207 D 
Z5 228 0.5 1 1 1 221 0 1 1 1 220 0.5 
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Figure 43.  Kaplin-Meyer Survival Curves for rats given 500mg/kg 
Thioacetamide +/- Caspase inhibitors 
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Figure 44.  Encephalopathy score over time for male Wistar rats treated with 
Thioacetamide 500mg/kg (control), and Thioacetamide and Caspase inhibitors 
zVAD or VE 453 
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Figure 45.  Weight loss of animals given Thioacetamide +/-Caspase inhibitors 
Z-VAD or VE-453 
 174 
There was no statistically significant difference in the primary endpoint of 
mortality at time 96 hours post Thioacetamide injection.  There was also 
no difference at any time point for weight loss.  Encephalopathy was 
statistically significantly lower at t=42 hours but not at any other time 
point.  
These results suggest that caspase inhibitors do not significantly improve 
clinical outcome in the Thioacetamide induced liver failure.  However the 
mortality in the control group, Thioacetamide only was not as high as predicted 
from previous studies, despite using the same breed, source and feed of rat.  
Experiments were therefore repeated using a higher dose (and new batch) of 
Thioacetamide.  The protocol was identical to that described above but instead a 
dose of 600mg/kg body weight of Thioacetamide was used.   
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Results 
 
Anim
al 
Code 
Substanc
e 
Wg
ht 
T=0 
Enc 
T=0 
Enc 
T=6 
Enc 
T=1
2 
Enc 
T=1
8 
Wg
ht 
T=2
4 
Enc 
T=2
4 
Enc 
T=3
0 
Enc 
T=3
6 
Enc 
T=4
2 
Red1 Control 308.
2 
0 1 2 1 290 1 1 0.5 0.5 
Red2 Control 314.
6 
0 1 3 2 301 1.5 1 0 0 
Red3 Control 312.
5 
0 1 1.5 1 291 1 1 0 0 
Red4 Control 301.
2 
0 1 2 1 275 1 0.5 0 0 
Red5 Control 315.
3 
0 1 2 1 296 0.5 0.5 0 0 
Red 6 Control 265 0 0.5 0.5 1.5 241 1 1 0.5 0.5 
Red 7 Control 270.
3 
0 0.5 0 1.5 253 1 1 0.5 0.5 
Red 8 Control 254.
4 
0 0.5 0.5 2 243 1.5 3.5 D D 
Grn1 VE-453 307 0 0.5 1 1.5 288 0.5 0.5 0 0 
Grn2 VE-453 293 0 0.5 2 1.5 277 1 0.5 0 0 
Grn3 VE-453 297 0 1 1.5 1.5 288 1.5 0.5 0 0 
Grn4 VE-453 337 0 0.5 1 1.5 310 1 0.5 0 0 
Grn5 VE-453 314.
1 
0 0.5 1 1 291 0.5 0.5 0 0 
Blu1 Z-VAD 334.
3 
0 0.5 1 1 318 1 0.5 0 0 
Blu2 Z-VAD 289 0 1 1 1 260 1.5 0.5 0 0 
Blu3 Z-VAD 350 0 0.5 2 1.5 331 0.5 0.5 0 0 
Blu4 Z-VAD 329.
6 
0 0.5 1 1.5 318 1 0.5 0 0 
Blu5 Z-VAD 307.
4 
0 1 2 2 289 1 0.5 0 0 
 
 
 
 
Anim
al 
Code 
Wg
ht 
T=4
8 
Enc 
T=4
8 
Enc 
T=5
4 
Enc 
T=6
0 
Enc 
T=6
6 
Wg
ht 
T=7
2 
Enc 
T=7
2 
Enc 
T=7
8 
Enc 
T=8
4 
Enc 
T=9
0 
Wg
ht 
T=9
6 
Enc 
T=9
6 
Red1 278 0 0 0 0 268 0 0 0 0 268 0 
Red2 284 0 0 0 0 282 0 0 0 0 281 0 
Red3 276 0 0 0 0 265 0 0 0 0 262 0 
Red4 263 0 0 0 0 257 0 0 0 0 259 0 
Red5 285 0 0 0 0 275 0 0 0 0 275 0 
Red6 231 0 0 0 0 229 0 0 0 0 230 0 
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Red7 240 0 0.5 0.5 0.5 241 0 0 0 0 243 0 
Red8 D D D D D D D D D D D D 
Grn1 273 0 0 0 0 270 0 0 0 0 272 0 
Grn2 262 0 0 0 0 256 0 0 0 0 251 0 
Grn3 285 0 0 0 0 266 0 0 0 0 266 0 
Grn4 302 0 0 0 0 257 0 0 0 0 289 0 
Grn5 273 0 0 0 0 271 0 0 0 0 274 0 
Blu1 300 0 0 0 0 294 0 0 0 0 301 0 
Blu2 277 0 0 0 0 252 0 0 0 0 257 0 
Blu3 D - - - - - - - - - - - 
Blu4 295 0 0 0 0 290 0 0 0 0 292 0 
Blu5 268 0 0 0 0 269 0 0 0 0 275 0 
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Figure 46.  Encephalopathy score over time for male Wistar rats treated with 
Thioacetamide 600mg/kg (control), and Thioacetamide and Caspase inhibitors 
zVAD or VE 453 
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Figure 47.  Graph showing encephalopathy score over time for male Wistar rats 
treated with Thioacetamide 600mg/kg (control), and Thioacetamide and Caspase 
inhibitors zVAD or VE 453 
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Figure 48.  Graph showing weight loss of animals given 600mg/kg 
Thioacetamide +/-Caspase inhibitors Z-VAD or VE-453 
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No statistically significant difference could be detected in any of the primary or 
secondary clinical endpoints.  Despite using an increased dose of Thioacetamide 
the mortality within the control group of Thioacetamide + vehicle alone 
remained lower than expected from previous studies.   
 
 
Caspase 3 activation demonstrated by histology 
Liver tissues were stained immunohistochemically using an antibody to 
activated Caspase 3 to investigate if TUNEL staining was accurately identifying 
apoptotic cells; to investigate if apoptosis induced by Thioacetamide was 
occurring via Caspase 3 activation; and to quantify if the caspase inhibitors used 
in the above animal model had inhibited Caspase 3 activation.  The primary 
antibody chosen was an anti-human/mouse Active Caspase 3 antibody 
(R&DSystems AF835).  Manufacturers recommendations stated that due to high 
degrees of homology between mouse and rodent Caspases and previous work, 
the antibody should bind with a high degree of specificity to activated Caspase 3 
in both human and rodent tissue.  We confirmed this using Human Tonsil, which 
is known to contain large numbers of lymphocytes undergoing apoptosis via a 
Caspase 3 dependent pathway, and used this as a biological positive control. 
 
Method 
Tissue on Apes coated slides was deparaffinised by thrice sequential 5 minute 
washes in 100% xylene, followed by rehydration  with two 5 minute washes in 
absolute ethanol, a 3 minute wash in 95%ethanol, a 3 minute wash in 70% 
ethanol and a 5minute wash in Phosphate Buffered Saline (PBS). 
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Antigen retrieval was performed by heating for 5 minutes in citrate buffer (0.1M 
Citric acid 9mls, 0.1M Sodium Citrate 41mls, 450mls ddH20, pH to 6.0) and 
then washed in PBS. 
Cross reacting antigens to secondary antibody species were blocked by 15 
minute incubation with 10% goat serum in PBS.  The primary antibody 
Polyclonal Rabbit Anti-human mouse Active Caspase 3 antibody (R&DSystems 
AF835 stored -20ºC) was diluted to working strength (0.3μg/ml in PBS) was 
applied to slides and incubated for 1 hour at room temperature in a humidified 
chamber.  Slides were then thrice washed with 15 minute washes in PBS before 
application of the secondary antibody Goat anti-Rabbit human, mouse, and rat 
adsorbed polyclonal IgG (BD Biosciences 554020 store 4ºC protected from 
light) working strength 10μg/ml, and incubation for 1 hour at room temperature 
in a humidified chamber.  Antibody solution was removed and slides washed 
thrice for 15 minutes in PBS.  Nuclei were counterstained by incubating with 
Hoechst stain (5uLin 1ml PBS) for 5 minutes followed by a PBS wash.   
Autofluorescence (particularly high in liver tissue due to lipofuscin) was 
reduced by immersion of slides for 20 minutes in 10mM Copper sulphate in 
50mM ammonium acetate Buffer pH5 for 20minutes, followed by three five 
minute washes in PBS.  Slides were mounted in Antifade mountant.  
 
 
 
 
Results 
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Figure 49.  Human Tonsil positive control for Active Caspase 3 (Left) and 
Thioacetamide treated t=36 hours rat liver (Right) x40. 
 
Caspase 3 positive cells (green) were clearly seen on the slides of human Tonsil 
(positive control), but no Caspase 3 positive cells could be seen in 
Thioacetamide treated rat liver. 
The inability to identify Caspase 3 positive cells in liver tissue, at a time after 
the administration of Thioacetamide when apoptosis had been identified by 
TUNEL cell positivity could have a number of explanations.   
The negative Caspase staining in rat tissue could represent a true finding.  This 
would suggest that if the TUNEL cell staining is a true positive that 
Thioacetamide induces apoptosis via a non-Caspase 3 dependent pathway.  
Apoptosis can occur by direct activation of mitochondria and be Caspase 3 
independent, it may also explain why Caspase 3 inhibitors failed to have any 
effect on clinical outcomes in protecting the rodents from Thioacetamide 
induced liver injury.  However previous studies have shown increased Caspase 3 
activity in rat liver and plasma after Thioacetamide induced injury (Hayami, 
Ikeda, Sun, Tanaka, & Kojo, 1999). 
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Alternatively the TUNEL  staining could be a false positive marker for apoptosis 
and be concordant with the negative Caspase 3 activity, it has been previously 
suggested that TUNEL staining may also identify necrotic cells (Hahn et al., 
2001) and Thioacetamide is known to induce liver necrosis at some doses. 
Finally lack of specificity of the primary antibody for rodent activated Caspase 3 
could explain the lack of staining, if there is insufficient homology between rat 
and human Caspase 3 the primary antibody could fail to recognise rat Caspase 3 
and coupled with background non-specific Caspase 3 antibody binding and 
tissue autofluorescence this could result in falsely negative staining.   
Finally the timing of the Caspase 3 activation could be earlier than the timing of 
peak TUNEL cell positivity. 
To try to differentiate between the above possibilities, a number of experiments 
were performed, the main aim of which was to identify a rat tissue positive 
control.   
The D-galactosamine + LPS rat model in which increased apoptosis and Caspase 
3 activity have already been demonstrated was prepared, and liver tissue samples 
treated according to the same methodology, but despite demonstrating increased 
apoptosis using TUNEL cell positivity in the treated rat (Picture A), compared to 
normal liver tissue (picture B), increased Active Caspase 3 could not be 
demonstrated using immunohistochemistry (Figure 76). 
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Figure 50.  Photomicrograph A- TUNEL cell positive cells (red) seen in liver 
tissue of a rat treated with D-GAL/LPS to induce liver injury (left), compared to 
normal rat liver tissue (right), Magnification x40. 
 
 
 
 
  
 
 
 
 
 
 
 
Figure 51.  Photomicrograph of liver tissue from D-GAL/LPS treated rat 
labelled with primary anti-activated Caspase 3 antibody, and appropriate 
secondary  FITC labelled antibody, demonstrating absence of activated Caspase 
3 (green). 
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Subsequent experiments were performed using a new batch of identical 
antibody, an alternative, anti-active Caspase3 antibody from a different 
manufacturer, secondary labelling with a non-fluorescent horseradish peroxidase 
system, amplification of signal using an additional biotin step (ABC) and 
different techniques of antigen retrieval but no activated Caspase 3 could be 
identified in rodent tissue using immunohistochemistry despite consistently 
positive human Tonsil controls.   
Western blotting of rodent liver tissue was also undertaken using cell lysates as 
positive controls but again no positive activated Caspase 3 could be identified in 
rat tissue.  
 
4.6   DISCUSSION 
Having identified in earlier chapters that humoral substances within acute 
liver plasma can induce apoptosis in primary hepatocytes, and that this can 
be attenuated by Caspase inhibition in-vitro, we aimed to identify if this 
inhibition would translate to an in-vivo model of acute liver failure, the 
Thioacetamide induced acute hepatic failure model.   Unfortunately, and 
for reasons that are unclear the Thioacetamide model control group did 
not have its usual predictably high mortality, despite identifying increased 
apoptosis by TUNEL cell positivity in Thioacetamide treated animals and 
animals suffering significant encephalopathy and weight loss.  Thus any 
possible decrease in mortality or improved clinical outcome was not 
identifiable in the Caspase inhibitor groups.   
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Also due to the inability to identify a reliable antibody to rodent activated 
Caspase 3, further experiments quantifying inhibition of Caspase 3 by 
inhibitors could not be undertaken. 
 
 
4.7   FUTURE WORK WITH ANIMAL MODEL 
We demonstrated apoptosis in liver tissue of animals with Thioacetamide 
induced liver injury but this failed to have its usual high mortality.  If time and 
resources had allowed we would initially have investigated the Thioacetamide 
model, to re-establish its validity; having done this the next step would be to 
identify and validate an alternative method to quantify Caspase 3 activation via 
an enzymatic method.  Initial studies in small numbers of animals could then be 
initially undertaken looking at alternative non-clinical markers of liver injury, 
particularly liver histology and plasma markers including serum transaminases.  
Having established that Caspase inhibitors did decrease these parameters of liver 
injury then a larger animal study could be undertaken looking at mortality as a 
primary outcome.    
If inhibition of apoptosis was shown to attenuate acute liver injury then further 
studies on the functionality of surviving hepatocytes and the ability of 
hepatocytes to proliferate allowing regeneration and longterm safety would need 
to be investigated. 
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CHAPTER 5: THERAPEUTIC METHODS FOR REMOVAL OF 
ALBUMIN BOUND TOXINS – MARS.  
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5.1  INTRODUCTION 
Artificial liver devices 
Liver transplantation cures approximately 90% of patients with acute liver 
failure, however a shortage of donor organs, unsuitability of patients to receive a 
transplant combined with the fact that many patients will become too ill to 
undergo transplantation, means despite this mortality remains high (Williams & 
O'Grady, 1990).  Therapeutic strategies that allow temporary liver support 
buying time for transplantation or endogenous liver recovery are therefore 
required.   
By performing the detoxifying function of the liver it is hoped an ―artificial 
liver‖ would not only prevent other end-organs from damage and preserve life, 
but by removing toxic substances from the plasma may make the general 
environment of the patient‘s own hepatocytes less toxic thus decreasing liver 
cell death and promoting regeneration and repair, breaking the vicious circle of 
liver failure (Riordan & Williams, 2000).   The aim of this chapter was to 
investigate whether one such form of liver support – the molecular Adsorbents 
Recirculating system (MARS) would remove the pro-apoptotic effect of acute 
liver failure plasma (demonstrated in earlier chapters) on primary human 
hepatocytes.  Removal of the pro-apoptotic effect would suggest that artificial 
liver support devices may improve patient outcome by improvements in 
endogenous liver function, and these systems could be valuable adjuncts to the 
protection of hepatocytes given either therapeutically (organ or cell 
transplantation)  or in a bioreactor as part of a liver support device.  A brief 
summary of artificial liver devices follows. 
 187 
Extracorporeal organ support:  The earliest forms of liver support used cross-
circulation of animal livers initially baboons (Abouna, 1968) and later porcine 
organs (Shimahara et al., 2001) for periods up to several days in duration; there 
was some improvement in the patients‘ condition, and human bile salts were 
found to be excreted by the non-human organ suggesting that they were indeed 
performing detoxicatory function, however ultimately due to immunological 
intolerance, risk of zoonosis, poor efficiency, and procedural complexity very 
few patients were treated. The procedure demonstrated proof of principle that 
replacement of endogenous liver function could improve a patients‘ clinical 
condition, but alternative methods would have to be derived.  
Whole blood exchange: Also in the 1970‘s removal of toxins by whole blood 
exchange in acute liver failure was used but with limited success (Barlyn et al., 
1971, Demedts et al., 1974)  and subsequent animal experiments have 
demonstrated that whole blood exchange may result in removal of factors 
necessary for liver regeneration limiting its use (Eguchi et al., 1998).  
Plasmapheresis: High volume plasmapheresis, is a much more selective 
method for removal of toxins from plasma (Inoue, 1981), it has been shown to 
improve neurological status (Freeman et al., 1986), decreases intracranial 
pressure, increase mean arterial blood pressure (Clemmesen et al., 1997) and 
improve cerebral blood flow(Larsen et al., 1994a) and oxygenation and possibly 
improves survival in acute liver failure (De Silvestro et al., 2000, Larsen, 
Hansen, Jorgensen, Secher, Kirkegaard, & Tygstrup, 1994b).  Large randomised 
trials are lacking but again the technique suggested that selective removal of 
substances within plasma of patients with liver failure may be beneficial 
(Clemmesen et al., 2001).  
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Haemodialysis and haemofiltration:  Simultaneously advances in the 
development of haemodialysis and haemofiltration membranes, which could 
efficiently remove water soluble substances, including abnormal middle-sized 
molecules seen on the chromatograms of sera in patients with liver disease 
(Matsubara et al., 1990), showed hope of removing toxic substances that may 
accumulate in liver failure.  Some trials did demonstrate improvement of level of 
consciousness, however they did not reverse liver failure or reduce mortality 
(Denis et al., 1978, Hughes & Williams, 1993, Opolon, 1979, Opolon, 1981, 
Rakela et al., 1988).  
Charcoal haemoperfusion, another technique which removes water soluble 
substances was developed but again controlled trials in acute liver failure were 
disappointing, failing to show significant removal of albumin bound substances 
or reduction in complications of liver failure e.g. cerebral oedema and renal 
failure, or mortality (Gimson et al., 1982, O'Grady et al., 1988b, Silk & 
Williams, 1978) 
The consistent inadequacy of these systems has been interpreted as due to the 
inability to remove significant amounts of albumin-bound substances (Hughes et 
al., 1992).  Activated charcoal which showed the capability of binding albumin 
bound substances such as bilirubin had been developed but was not 
biocompatible (exposure of whole blood to activated charcoal resulted in 
activation of cytokine and coagulation cascades) limiting its usefulness; 
alternative resins with improved biocompatibility and efficiency of removal of 
albumin bound toxins were required.  Amberlite XAD-7 was used for this 
application and whilst in-vitro it removed albumin bound toxins, including 
cytokines, from plasma, and albumin coating improved biocompatibility (Ton et 
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al., 1979), in-vivo trials showed limited removal of toxins (Hughes et al., 1979).  
Its binding capacity was inadequate, rapidly becoming saturated, the volume of 
resin required meant that columns would be too large for practical use and 
further development was abandoned. 
All of these early non-cell based artificial liver support devices failed to show 
any significant survival benefit in either acute liver failure or in acute-on-chronic 
liver failure in open label studies although some did improve encephalopathy 
(Ash, 1991, Kjaergard et al., 2003b).   
Bioartificial liver support:  Due to the complexities of liver function it seemed 
unlikely that any purely mechanical artificial device would be able to reproduce 
the myriad of functions performed by the liver.  Bio-artificial liver support 
systems containing hepatocytes in a bio-reactor were therefore proposed in an 
attempt to replicate normal liver function.  In 1987 Matsumura et al described 
the first case report of extracorporeal bioartificial support using rabbit 
hepatocytes in a plate dialyzer  to treat a patient  with an inoperable bile duct 
tumour (Matsumura et al., 1987). Subsequently in 1989 Margulis et al published 
a large controlled trial of 126 patients (59 subjects and 67 controls) with acute 
liver failure using porcine hepatocytes in an AV shunt cell, which showed a 
reduction in mortality, 37% in the treated group versus 59% in control group 
(Margulis et al., 1989).   
Demetriou et al also used porcine hepatocytes in hollow fibre plasmapherisis in 
ten patients with AHF, eight of which survived to transplantation (Demetriou et 
al., 1995). The same group subsequently entered their system into phase I 
clinical trials in patients with AHF (16/18 bridged to transplantation), primary 
non-function, (3/3 bridged to retransplantation) and acutely decompensated 
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chronic liver disease (2/10 recovered)(Watanabe et al., 1997).  The refined 
system was subsequently named the HepatAssist® system and is in commercial 
use. 
The HepatAssist® system (Circe Biomedical) developed Demetriou‘s system 
and utilizes primary porcine hepatocytes cryopreserved in liquid nitrogen. The 
cells can be thawed and are available to treat patients within three hours. Patients 
undergo standard plasmapheresis with the plasma directed toward the 
HepatAssist® system where it circulates through a charcoal column, an 
oxygenator, and the hollow fibre cartridge containing the freshly thawed, viable 
porcine hepatocytes.  The largest controlled trial included 171 patients with 
severe acute liver failure who were randomly assigned to the HepatAssist® 
system or usual care (Demetriou et al., 2004b). No significant difference in 
survival at 30 days was observed between the two groups overall (71 versus 62 
percent) or after adjusting for other known covariables. A statistically significant 
survival benefit was observed in a subgroup of patients with 
fulminant/subfulminant hepatic failure (RR 0.56, p=0.048) 
Several other systems have undergone large clinical trials.   
The Bioartificial Extra-corporeal Liver Support (BELS) system is a also a 
porcine cell-based extracorporeal liver assist device constructed with four 
separate capillary systems that mimic hepatic architecture (Gerlach, 1997). The 
system has successfully bridged eight out of eight patients with acetaminophen-
induced acute liver failure to either transplantation or recovery (Detry et al., 
1999) .  
The Extra-corporeal Assist Device (ELAD™, Hepatix Corporation, now 
Vital Therapies Inc) utilises a human hepotoblastoma cell line (HepG2 subclone 
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C3A) in its bioreactor.   An initial open labelled study of 11 patients with FHF 
demonstrated that ELAD was associated with improvement in encephalopathy 
and liver function tests; survival was 70 percent at 30 days (Sussman et al., 
1994). A subsequent controlled trial included 24 patients (17 of whom were 
considered to have potentially recoverable causes of liver failure and 7 of whom 
were listed for liver transplantation). Patients were randomized within these 
groups to conventional therapy or conventional therapy plus ELAD therapy; 
survival was not significantly different within the two groups (recoverable group 
survival 78% versus contols 75%, transplant listed group 33% versus 25% in 
controls) (Ellis et al., 1996b). 
Whilst biological systems perform more of the livers endogenous functions, no 
bio-artificial device has been shown to reduce mortality in acute liver failure. 
Clinical trials are small and therefore often underpowered making demonstration 
of survival benefit unlikely.  Larger trials are difficult due to the relative rarity of 
the condition, the heterogeneity of the pathogenesis and temporal differences 
with regard to the precipitating insult and presentation, and the issue of 
consenting patients who lack capacity into trials where best interest is unknown.  
There are also unique considerations with systems that contain live hepatocytes.  
Identifying hepatocyte sources that are biocompatible, readily available in large 
numbers, perform all the required detoxificatory and metabolic functions, that 
are pose no safety concerns has thus far remained elusive and so attention again 
shifted back to the use of mechanical detoxifying systems that would be highly 
selective, have a high capacity and be biocompatible.   
Charcoal haemoperfusion had shown some promise in improvement of 
encephalopathy and blood pressure, and activated charcoal had a greater 
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potential binding capacity.  The difficulties in biocompatibility and poor 
selectivity were overcome by keeping the patients blood from the charcoal and 
anion exchange resins separate from blood using a dialysis membrane.  The 
Hemotherapies liver dialysis unit, and Prometheus System both work on this 
principal termed haemodiabsorption, a hybrid between hemodialysis and 
charcoal/resin hemoperfusion. 
The HemoTherapies Unit™ — The HemoTherapies liver dialysis unit 
(www.hemotherapies.com) is based on the BioLogic-DT® System. A plate 
dialyzer (membrane 5000kDa molecular weight cut-off) separates the blood side 
from a suspension of sorbents (charcoal and cation exchangers), with 
biocompatibility similar to that of haemodialysis, but with chemical selectivity 
much greater than in hemodialysis/ hemoperfusion. The chemical capacity for 
adsorption of compounds by charcoal in hemodiabsorption is also greater than 
hemoperfusion columns. A blood treatment rate of 200 to 250 mL/min is 
achieved but instead of a dialysate solution, the liver dialysis system contains a 
two-litre suspension of powdered sorbents, including 140 grams of powdered 
activated charcoal (300,000 square meters) and 80 grams of the cation exchanger 
polystyrene sulfonate sodium (PSS, 80 meq binding capacity).  
Effectively suction draws plasma water and substances with a molecular weight 
below the cut off of the cellulose membrane from the blood into the suspension 
of sorbent components where protein bound hydrophobic and organic substances 
are transferred to the powdered charcoal and ammonium and other cations are 
removed by the cation exchanger.  The addition of plasmapheresis capability 
across the membrane allowed increased clearance of albumin bound substances 
(Ash et al., 1998).  Small controlled trials demonstrated reduction in albumin 
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bound substances and improvement in encephalopathy score and blood pressure, 
however overall improved survival in either acute or chronic liver disease has 
not been demonstrated (Ash et al., 2000, Wilkinson et al., 1998).  Certain 
subgroups of patients with decompensated cirrhosis with grade III/IV 
encephalopathy, many with renal or pulmonary failure showed improved 
survival with treatment (71 versus 36 percent, p<0.05) (Ash, 2000). 
Prometheus® — The Prometheus® is another extracorporeal device based on 
haemodiabsorption, it uses high-flux hemodialysis against a special adsorber to 
remove albumin-bound substances from the blood.  A pilot study of 11 patients 
suggested improvement in laboratory tests after only two treatments (Rifai et al., 
2003).  However the results of a much larger trial (HELIOS) presented recently 
in abstract at EASL 2010 confirmed no significant survival benefit. 
Albumin dialysis – Another way to selectively remove albumin bound 
substances is by single-pass haemodialysis against an albumin solution.  This 
technique removed albumin bound substances (Peszynski et al., 2002) but would 
require a large volume of albumin with a high binding capacity.  Thus systems 
were developed that would ‗clean‘ the albumin which had become saturated 
with albumin bound substances.  Since it was known that activated charcoal and 
anion exchange resins had a high capacity for such substances the passage of 
used albumin across such sorbent columns could be used to regenerate albumin.  
A hybrid system was developed, allowing the selectivity and biocompatibility of 
albumin dialysis with the clearance capability of haemodiabsorption, the 
albumin dialsylate effectively acting as a carrier molecule between charcoal and 
adsorbent columns and dialysate membranes. The molecular adsorbents 
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recirculating system (MARS) is such a system and is currently the main liver 
support system used in the U.K.  Chapter 5 of this thesis reports the experience 
of MARS use at the Royal Free Hospital and investigates some of the 
mechanisms of its effects. 
 
5.2  MOLECULAR ADSORBENS RECIRCULATING SYSTEM (MARS)   
Introduction 
The pathophysiology of liver failure is poorly understood (Sen et al., 2002b).  
Ammonia, aromatic amino-acids, tryptophan, indoles, endogenous 
benzodiazepines and digoxin-like substances have all been implicated in the 
pathophysiology of encephalopathy; nitric oxide, prostanoids and other 
cytokines have been implicated in the pathogenesis of circulatory and renal 
dysfunction; other cytokines, bile acids and oxidative stress are known to be 
hepatotoxic and the vast majority of these substances are water-insoluble and 
therefore transported bound to albumin.  
Biochemistry and physiology of Albumin 
Human albumin, a major component of human plasma, produced by the liver, it 
is a 66kDa molecule with a strong net negative charge which binds weakly and 
reversibly to both anions and cations acting as a transporter/scavenger as well as 
being largely responsible for plasma‘s high oncotic pressure (Evans, 2002).  In 
addition to its binding capacity a cysteine residue at position 31 has an exposed 
reduced sulphydryl group (thiol) and this acts as a scavenger of reactive oxygen 
and nitrogen species, especially superoxide, hydroxyl and peroxynitrite radicals. 
This gives albumin the capacity to directly reduce oxidative stress and is indeed 
the major extracellular source of reduced sulphydryl groups.  In addition to 
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directly buffering oxidative stress albumin can bind free Cu
2+
 which is known to 
be a catalyst in the production of free radicals, thus also indirectly reducing 
oxidative stress.  Since oxidative stress is known to be able to induce cell 
necrosis and apoptosis the reduction of oxidative stress may be another of 
albumin‘s beneficial effects.  Albumin‘s effects on oxidative stress are known to 
be able to effect transcriptional events by inducing nuclear factor kappa B (NF –
κβ) (Cantin et al., 2000).  Patients with liver disease have reduced quantities of 
albumin, and increased demand for its binding properties, albumin may also 
undergo qualitative changes decreasing its binding capacity (Bertucci et al., 
2001). 
The possible beneficial effects of albumin as a scavenger/anti-oxidant in liver 
disease (Gines et al., 2002) is suggested by the increased survival in patients 
with liver disease and Spontaneous Bacterial Peritonitis (Sort et al., 1999) and 
the reduction in mortality seen when used together with glypressin in the 
treatment of type1 hepatorenal syndrome (Moreau et al., 2002, Uriz et al., 2000) 
when treated intravenously.  These benefits cannot be accounted for by the 
plasma expanding effects of albumin alone as head to head trials of albumin 
versus other colloids have always demonstrated superiority of albumin 
(Fernandez et al., 2005, Garcia-Compean et al., 2002, Ortega et al., 2002).  
Since many of the toxins postulated to have a role in the pathogenesis of liver 
failure are albumin bound, and intravenous albumin is of benefit in liver disease, 
it has been suggested that systems which remove these toxic molecules, 
effectively ―cleaning‖ the patients‘ own albumin, may improve outcome. 
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Function of MARS 
 The molecular adsorbents recirculating system (MARS) is an extracorporeal 
albumin dialysis system which allows removal of albumin bound substances.  In 
brief via a special membrane the system allows transfer of water soluble and 
albumin bound toxins with molecular weight less than 50kDa from blood into a 
dialysate solution containing 20% human albumin; this albumin solution is then 
―cleaned‖ by passing it over a charcoal filter, resin adsorbents and a 
haemofilter/haemodialyser before recirculating it (Stange et al., 1993).      
The patient‘s venous blood is drawn off a large bore central venous double 
lumen catheter by a mechanical pump at a rate of up to 200mls/min via sterile 
heparin primed polyurathane dialysis tubing. The blood passes through a hollow 
fibre cartridge which is composed of an albumin-impregnated polysulfone 
membrane with a pore size of 50kDa.  On the outside of the hollow fibre, in a 
counter current direction, flows 20% human albumin solution and is then 
returned to the patient via the central venous catheter.  Albumin has been shown 
to have a higher affinity for toxins when bound to polymers (Hughes, Ton, 
Langley, Davies, Hanid, Mellon, Silk, & Williams, 1979), toxins therefore 
dissociate from the patient‘s albumin and bind to the albumin impregnated 
membrane.  Since there is a gradient between the concentration of toxic 
molecules bound to the membrane and the albumin in the 20% dialysate 
solution, the toxins are effectively removed by dialysis.  Since single pass 
dialysis would require massive quantities of albumin, the albumin in the 
diasylate‘s binding capacity is regenerated.  After the 20% albumin solution has 
passed across the dialysis membrane (it being on the outside of the hollow 
fibres, contained within the dialysis cartridge), it is pumped through sterile 
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polyurethane tubing across a conventional haemofiltration/haemodialysis filter 
where water soluble substances are removed by either by passing a dialysate 
solution in a counter-current direction (if dialysis is chosen)  or by ultrafiltration 
(if haemofiltration is required) (Sen et al., 2002a).  The albumin is then perfused 
through a column of activated charcoal and a subsequent anion-exchange resin 
which removes the albumin adsorbed substances.  The ‗clean‘ albumin is then 
recycled through the initial cartridge in a countercurrent direction to the patients 
blood.  The flow rate in the albumin circuit is 200ml/min. 
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Figure 52.   Schematic representation of MARS circuit (courtesy of Teraklin 
UK) 
1 = Return of “detoxified” whole blood to the circulation via venous 
vascular catheter having passed through blood/20% albumin dialysis 
membrane cartridge. 
2 = Removal of whole venous blood via venous vascular catheter using 
mechanical pump on haemodialysis/haemofiltration machine. 
3 = Passage of 20% “dirty” human albumin dialsylate via albumin pump on 
MARS monitor to haemodialysis/haemofiltration membrane. 
4 = Removal of water soluble molecules via haemodialysis/haemofiltration 
membrane (pumps & lines part of haemodialysis/haemofiltration machine). 
5 = Passage of 20% human albumin across activated charcoal cartridge. 
6 = Passage of 20% human albumin across anion exchange resin cartridge. 
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Table 10. Substances removed by MARS 
Substance References 
Ammonia (Awad et al., 2001, Seige et al., 
1999, Stange et al 1999) 
Bilirubin (Awad et al., 1997, Mitzner et 
al., 1996) 
Bile Acids Stange et al., 2000) 
Aromatic amino acids (increase Fischer 
ratio) 
(Loock et al., 1997) 
Middle and short chain fatty acids (Mitzner et al, 2001) 
Tryptophan (Stange et al., 2002) 
Copper (Kreymann et al., 1999, Manz et 
al., 2001) 
Urea (Sorkine et al., 2001,) 
Creatinine Mitzner et al, 2000) 
Cytokines – TNF-α, Interleukin 6 (Ambrosino et al., 2003, Awad et 
al., 1999) 
Diazepam (Majcher-Peszynska j et al., 
1999) 
Nitric Oxide (Guo L-M, 2003, Kurtovic et al., 
2004) 
Drugs e.g. Phenytoin (Sen et al., 2003, Sen et al., 
2004) 
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Physiological effects of MARS 
Treatment with MARS has been shown to have a number of beneficial 
physiological effects: 
Cardiovascular system  Increased systemic vascular resistance (Schmidt et 
al., 2001)  
Increased mean arterial blood pressure (Mitzner et 
al, 2000) 
Reduces portal pressure (Sen, 2005) 
Cerebral function  Decreased hepatic encephalopathy (Awad et al, 
Mitzner et al., 2002) 
Decreased intra-cranial pressure/brain oedema 
(Ben Abraham et al., 2001) 
Increased cerebral blood flow  
Kidney function   Increase in urine output (Mitzner et al., 2001) 
Decreased serum creatinine (Steiner & Mitzner, 
2002) 
Liver function   Indocyanine green excretion increased  
Quality of life   Decreased pruritus (Macia et al., 2003)  
Decreased fatigue  
 
Clinical benefits of MARS  
In small trials MARS has shown a survival advantage in acute-on-chronic liver 
failure (Heemann et al, 2002), Alcoholic Hepatitis (Jalan et al., 2003) and 
Hepato-Renal Syndrome (Mitzner et al, 2000).  Despite improvement in several 
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parameters, particularly encephalopathy, MARS therapy has yet to be shown to 
produce any survival benefit in acute liver failure, although small case series 
describe positive results largely using MARS as a bridge to transplantation 
(Novelli et al, 2002), or in primary non-graft function as a bridge to recovery.  A 
larger study (The RELIEF study) on 189 patients was presented at EASL 2010 
again showed no significant survival benefit in patients with acutely 
compensated liver disease.  A recent metanalysis of MARS therapy failed to 
show any benefit in either acute liver failure or acutely decompensated chronic 
liver disease. 
 Recent meta-analysis of all liver support devices (including MARS) compared 
with standard medical therapy has failed to show any significant reduction in 
mortality (RR 0.86, 95% CI 0.65-1.12).  However stratified meta-analysis has 
shown that in acutely decompensated chronic liver disease mortality is reduced 
by 33%, whereas mortality in acute liver failure shows no reduction {Liu, 2002 
20 /id}.  Despite the paucity of large randomised controlled trials, more than 
4500 patients have been treated with the MARS
®
 Liver Support Therapy to date 
Possible mechanism of action of MARS 
The exact mechanism of the possibly improved clinical outcome remains 
unknown.  The removal of albumin bound mediators that have direct toxic 
effects on organ function has been suggested as the primary mechanism of 
action of MARS.  This assumes that this/these molecules are directly toxic, 
albumin bound and less than 50kDa in size so as to be able to cross the primary 
dialysis membrane and are efficiently removed by the dialysis process, and/or 
the charcoal/anion exchange resin.  
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An alternative explanation could be that by removing albumin bound substances 
from the patients endogenous albumin (these may not necessarily be toxic) the 
specific binding capacity of the patient‘s albumin (Klammt et al., 2001) is 
increased and that in-vivo toxins are therefore bound, decreasing their toxic 
effects.  This would mean that the toxic molecules need not be <50kDa in size or 
removed by the dialysis process.   
Finally, the ―toxic‖ molecules removed by MARS itself or made less toxic by 
MARS therapy by allowing increased albumin binding need not be directly toxic 
to cells.  Indeed many of the improvements in end-organ function could be 
explained by improved organ perfusion due to improved haemodynamics 
(increased blood pressure and increased systemic vascular resistance) due to the 
removal/increased binding of mediators that have direct effects in the 
vasculature rather that the removal of directly organ toxic molecules.   
Since albumin may also bind beneficial substances, the removal of which may 
have deleterious effects on hepatocytes and other cells, MARS therapy may in 
fact decrease the likelihood of organ regeneration. 
Plasma from patients taken before and after MARS therapy could therefore be 
utilised to differentiate between some of these possibilities and could provide 
useful information for the development/improvement of artificial liver support 
devices and other therapeutic strategies.  In this chapter, using the assays 
developed to look at the effect of human liver failure plasma on primary human 
hepatocytes described in the previous chapters  we investigate the effects of 
MARS therapy both on patient physiology, particularly renal function, and 
outcome and on qualitative effects on plasma. 
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5.3   USE OF MARS AT THE ROYAL FREE HOSPITAL 
Patients who reached inclusion criteria, had no exclusion criteria and gave 
informed consent (or assent of relatives) were enrolled on a trial of MARS 
therapy (see consent form appendix).  Blood samples were obtained before and 
after each session of MARS therapy.  Ethical approval for this trial was been 
obtained from the local ethics committee (see appendix). 
 
Inclusion Criteria     
Hepatic decompensation as evidenced by two out of three of the following: 
Severe jaundice (Bilirubin >205μmol)  
Hepatic encephalopathy   
Hepatorenal syndrome 
 
Exclusion criteria 
Age <16 or>75 
Lack of consent/assent of next of kin 
Viral Hepatitis 
Contraindications to MARS therapy: Disseminated Intravascular Coagulation 
     Active/recent haemorrhage 
Significant Hypotension (systolic 
<90mmHg) 
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Table 11. Summary of Patients treated with MARS therapy at Royal Free 
Hospital 
 
Patient  Age Sex Diagnosis MELD Score 
Pre-
Treatment 
1. SD 40 M Alcoholic Hepatitis 
Cirrhotic 
Renal impairment 
20 
2. FA 42 F Fulminant Wilsons disease 
Encephalopathy 
Renal impairment 
23 
3. JW 34 M Benign Recurrent Intrahepatic Cholestasis 
Renal impairment 
16 
4. SR 54 F Alcoholic Hepatitis 
Renal impairment 
17 
5. AG 57 M Decompensated Cirrhosis 
Obstructive jaundice 
Renal Impairment 
19 
6.  TN 33 F Decompensated Alcoholic Cirrhosis 
Encephalopathy 
Renal impairment 
17 
7. AM 60 M Erythropoitic protoporphyria 
Acute liver failure previous transplant 
Renal failure 
Encephalopathy 
13 
8. NS 33 F Alcoholic Hepatitis 
Renal impairment 
17 
9. BM 62 M Primary graft non-function 
Renal Failure 
Multi-organ Failure 
19 
10. KB 40 F Alcoholic Hepatitis 
Renal impairment 
20 
11.MR 56 F Alcoholic Hepatitis 
Cholestatic drug reaction 
Cirrhosis 
16 
12.DW 31 F Alcoholic Hepatitis 
Cirrhosis 
20 
13.DS 65 M Hepato-Renal Syndrome  
Alcoholic Cirrhosis 
23 
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Procedure 
A double lumen vascular catheter was inserted into the femoral vein (FFP or 
platelets were given as prophylaxis if necessary) under local anaesthetic using 
aseptic technique. 
The MARS monitor and haemofiltration (Baxter) or haemodialyisis machine 
(Baxter) were prepared and primed according to the manufacturer‘s instructions.  
In brief both haemodialysis and MARS circuits were primed using 1L of sterile 
normal saline containing 5000 iu of Heparin, ensuring there were no 
airlocks/bubbles in the circuit.  The MARS circuit was then loaded with 600ml 
of sterile 20% salt-poor human albumin (Zenalb) which was circulated around 
the albumin circuit for 15 minutes prior to attachment to the patient to allow 
removal of stabilisers in the 20% human albumin and thus increase its albumin 
binding capacity.  The patient‘s vascular catheter was then connected to the 
blood dialysis circuit and dialysis commenced initially at a blood flow rate of 
50ml/min rapidly increasing to 200ml/min as haemodynamic status would 
allow. 
Patients were treated with the MARS circuit at a flow rate of 200ml/min with 
haemofiltration at 2L exchange/hour. Dialysis fluid was returned to the circuit in 
the post filter circuit (post-dilution).  The amount of potassium put in the 
dialysate bags and fluid balance over treatment duration was decided based on 
the individual needs of the patient.  The patient‘s blood circuit was 
anticoagulated with Heparin 100units/hour to prevent clotting in lines or dialysis 
filter unless contraindicated.  Patients were treated for 6 hours on 2-3 
consecutive days.  Blood samples were taken for full blood count, clotting, and 
routine biochemistry before and after each treatment.  Serum was also taken, 
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aliquoted and stored at -20 
o
C for measurement of Cystatin C, a measure of renal 
function (Hoek et al., 2003, Lamb et al., 2003) and heparinised blood was taken 
and plasma separated by centrifugation as described in previous chapter) and 
plasma stored at -20 
o
C for assessment of in-vitro toxicity assays.  Clinical 
parameters including encephalopathy score (where possible to assess), blood 
pressure and pulse, were also assessed before and after treatment.  Full blood 
count, clotting and routine biochemistry (Urea, Creatinine, Sodium, Potassium, 
Total Bilirubin, Alanine transaminase, Aspartanine transaminase, serum 
albumin, total protein, Alkaline Phosphatase, Calcium and Phosphate were 
measured using standard labatory methods by the routine clinical laboratory.   
MELD score pre-treatment was calculated using haematology and biochemistry 
parameters prior to treatment or transfusion of clotting factors for line insertion. 
 
Cystatin C was measured by Cystatin C Immunoparticles kit (Dakocytomation 
cat no:LX002) according to manufacturers instructions by a laboratory 
experienced in this technique (Biochemistry Department, St Hellier Hospital, 
Carshalton, UK).   A polyclonal rabbit antibody to cystatin C covalently coupled 
to polystyrene particles when mixed with heparinised plasma results in the 
formation of immune complexes that can be measured by turbidometry.  A 
calibration curve is produced using DakoCytomation Cystatin C Calibrator 
(X0974), the Cystatin C Control Set (X0973) was used as a control. 
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Statistical analysis 
Results are expressed as mean values ± SEM.  Results were tested for normality 
using Gaussian distribution, parametric data was analyzed using two-tailed 
paired student t-test, non-parametric paired data was analyzed using Wilcoxon 
matched pairs test.  P<0.05 was used to identify statistical significance.  
Statistical analysis was performed with Graphpad Prism version 3.02. 
 
5.4   RESULTS I – Clinical outcome 
Mortality 
Previous data  has shown that six-month actuarial survival while on the 
transplant waiting list is 90% with a MELD <17, whereas it decreases 
progressively to 40% at 6 months for those with a score of >16 (Adler et al., 
2005).  Thirty day mortality in a comparable subgroup to ours is scarce but a 
previous trial of renal support in patients with hepatorenal syndrome treated with 
renal support (Adler M et al) showed patients' 30-day survival was 8/30 (median 
survival time 21 days)(Witzke et al., 2004).  Another trial for patients with 
alcoholic hepatitis showed the mean MELD score at admission for survivors at 
30-days was 4.3, while for non-survivors was 18.7. Using a cut-off MELD score 
of greater than 11, the sensitivity and specificity of the MELD score for 
prediction of 30-day mortality was 86% and 82% respectively (Sheth et al., 
2002).  Our patients had a mean MELD score of 18.1 before their first treatment 
(range 16-23, median 18) indicating a group of patients with a poor prognosis.  
Survival at 30 days was 8/13 (62%). One patient received a successful liver 
transplant within 30 days of treatment.  Of the patients who died mean survival 
post treatment was 9.5 days (day 1=first day of treatment).  Cause of death was 
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pneumonia in two patients (day 7 and day 30), asystolic cardiac arrest (day 2), 
GI haemorrhage (day 10), cerebral oedema (day 6) and haemothorax (day 2). 
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Summary of Patients treated with MARS therapy at Royal Free Hospital 
Patient  Age Sex Diagnosis MELD Score 
Pre-Treatment 
Outcome 
Day 30 
1. SD 40 M Alcoholic Hepatitis 
Cirrhotic 
Renal impairment 
20 Died  
 
 
2. FA 42 F Fulminant Wilsons 
disease 
Encephalopathy 
Renal impairment 
23 Died 
 
3. JW 34 M Benign Recurrent 
Intrahepatic Cholestasis 
Renal impairment 
16 Alive  
 
4. SR 54 F Alcoholic Hepatitis 
Renal impairment 
17 Alive 
5. AG 57 M Decompensated 
Cirrhosis 
Obstructive jaundice 
Renal Impairment 
19 Died 
 
6.  TN 33 F Decompensated 
Alcoholic Cirrhosis 
Encephalopathy 
Renal impairment 
17 Died 
7. AM 60 M Erythropoitic 
protoporphyria 
Acute liver failure 
previous transplant 
Renal failure 
Encephalopathy 
13 Alive 
8. NS 33 F Alcoholic Hepatitis 
Renal impairment 
17 Alive 
9. BM 62 M Primary graft non-
function 
Renal Failure 
Multi-organ Failure 
19 Alive 
10. KB 40 F Alcoholic Hepatitis 
Renal impairment 
20 Alive 
11.MR 56 F Alcoholic Hepatitis 
Cholestatic drug 
reaction? 
Cirrhosis 
16 Alive 
Liver 
transplant 
12.DW 31 F Alcoholic Hepatitis 
Cirrhosis 
20 Died 
 
13.DS 65 M Hepato-Renal Syndrome  
Alcoholic Cirrhosis 
23 Died 
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Haemodynamic status 
There was a statistically significant increase in mean arterial blood pressure 
(MAP) by an average of 3.8mmHg per 6 hour MARS treatment, from a mean of 
81.6 (sd=11.3) mmHg pre-treatment to 85.4 (sd=10.6) mmHg post-treatment 
(p=0.044) (95% confidence interval -7.519 to -0.111). 
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Figure 53.  Mean arterial blood pressure (mmHg) (n=27) immediately before 
and after each treatment with MARS therapy.   
 
 
S
D
1
S
D
2
F
A
H
1
F
A
H
2
A
M
1
A
M
2
T
N
1
T
N
2
S
R
1
S
R
2
N
S
1
N
S
2
B
M
1
B
M
2
B
M
3
K
B
1
K
B
2
M
R
1
D
S
1
D
S
2
D
W
1
D
W
2
J
W
1
J
W
2
J
W
3
A
G
1
A
G
2
0
50
100
150 Pre treatment
Post treatment
M
e
a
n
 a
rt
e
ri
a
l 
b
lo
o
d
p
re
s
s
u
re
 m
m
H
g
 
Figure 54.  Mean arterial blood pressure for each individual before and after 
each treatment with MARS therapy. 
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Encephalopathy 
Patients‘ degree of encephalopathy was scored before and after each treatment 
by clinical examination and graded accordingly. 
Grade Clinical findings 
O Normal 
1 Mild confusion, shortened attention span, mood disturbance, reversal of sleep 
wake pattern. Hepatic flapping tremor (asterexis) usually absent. 
2 Drowsiness, lethargy, gross deficits in ability to perform mental tasks, obvious 
personality changes, intermittent disorientation, lack of sphincter control.  Hepatic 
flapping tremor (asterexis) usually present. 
3 Somnolent but rousable, persistent disorientation in time and place, pronounced 
confusion, unable to perform mental tasks. Hepatic flapping tremor (asterexis) 
usually present. 
4 Coma Hepatic flapping tremor (asterexis) usually absent. 
 
In those patients where encephalopathy score could be assessed, (19 treatments), 
there was a significant improvement in mean encephalopathy score from 1.5 pre-
treatment to 0.9 post-treatment p=0.003.  Eight treatments were undertaken in 
patients who were paralysed and ventilated such that encephalopathy score could 
not be assessed.   
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Figure 55.  Mean encephalopathy score immediately before and after each 
treatment with MARS therapy.   
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5.5  ADVERSE CLINICAL EVENTS 
Serious adverse effects which could possible be a result of the trial/MARS 
therapy occurred in three of the thirteen patients treated. 
The original trial format included the measurement of Iohexol clearance as a 
measure of renal function before and after treatment with MARS therapy.  
Iohexol is a small molecule commonly used as radio-opaque contrast medium 
which is filtered by the glomerulus and not reabsorbed by the more distal parts 
of the nephron.  Thus its elimination from the circulation after a single bolus 
intravenous injection provides a direct measurement of Glomerular Filtration 
Rate, which is both accurate and avoids the need for complex continuous 
infusions (as in the measurement of inulin clearance).  The first two patients 
treated with MARS therapy were done according to this protocol.  Patient 2 F.A. 
a 42 year old female with fulminant hepatic failure due to Wilson‘s disease 
suffered an asystolic cardiac arrest 5 minutes after injection of 5ml Iohexol 300 
via an internal jugular line given after completion of the patients‘ second session 
of treatment with MARS therapy.  The previous injections of Iohexol and the 
MARS therapy itself had been uneventful and there was no hypotension prior to 
the arrest or history of Iodine allergy.  Basic cardiopulmonary resuscitation was 
instituted and Atropine 3mg, adrenaline 1mg and calcium chloride were given to 
the patient who transiently returned to sinus rhythm before suffering a further 
refractory asystolic arrest.  The patient‘s past medical history revealed she had 
moderate mitral valve regurgitation but otherwise no cardiac history.  Possible 
explanations for the patient‘s demise included the use of Iohexol which has an 
incidence of 2 in 10
6
 of serious arrythmias and in case reports in animals may 
cause asytole.  Alternative explanations included lyposomal Amphotericin 
 213 
which can also cause asystole, undiagnosed cardiac Wilson ‘s disease which can 
cause serious arrythmias, or asystole as a terminal event in a septic patient with 
fulminant liver failure whose condition had been progressively deteriorating 
over the previous days despite appropriate medical therapy.  In view of the 
possibility that Iohexol had contributed to this patient‘s death the use of MARS 
was temporarily halted and the ethics committee was informed of the adverse 
event. Whilst it was felt unlikely that Iohexol was the cause of death we 
removed Iohexol as a measurement of renal function from the protocol and 
replaced it with serum Cystatin C analysis.  Cystatin C is a small, 13 kDa, non-
glycosylated basic protein belonging to the cystatin super-family of cysteine 
protease inhibitors. Cystatin C is produced by virtually all nucleated cells, and is 
present in all body fluids investigated. The production rate is constant and is 
unaltered in inflammatory conditions. In the normal kidney, cystatin C is almost 
freely filtered through the glomerular membrane and then nearly completely 
reabsorbed and degraded by the proximal tubular cells. Therefore, the plasma 
concentration of cystatin C is almost exclusively determined by the glomerular 
filtration rate (GFR), making cystatin C an excellent indicator of GFR. 
Moreover, the cystatin C plasma concentration is uninfluenced by gender and 
muscle mass. Numerous studies and a meta-analysis incorporating 4492 subject 
samples have shown that serum cystatin C is clearly superior to serum creatinine 
as a marker for GFR. Measurement of serum Cystatin C was therefore 
performed pre- and post- each treatment of MARS therapy. 
The amendment from Iohexol clearance to Cystatin C analysis as a measure of 
renal function was cleared by chairman‘s action of the ethics committee prior to 
recommencement of the trial.  Stored samples were used for retrospective 
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measurement of Cystatin C for the initial two patients treated by the alternative 
methodology. 
The other two complications of MARS therapy were the development of a 
bleeding diathesis whilst on treatment.  Patient 10. K.B. developed bleeding 
spontaneously from a spider naevus over the right clavicle, which had bled after 
minor trauma two days earlier, in the last 10 minutes of her second session of 
MARS therapy.  Approximately 200 mls of blood was lost, the patient remained 
haemodynamically stable.  Clotting results showed large derangements in APTT 
(Pre treatment 51.6s post treatment >350s) and INR (Pre treatment 2.2, post 
treatment >8) and although the patients platelets did not fall (pre-treatment 126, 
post-treatment 161) it was suspected that the patient had developed a low grade 
DIC.  (the patients Hb fell by 1.2g (pre-treatment 9.8g/dL, post treatment 
8.6g/dL.  Bleeding was controlled by direct pressure of the bleeding point and 
cessation of MARS therapy. 
The second complication occurred in patient 11; in the last hour of treatment the 
patient developed cyanosis and shortness of breath, and developed a large 
haematoma (20cm diameter) on the right side of the neck, the site where a 
transjugular biopsy sheath had been removed 2 days earlier.  Significant blood 
loss into a haematoma/haemolysis resulted in drop in Hb of 2g/dL.  Blood 
results (PT 54.2, INR 4.8, APTT >250, TT 22, Fibrinogen 1, Platelets 30, Hb 
8.4) which suggested the patient had developed disseminated intravascular 
coagulation.  The patient was haemodynamically stable throughout.  Local 
pressure was applied to the haematoma site and the patient was transfused with 
fresh frozen plasma 1500ml, Platelets 1 pool and packed red cells 2 units. 
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Complications were reported to Teraklin AG as part of their ongoing safety 
monitoring.  All patient data was recorded in the international MARS registry. 
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5.6  RESULTS II - Biochemical parameters 
Renal function 
There was no statistically significant fall in serum urea before and after each six 
hour MARS treatment. Paired student t-test p=0.052, (n=26, (95% confidence 
interval 0.014 – 2.914).  
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Figure 56.  Mean Urea (mMol/dL) immediately before (pre-treatment) and after 
(post-treatment) a single six hour MARS treatment.   
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Figure 57.  Individual Urea (mMol/dL) immediately before (pre treatment) and 
after (post treatment) each six hour MARS treatment. 
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Mean serum creatinine fell by 20% from a mean pre-treatment of 201 uM/dL to 
161uMol/dL with each six hour MARS treatment session.  This decrease was 
statistically significant.  Paired student t-test p<0.005, (n=26, 95% confidence 
interval 15.2-59.9). 
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Figure 58.  Mean serum creatinine (uMol/dL) before (pre treatment) and after 
(post treatment) a single six hour MARS treatment.  
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Figure 59.  Individual Creatinine (uMol/dL) immediately before (pre treatment) 
and after (post treatment) each six hour MARS treatment. 
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Mean plasma Cystatin C concentration fell by 10.4% from a mean pre treatment 
of 2.33 IU/L to 2.09 IU/L with each six hour MARS treatment session.  This 
decrease was statistically significant.  Paired student t-test p<0.05, n=26, (95% 
confidence interval 0.074 - 0.410). 
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Figure 60.  Mean plasma Cystatin C (IU/L) before (pre-treatment) and after 
(post-treatment) a single six hour MARS treatment.  
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Figure 61.  Individual Cystatin C (IU/L) immediately before (pre treatment) and 
after (post treatment) each six hour MARS treatment. 
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Liver function 
Mean plasma Bilirubin concentration fell by 26.6% from a mean pre treatment 
of 380uMol/dL to 279uMol/dL with each six hour MARS treatment session.  
This decrease was statistically significant.  Paired student t-test p<0.001, n=26, 
(95% confidence interval 51.9-134). 
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Figure 62.  Mean plasma Bilirubin (µMol/dL) before (pre-treatment) and after 
(post-treatment) a single six hour MARS treatment.  
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Figure 63.  Individual Bilirubin uMol/dL immediately before (pre treatment) 
and after (post treatment) each six hour MARS treatment. 
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Mean plasma AST (IU/L) concentration fell by 37% from a mean pre-treatment 
of 428IU/L to 270IU/L with each six hour MARS treatment session.  This 
decrease was statistically significant.  Data was not normally distributed 
therefore was analysed using Wilcoxon ranked pairs test p<0.01, n=26. 
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Figure 64.  Mean AST (IU/L) before (pre treatment) and after (post treatment) a 
single six hour MARS treatment.  
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Figure 65.  Individual serum AST levels (IU/L) immediately before (pre-
treatment) and after (post-treatment) each six hour MARS treatment. 
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Mean plasma ALT (IU/L) concentration fell by 20% from a mean pre-treatment 
of 485IU/L to 386IU/L with each six hour MARS treatment session.  This 
decrease was statistically significant.  Data was not normally distributed 
therefore was analysed using Wilcoxen ranked pairs test p<0.05, n=23. 
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Figure 66.  Mean ALT (IU/L) before (pre treatment) and after (post treatment) a 
single six hour MARS treatment.  
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Figure 67.  Individual serum ALT levels (IU/L) immediately before (pre 
treatment) and after (post treatment) each six hour MARS treatment. 
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Mean plasma ALP (IU/L) concentration fell by 5% from a mean pre-treatment 
of 202IU/L to 193IU/L with each six hour MARS treatment session.  This 
decrease was statistically significant.  Paired student t-test p<0.05, n=26 (95% 
confidence interval 2.23-27.3). 
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Figure 68.   Mean ALP (IU/L) before (pre treatment) and after (post treatment) 
a single six hour MARS treatment.  
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Figure 69.  Individual serum ALP levels (IU/L) immediately before (pre 
treatment) and after (post treatment) each six hour MARS treatment. 
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Mean plasma albumin (g/dL) concentration was unchanged by treatment mean: 
pre-treatment of 29g/dL to 30g/dL by each six hour MARS treatment session.  
Paired student t-test p=0.34, n=26 (95% confidence interval -1.32 to 0.471)..  
 
Pre treatment Post treatment
0
10
20
30
40 p=0.3388
A
lb
u
m
in
 g
/d
L
 
Figure 70.  Mean serum albumin (g/dL) before (pre treatment) and after (post 
treatment) a single six hour MARS treatment.  
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Figure 71.  Individual serum albumin levels (g/dL) immediately before (pre 
treatment) and after (post treatment) each six hour MARS treatment. 
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5.7  RESULTS III – Apoptosis and cell viability 
The quantity of apoptosis, measured by percentage cells TUNEL positive, 
induced in primary human hepatocytes exposed to patients‘ plasma samples 
taken immediately before and after treatment with MARS therapy showed no 
reduction in the amount of apoptosis induced by plasma.  Paired student t-test 
p=0.134, n=27.    
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Figure 72.  Mean TUNEL cell positivity induced in primary human hepatocytes 
exposed to plasma taken before (pre treatment) and after (post treatment) a 
single six hour MARS treatment (95% confidence interval -0.417 to 1.006). 
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Figure 73.  TUNEL cell positivity (%) induced in primary human hepatocytes 
exposed to plasma taken before (pre treatment) and after (post treatment) 
individual six hour MARS treatment sessions. 
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The quantity of apoptosis, measured by caspase 3 activity, induced in primary 
human hepatocytes exposed to patients‘ plasma samples taken immediately 
before and after treatment with MARS therapy showed no reduction in the 
amount of apoptosis induced by plasma.  Paired student t-test p=0.078, n=27 
(95% confidence interval -35.67 to 626.2). 
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Figure 74.  Mean Caspase 3 activity induced in primary human hepatocytes 
exposed to plasma taken before (pre treatment) and after (post treatment) a 
single six hour MARS treatment. 
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Figure 75. Caspase 3 activity induced in primary human hepatocytes exposed to 
plasma taken before (pre treatment) and after (post treatment) individual six 
hour MARS treatment sessions. 
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Cell viability assessed by MTT activity measured in primary human hepatocytes 
exposed to patients‘ plasma samples taken immediately before and after 
treatment with MARS therapy showed no reduction in the cell viability induced 
by plasma.  Paired student t-test p=0.568, (n=27, 95% CI -0.0491 to 0.028). 
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Figure 76.  MTT activity in primary human hepatocytes exposed to plasma 
taken before (pre treatment) and after (post treatment) a single six hour MARS 
treatment. 
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Figure 77.  MTT activity in primary human hepatocytes exposed to plasma 
taken before (pre treatment) and after (post treatment) individual six hour 
MARS treatment sessions. 
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Correlation 
Measurement of Caspase 3 activity (LU) showed a strong positive correlation to 
TUNEL cell positivity as a measure of apoptosis. Pearson r +0.6851, n=54, 
p<0.001. 
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Figure 78.  Correlation between Caspase 3 activity and TUNEL cell positivity 
for primary human hepatocytes incubated in plasma samples of patients treated 
with MARS. 
 
Measurement of Caspase 3 activity (LU) as a measure of apoptosis showed a 
week negative correlation to cell viability measure by MTT activity. Pearson r -
0.3582, n=54, p<0.01. 
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Figure 79.  Correlation between Caspase 3 activity and MTT activity for 
primary human hepatocytes incubated in plasma samples of patients treated with 
MARS. 
 
Measurement of TUNEL cell positivity (%) as a measure of apoptosis showed 
no significant correlation to cell viability measure by MTT activity. Pearson r -
0.1268, n=54, p=0.361 
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Figure 80.  Correlation between TUNEL cell positivity and MTT activity for 
primary human hepatocytes incubated in plasma samples of patients treated with 
MARS. 
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5.8  DISCUSSION 
Hepatocyte apoptosis increases in chronic but particularly in acute liver disease. 
There are multiple mechanisms potentially leading to hepatocyte apoptosis, and 
this may be initiated by soluble or cellular factors at the cell surface, through 
direct or indirect interactions with death receptors, and through the intrinsic 
pathway affecting mitochondrial energetics leading to cytochrome c release.   It 
is a reasonable hypothesis that factors in the plasma in acute liver disease 
initiating apoptosis through the death receptors may be responsible for a 
significant proportion of the liver dysfunction present, although additional 
contributions via direct cell-to-cell contact or through the intracellular pathway 
may also play a significant role.  
It has been demonstrated in subgroups of meta-analysis that MARS therapy 
decreases mortality in acutely-decompensated chronic liver disease and 
hepatorenal syndrome.  The exact mechanism of this improvement is unknown 
but the removal of substances that are toxic to hepatocytes (and other organs) is 
suggested.  The identity of these substances are unknown, and difficulties in 
isolating and identifying them have been described in previous chapters.   The 
clinical context of a series of patients who had been exposed to MARS dialysis 
provided the opportunity to evaluate its clinical effectiveness, and in addition to 
determine whether this dialysis system – which involves the depletion of both 
albumin bound molecules and those low molecular substances mobilised in a 
conventional haemodialysis system – would remove toxic factors which induce 
apoptosis and cell death. The hypothesis was that by improving the milieu in 
which endogenous hepatocytes are bathed would promote endogenous liver 
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recovery, this would be confirmed if apoptosis was reduced by MARS 
treatment.   
Thirteen patients with either acute or acute on chronic liver failure were treated 
with between 1 and 3 treatments of 6 hours of MARS therapy.  MARS treatment 
was generally well tolerated in our patient cohort with 2 patients suffering 
significant side effects during therapy, both of which responded to conservative 
management.   
Significant removal of albumin bound toxins was achieved; using bilirubin as a 
marker for other albumin bound substances, there was a 27% reduction in 
bilirubin per 6 hour treatment. 
Our patients were not part of a randomised trial therefore there is no control 
group with which to compare mortality.  However from the patients‘ pre-
treatment MELD scores (18.1) it can be seen that they constituted a group with a 
particularly poor prognosis.  The 30 day survival rate of 62%, with only one 
patient undergoing transplantation in this time, would therefore suggest a 
favourable response to MARS therapy.  Patients had a favourable 
haemodynamic response with a small but significant increase in mean arterial 
blood pressure.  Patients also had an improvement in encephalopathy grade.   
Renal function as assessed by a reduction in serum creatinine improved, 
however since MARS therapy is known to remove creatinine it may be a poor 
measure of intrinsic renal function.  An alternative measure of renal function 
unaffected by MARS therapy was required.  Cystatin C (an alternative measure 
of GFR) was also reduced after treatment with MARS therapy, again suggesting 
improvement in renal function.  There are several possible explanations for this.  
The first is that the removal of substances from plasma that are directly 
 231 
nephrotoxic is responsible for the improvement.  This theory could be tested by 
in-vitro experiment using renal cells in a similar way to the methods we have 
used with hepatocytes.  A second explanation is that the improvement in renal 
function could be secondary to the improvement in liver function; this 
hypothesis could be tested by in-vivo animal studies using MARS in 
hepatectomised and non-hepatectomised animals.  A third explanation is that the 
improvement in renal function was a consequence of improved mean arterial 
blood pressure; this again could be tested in animal experiments.  Finally 
Cystatin C could also be removed by MARS therapy.  This could be tested by 
testing Cystatin C levels in the albumin dialysate in the MARS circuit or by 
spiking a volume of normal plasma with Cystatin and perfusing through the 
blood circuit in the MARS dialysis circuit, measuring Cystatin C levels before 
and after treatment.  Since renal impairment is an indicator of poor prognosis in 
liver disease, improvement in renal function may be responsible for improved 
outcome in patients treated with MARS therapy.   
As expected MARS therapy removed significant amounts of albumin bound 
substances, as demonstrated by a significant fall in the concentration of Bilirubin 
from pre- to post-treatment levels.  Bilirubin is not itself toxic to hepatocytes 
(indeed biliprotein is thought to be a growth factor), but its removal is used as a 
marker of removal of other putative toxic albumin bound molecules.  The 
significant reduction in bilirubin during treatment of these patients thus showed 
that MARS therapy had performed effective ―detoxicatory‖ function. 
Serum transaminases also fell during treatment, this is in accordance with 
findings from other groups.  There are several possible explanations for these 
findings.  Firstly the transaminases could be being removed by MARS therapy 
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itself.  Secondly since serum transaminases represent leak from damaged 
hepatocytes it could suggest that hepatocyte damage in-vivo was less as a result 
of treatment.  This could be via two possible mechanisms, either the direct 
removal of hepatotoxic substances by MARS therapy or due to improved 
perfusion of the native liver via improved arterial blood pressure, improved 
regional perfusion,  improved delivery of  oxygen or a combination of these 
factors .  These effects occur via removal of albumin bound vaso-active 
intermediates by MARS therapy, for example nitrous oxide.   
Alkaline phosphatase also fell during treatment and the same arguments (direct 
removal of ALP via MARS, removal of substances that are directly toxic to 
cholangiocytes or reduce cholangiocyte function or indirect effects) as outlined 
above could be postulated for the improvement in biliary function for which 
ALP is a marker. 
Changes in concentrations of substances within plasma could also be explained 
by dilution if significant volumes of fluid were given during treatment.  All 
patients were in fact kept at neutral fluid balance during treatment and this is 
confirmed by there being no change in serum albumin pre- and post-treatment.  
Finally falling liver enzymes could be the result of spontaneous improvement in 
the patient‘s general condition.  This would seem unlikely since up to the 
institution of MARS therapy all the patient‘s condition (measured by increasing 
Bilirubin) had been deteriorating. 
Previous trials of MARS therapy have not been shown to directly remove liver 
enzymes, therefore improvements in liver enzymes by direct removal by MARS 
seems unlikely. 
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Despite significant reduction in albumin bound substances, improvement in 
clinical parameters in our patients, and the improvement in many biochemical 
parameters used as markers of renal and liver function, MARS dialysis did not 
effect the cytotoxicity of plasma. 
Comparison of the extent of apoptosis induced in primary human hepatocytes by 
100% heparinised plasma, taken before or after the dialysis, showed no change 
in apoptosis measured either by TUNEL cell positivity  or the induction of 
Caspase 3 activity.   Total hepatocyte viability measured by MTT assay also 
showed no improvement before and after therapy.  This is highly suggestive that 
improvements in liver function are not the result of removal of albumin bound 
toxins that are directly hepatotoxic.   
Looking at hepatocyte death is however only half the equation, improvements in 
liver function post MARS therapy could be the result of improved liver 
regeneration.  This theory could be tested either in-vitro using hepatoma cell 
lines or organ bath experiments to assess removal of directly inhibitory 
substances or in-vivo in animal models performing liver histology (BRDU 
staining) before and after therapy to assess both direct and indirect effects. 
Further studies need to be performed on a larger group of patients, particularly 
those with acute liver failure.  In the previous chapter we have demonstrated that 
there are humoral factors that increase hepatocyte apoptosis in acute liver 
failure, but that these are not present in acutely-decompensated chronic liver 
failure.  It therefore seems unlikely that MARS therapy detoxifying plasma in 
acutely decompensated chronic liver disease will remove humoral factors 
directly improving hepatocyte viability by reducing apoptosis.  Patients with 
acute liver failure represent a very different pathophysiology and having 
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demonstrated humoral factors that induce apoptosis it remains possible that 
MARS therapy does remove directly toxic substances.  Our patient cohort 
contains only 2 patients with acute liver failure, too few for subgroup analysis. 
In summary whether or not this dialysis system will turn out to be of significant 
clinical value, an issue still under investigation, it does not however appear to 
offer benefit through alteration of the apoptotic capacity/cytotoxicity of plasma 
in acutely-decompensated chronic liver disease.  It seems likely that improved 
outcome in these patients is a result of improved arterial blood pressure, 
alterations in regional perfusion, or indirect effects by improving other organ 
function, probably by removal of albumin bound cytokines and vaso-active 
mediators e.g Nitric oxide.  This observation is particularly important in the 
development of future therapies for liver failure; it calls into question the use of 
therapies aimed at detoxifying plasma as a means of promoting liver recovery, 
particularly in acutely-decompensated chronic liver disease, and suggests that 
alternative approaches particularly antagonising vascular and cytokine effects 
may be beneficial.   
   
5.9  CASE REPORTS 
Two patients treated with MARS offered unique insights into the possible 
pathogenesis of Erythropietic Protoporphyria (EPP) associated liver disease and 
Benign Recurrent Intrahepatic Cholestasis (BRIC) and offered new therapeutic 
strategies; as such both were studied in more depth and are submitted as case 
reports (see appendix). 
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CHAPTER 6:  CONCLUSIONS 
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Hepatocyte cell death with resultant loss of functional liver cell mass, and the 
release of inflammatory mediators from the failing liver are the cause of the 
syndrome of acute liver failure.  Strategies to treat this syndrome need to address 
the issue of a reduction of functional liver mass by decreasing the amount of 
hepatocyte loss and increasing liver cell regeneration.  One of the mechanisms 
of cell loss is apoptosis, which leads to loss of cell number both directly, and 
indirectly by generating secondary necrosis.  Understanding the factors that lead 
to, and the pathways by which, apoptosis is executed in hepatocytes is essential 
in developing strategies to protect hepatocytes.  Some of these toxic factors are 
present in plasma in liver failure.   
The liver is known to have a tremendous capacity for regeneration and this has 
led to the aim of developing an artificial liver that would act as a bridge to 
transplantation or recovery.  Mechanical detoxifying systems such as MARS do 
this to some extent, however due to the complexity of liver function it is likely 
that any successful ―artificial liver‖ would contain a bio-reactor full of liver 
cells.  These cells would be exposed to the plasma of patients with liver failure 
plasma.  The induction of apoptosis in these cells by liver failure plasma would 
result in loss of function of the bio-artificial liver. 
Another alternative strategy is the transplantation of hepatocytes or stem cells.  
These cells are again however exposed to liver failure plasma and any toxicity is 
therefore likely to have deleterious results. 
For the above reasons it can be seen that the identification of toxins and 
identifying there mechanism of action is crucial to the development of strategies 
for the treatment of acute liver failure. 
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The aim of this project was to characterise the toxic molecules in liver failure 
plasma, their mechanism of action and possible ways to antagonise their effects, 
or remove them.  At the outset of this project the aim was to identify these 
toxins.  Identification of any substance initially requires purification and by 
using the biological assay of MTT as a measure of cell number in HepG2 cell 
lines as our measure of toxicity we had hoped to ―track‖ the toxic fraction 
through various processes and ultimately identify these factors, then having 
identified the molecule/s ways of eliminating there effects could be logically 
developed.  These attempts were hampered by difficulties with cellular adhesion 
and whilst the effects of liver failure plasma on cellular adhesion were of interest 
(indeed the paper by Newsome et al subsequently demonstrated acute liver 
failure plasma causes loss of adhesion) they were not the aim of study of this 
project.   
Having eliminated the problems of cellular adhesion it became apparent that 
whilst there was variability in the toxicity of plasma that the effects where not as 
large as originally hoped.  The toxic effect was not therefore significant enough 
to use a biological assay to ―trace‖ the toxicity through purification steps.  In 
many ways this was rather unsurprising firstly because HepG2 cells are tumour 
cell lines and due to their dysregulated cell growth and death pathways they are 
extremely resilient, and secondly because any toxin that could be significantly 
toxic to tumour cell lines over a short time period would be likely to have an 
even more pronounced effect in vivo to the far more fragile primary human 
hepatocyte.  Essentially if acute liver failure plasma contained a substance that 
could cause cell death in, for example, 25% of tumour cell lines in 16 hours and 
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we assumed equal toxicity in primary hepatocytes there would be less than 10% 
of Hepatocytes remaining in the liver within 5 days. 
 
Furthermore the processes involved in separating the soup that is plasma would 
almost certainly dilute and denature any toxin, finally the toxin is almost 
certainly there in minute quantities and large volumes of liver failure plasma 
would be required for purification, isolation and subsequent identification.  A 
better system for the study of toxins in liver failure plasma was therefore 
required.   
Using primary human hepatocytes on collagen coated slides a robust, reliable, 
quantifiable in-vitro system that could be easily manipulated was developed.  
This system can be used to test toxic molecules in liver failure plasma using a 
candidate molecule approach and can be used to assess factors that may be 
protective against apoptosis.   Using this system we determined that Epidermal 
Growth Factor and not Hepatocyte Growth Factor protected cells against Fas-
Ligand binding induced apoptosis.  This system can also be used to assess 
strategies designed to reduce toxins in liver failure plasma.  This has the 
advantage of not requiring the identity of the putative toxins to be known, and 
being able to assess the effect of multiple substances in combination.   Whilst 
not perfect, the model was sensitive and looked at a specific biological pathway.  
The use of human hepatocytes eliminated any cross-species differences, 
important since it is known that apoptotic responses are species dependent with 
rat hepatocytes relatively insensitive to Fas-ligand induced apoptosis and 
cultured human hepatocytes being exquisitely sensitive.  It also eliminated any 
changes in behaviour due to tumour cell line origins.  The model was however 
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not without its drawbacks, firstly there is a very limited supply of hepatocytes 
and secondly the harvesting of cells may activate cell survival pathways which 
may alter the cells response.  An example of this is demonstrated by the fact that 
mouse hepatocytes in culture do not undergo apoptosis when exposed to Fas-
ligand, whereas massive liver injury occurs in-vivo and this is thought to be due 
to activation of survival pathways during harvest and culture.  This effect can be 
overcome by blocking protein synthesis with Cyclohexamide,  thus preventing 
synthesis of the gene products of these survival genes.  Similar mechanisms may 
be activated by harvest of primary human hepatocytes.  Interestingly even death 
receptor activation itself can activate cell survival pathways. Activation of the 
death receptor TNFR1 results in proteins (TRAF2 and RIP) activating Iκβ kinase 
(IKK) and Iκβ degradation, leading to activation and nuclear translocation of 
NFκβ .   NFκβ induces expression of survival genes including BclXL, A1, XAIP, 
cFLIP and iNOS.  Stimulation of these pathways inhibits apoptosis.  This adds 
another level of complexity with activation of death receptors being able to kill 
or protect cells the response being unpredictable by any currently clearly defined 
factors. 
Hepatocyte apoptosis is increased in chronic but particularly in acute liver 
disease and using our system we demonstrated that plasma taken from patients 
with acute liver failure induced apoptosis, whereas plasma from patients with 
acutely decompensated liver failure did not.  This is despite similar increases in 
markers of liver insufficiency based on for example similar bilirubin.  This 
supports the argument that acute liver failure is not predominantly due to 
insufficient metabolic mass causing accumulation of toxins which then further 
damage the liver, as similar effects would be seen in acutely decompensated 
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chronic liver disease if this were the case.  It suggests that specific mechanisms, 
almost certainly involving inflammatory cytokines and possibly death receptors 
are at work.  The clear differentiation between acute and chronic liver disease 
having very different pathophysiology is very important particularly when 
looking at the mechanisms of removal/antagonism of factors inducing apoptosis 
because if there is no demonstrable toxicity induced by chronic liver failure 
plasma then there is no point in further of this patient group.   
There was also no correlation between apoptosis induced by the patients‘ plasma 
and any single parameter of liver or renal function, nor with aetiology nor 
prognosis. One simple hypothesis, was that if apoptosis was induced by toxins 
accumulating in plasma due to failure of liver excretion, markers of 
excretion/cholestasis (bilirubin, ALP, GGT) would correlate with apoptosis 
inducing capacity of liver failure plasma.  If factors in plasma were inducing 
apoptosis, leading to secondary necrosis other markers of hepatocellular 
damage, e.g. AST, ALT, might positively correlate with the apoptosis- inducing 
ability of plasma.  No such correlation could be demonstrated. If albumin binds 
hepatotoxins, a negative correlation between albumin concentration and 
apoptosis inducing ability of plasma might be expected, but no significant trend 
emerged.  
The next stage was to use this in-vitro system to test strategies that may reduce 
toxicity of liver failure plasma e.g. MARS to assess if such treatments are liable 
to improve the chances of endogenous liver recovery in addition to providing 
temporary replacement of some liver functions.  MARS therapy has been shown 
to improve outcome in Alcoholic Hepatitis and hepato-renal syndrome, it has 
not been shown to improve survival in acute hepatic failure.  We had proposed 
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that the putative toxic molecules were removed by MARS therapy and this may 
reduce the pro-apoptotic effects of plasma.  No such effect was identified despite 
other markers demonstrating significant reduction in albumin bound molecules. 
This could be because the toxic molecules are not significantly removed by 
MARS treatment, which is why no clinical benefit in terms of liver recovery is 
seen with MARS therapy.  Since the majority, 9 of the 11, of the patients 
undergoing MARS therapy had acutely decompensated chronic liver disease, 
and we had previously failed to demonstrate increased plasma toxicity in this 
group, there was no pro-apoptotic tendency to reverse in the majority of patients 
treated.  However it is exactly this patient group that have shown clinical benefit 
in terms of reduced mortality compared to acute liver failure patients who have 
not shown mortality benefit with MARS therapy.  Further study on patients with 
acute liver failure plasma pre and post MARS therapy is required. A plausible 
explanation would be that both the in-vivo studies in acute liver failure and our 
in-vitro study pre-and post-MARS therapy were underpowered in terms of 
patient numbers to demonstrate a response.  This is likely to always be the case 
as the ideal trial where patients were randomised to MARS therapy versus 
placebo (+/-renal  support) with a primary outcome of mortality would be 
unethical, patients would almost certainly be near to reaching transplant criteria 
at enrolment and those who deteriorated would be transplanted as soon as an 
explants became available.  If transplant was used as an endpoint then the results 
would be skewed by the availability of a graft and so other markers of outcome 
would be required, encephalopathy cannot be assessed in a patient once 
intubated, clotting would have to be corrected for line insertion and so could not 
be used and other biochemical parameters are affected by the MARS therapy 
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itself.  Finally since MARS dialysis improved the clinical status in the patients 
in this series, and the expected improvement in biochemical parameters but left 
the degree of apoptosis induced by plasma entirely unchanged another 
possibility is that the removal of pro-inflammatory molecules by the dialysis 
process is matched, and therefore the beneficial effect cancelled, by 
simultaneous clearance of anti-apoptotic molecules. HGF for example, 
protective against apoptosis, and elevated in the plasma of patients with liver 
failure, is one candidate for such a substance.   
A more rational approach would be to use our in-vitro system to test for toxicity 
in mechanical treatments which have been shown to improve outcome in acute 
liver failure.  The ultimate plasma detoxifying treatment in acute liver failure is 
plasmapheresis, and this treatment has been shown to reduce mortality in 
fulminant hepatic failure, initial experiments using plasma samples pre and post 
plasmapheresis would therefore seem to be a good starting point for any further 
study investigating the toxic effects of acute liver failure plasma using our in-
vitro model. 
Since there appear to be substances in liver failure plasma which can induce 
apoptosis and the only detoxifying therapy available to us did not appear to 
remove this effect then alternative ways of antagonising the effect were 
investigated.  We found that treatment of hepatocytes with either a Caspase 8 or 
a Caspase 3 inhibitor protected against the apoptosis induced by acute liver 
failure plasma in-vitro.  This suggests that the apoptotic effect is dependent on 
pathways involving both these enzymes, which would suggest involvement of 
death receptor pathways.  To study this in-vivo we used Caspase inhibitors in an 
animal model of acute liver failure.  
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Caspase inhibitors have been proposed in the treatment of a number of different 
diseases.  Since caspase inhibition may prevent deletion of auto-reacting clones 
of lymphocytes, and other abnormal cells, their use in chronic disease processes 
is likely to be limited, due to the risk of both of generating auto-immune disease 
and malignancy.  Acute insults such as stroke or acute liver failure may be 
diseases where preventing apoptosis would be of value.  Animal studies in 
models of acute liver failure by induction of apoptosis using known death 
receptor pathways, for example the agonistic jo-1 antibody which trimerises and 
activates death receptors, have been shown to be attenuated by treatment with 
caspase inhibition. 
We chose a toxic liver injury model of acute liver failure because this is a model 
not previously explored with inhibition by caspase inhibitors, and since 
paracetamol toxicity remains the commonest cause of acute liver failure, would 
be a disease in which there is the greatest utility for a therapeutic option.  Finally 
this model of toxic liver injury was developed and licensed for use in our 
laboratory.  
We initially needed to investigate if apoptosis was implicated in induction of 
liver injury by Thioacetamide.  Apoptosis was demonstrated by showing 
increased TUNEL staining, and the time course of this histological event was 
documented.  Treatment with caspase inhibitors, including caspase 8 and 
caspase 3 inhibition, which we had previously shown reduced apoptosis by 
plasma in primary human hepatocytes in our in-vitro model were used in the 
animal model.  The caspase inhibitors did not reduce mortality in this animal 
model.  This effect was at least in-part due to the lower than expected mortality 
in the control group of animals.  Further animal studies of caspase inhibitors are 
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required using a larger number of animals and an animal model with a 
reproducible mortality. 
Caspase inhibition may be a fruitful area in the treatment of acute liver failure 
although there are two potential barriers over this approach being of clinical 
benefit, firstly survival of cells is not the be all and end all of such interventions 
the cells must be functionally viable and lack of functionality in ―saved‖ cells 
will not help, as demonstrated by the use if an apoptosis inhibitor in a model of 
Parkinson‘s disease, benzyloxycarbonyl-Val-Ala-Asp-(O-
methyl)fluoromethylketone (zVAD-fmk), which protected dopaminergic 
neurons in-vitro but did not prevent loss of neuritis and decrease in dopamine 
uptake (von Coelln et al., 2001).  Also the beneficial effects of Caspase 
inhibitors in the acute setting as Caspases are necessary for proliferation of some 
cells, including  t-cells.(Kennedy et al., 1999), and increased apoptosis and 
Caspase-3-like protease activity is seen in regeneration after partial hepatectomy 
with bursts of apoptosis correlated with DNA synthesis taking place when a 
large body a cells are in S-phase, this may be mediated by cytokines for example 
TGF-β and may be important in terminating proliferation (Hayami et al., 2000).  
Thus interference with apoptosis may also effect liver regeneration. 
The preliminary work in this study developed and validates an in-vitro model for 
apoptosis assays relevant to human hepatocytes.  It shows toxic molecules is 
liver acute liver failure plasma but not chronic liver failure plasma, highlighting 
the differences in pathophysiology of the two disease processes.  The inhibition 
of this pro-apoptotic effect by direct inhibition of Caspase 3 and of Caspase 8 
point the way to alternative novel therapeutic approaches in the treatment of 
acute liver failure.  Non-toxic caspase inhibitors are now emerging in 
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experimental studies and in clinical trials.  The failure of benefit in removal of 
toxic molecules by treatments such as MARS must question the validity of these 
treatments and time will prove whether removal strategies such as this will 
improve outcome in acute liver failure. 
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MATERIALS AND METHODS 
 
Materials 
Reagents were from Sigma Chemicals or BDH, and of biochemical or analytic 
grade.  Reagents from other sources are noted. 
Cell isolation and culture reagents including cell culture media, Fetal Calf 
Serum (FCS), penicillin-streptomycin, L-glutamine, Dexamethasone, Insulin, 
EGTA tetrasodium salt, Bovine Serum Albumin (BSA), Collagen, Collagenase 
type IV and DNAseI were purchased from Sigma UK .  PBS, HBSS (containing 
Calcium and Magnesium) and HEPES were purchased from Invitrogen.  
Trypsin/EDTA solutions were from Gibco BRL (Life Sciences, Paisley, 
Scotland) 
Consumables – Tissue culture plates, dishes and flasks were all obtained from 
Nunc (Nunclon, Nunc A/S, Roskilde Denmark) supplied by Gibco.  Membrane 
filters (0.2µM) were obtained from Sartorius, Goettingen, Germany. 
Batches of foetal calf  serum (FCS) were tested for relative hepato-toxicity and 
batches held on reserve at Gibco.  FCS was prepared before use by heating to 
56ºC for 30 minutes to inactivate complement and aliquots stored at -20ºC until 
use 
 
Generalised Cell Culture - HepG2 cells  
HepG2 cells were kept in continuous culture in alpha modified Eagles minimal 
essential medium (α-MEM) with nucleosides, supplemented with 10% v/v FCS 
with the following additives; L-Glutamine 2mM, Penicillin (200U/ml) and 
Streptomycin (200IU/ml), Fungizone 2.5ug/ml, Insulin 0.01ug/ml, 
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Dexamethasone 10
-8
M, Selenic Acid 10
-7
M, Linoleic Acid/BSA 
(0.5ug/ml,0,05mg/ml), Thyrotropin releasing hormone 10
-6
M 
This is hereafter referred to as Complete α-MEM medium.  Medium was 
refreshed every 48 hours. 
 
Passaging cell cultures 
Cell cultures were kept in continuous culture and regularly passaged when 
required (70-90% confluence). Cells were incubated at 37ºC in a humidified 
atmosphere of air and 5%CO2 
Medium was removed and cell monolayers washed twice with warm HBSS 
without calcium and magnesium to remove dead cells and residual protein.  
Cells were detached by incubating with trypsin/EDTA solution (filter sterilised) 
for 3-4minutes.  The cells were dislodged by gently tapping the flasks and 
transferred into fresh FCS containing medium to quench trypsin activity.  Cells 
were centrifuged (200g for 5 minutes), and resuspended in medium.  Clumps 
were dispersed by gentle aspiration through a 21G needle. 
Viability was assessed by trypan blue exclusion, cells were counted and seeded 
at densities as required in complete α-MEM medium. 
HepG2 cells were plated at 15000/well in 96-well slides and 33000/well in 8-
chamber slides in complete alpha-MEM.  Cells were allowed to attach for 12 
hours in 5%CO2 at 37ºC before washing with HBSS to remove unattached cells 
and cellular debris before exposure to test substance, for example plasma.   
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Trypan Blue Assay - Estimating cell viability 
 
Trypan Blue 2% solution in PBS was stirred overnight then centrifuged 
(14,000rpm for 30 minutes in a micro-centrifuge).  Supernatant removed, 
filtered (0.2uM filter, ministart, Sartorius) and stored as aliquots at -20ºC. 
A 20uL aliquot of cells suspended in serum free medium was mixed with 160uL 
of HBSS and 20uL of trypan blue solution and then mixed gently by flicking.  
After 3 minutes the cells were assessed using a haemocytometer chamber.  The 
intact membrane of viable cells excluding trypan blue and remaining uncoloured 
whereas dead cells appear blue because dye leaks through their damaged 
membrane.  From this an estimate of yield and cell viability could be obtained.  
HepG2 cells with viability >95% were used for experimental purposes. 
 
 
Primary human hepatocytes 
Isolation of primary human hepatocytes  
Liver tissue removed as part of the resection specimens was used as the source 
of hepatocytes.  Tissue donors: patients undergoing clinically indicated hepatic 
resections for the treatment of secondary colonic tumours; gave informed 
consent for experimental use of tissue.  Primary human hepatocytes were 
prepared by Dr Clare Selden by a modification of the Seglen method (Seglen, 
1971) using collagenase perfusion of segments of resected normal human liver.   
Wedges of human liver taken from partial hepatectomy specimens were placed 
on a sterile dish in a pool of phosphate buffered saline (PBS) on ice. Using a 
catheter sheath, 3 suitable branches of the portal vein were identified and 
cannulated.  Veins were flushed with ice cold PBS to remove blood and then 
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perfused for 30 minutes with chelation buffer (PBS, HEPES buffer 20mM, 
EGTA 0.5mM) at 37C  followed by 30 minutes with perfusion buffer (PBS, 
HEPES buffer 20mM),  followed by 30 minutes with digestion buffer (HBSS, 
0.5% BSA, Ascorbic Acid 50ug/ml, Insulin 4ug/ml, Collagenase Type IV 0.05% 
w/v, DNAseI 0.01% w/v)(Seglen, 1972).  The cells were released by cutting into 
the digested areas and gently agitating in ice-cold dispersal buffer (Williams E 
medium, FCS 10%v/v, DNAseI 0.01%w/v). The resultant slurry was then 
passed successively through 200μM and 100μM nylon filters and centrifuged at 
32g for 6 minutes at 4 
o
C. Cell pellets were pooled, resuspended in dispersal 
buffer and, centrifuged as before.  Finally cell pellets were washed with ice-cold 
Williams E medium centrifuged as before and resuspended in complete 
Williams E medium.  Cell viability was assessed using trypan blue and only 
preparations with viability >80% were used. 
 
Culture of primary human hepatocytes  
Primary human hepatocytes were cultured in Williams E medium containing the 
following additives; FCS 10% v/v, L-glutamine 2mM, Penicillin/Streptomycin 
100U/100Ug/ml, Fungizone 2.5ug/ml, Insulin 0.01ug/ml, Dexamethasone 10
-
8
M.  Hereafter known as complete Williams E medium.   Primary human 
hepatocytes were plated on collagen coated receptacles at 50000/well in 96-well 
plates and 250000/well in 8-chamber glass slides. Cells were allowed to attach 
for 12 hours in 5%CO2 at 37ºC before washing with HBSS to remove 
unattached cells and cellular debris and replacing with fresh medium prior to 
experimental use. 
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Preparation of rat-tail collagen 
Primary human hepatocytes require a suitable matrix on which to attach and 
survive in culture. An extract rich in Collagen type 1 was prepared from rat tails, 
by sequentially fracturing the tail and removing the inner central tendons.  The 
tendons were dissolved in 0.01M acetic acid at 1g of tendon per 300ml. The 
solution was stirred for 2-3days at 4ºC and centrifuged at 800g for 2hours.  
Aliquots were stored at 4ºC.  
 
Collagen Coating plates 
Tissue culture plates/slides were coated with rat-tail collagen solution 
(0.2ml/well for 96 well micro-titre plates) and incubated for ten minutes at room 
temperature in a laminar flow hood.  Excess collagen was ―flicked off‖ and the 
plate washed twice with 1 volume of HBSS and filled with 0.9%saline.  Plates 
were UV-irradiated with short wave UV (UVG-L Mineralight lamp, Gabriel Ca, 
USA) for 15 minutes at a distance of 7cm and stored for a maximum of 24hours 
at 4ºC.   
 
MTT Assay 
The MTT assay utilises the conversion of 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT, Sigma) to the purple formazan product 
which is quantified by optical density at 550nM. 
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma) in 
PBS (0.75mg/ml)  aliquots were stored at -20ºC and protected from light.  A  
working stock was stable for 1 week stored at 4ºC.  Acidified isopropanol 
equates to 0.04M HCl in isopropanol. 
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Medium was removed from cells in 96 well plate and 100uL of MTT solution 
0.75mg/ml PBS) was added per well and incubated at 37ºC for 3 hours.  After 
incubation excess MTT was removed and 100uL of acidified iso-propanol was 
added to dissolve the formazan product.  Cells were wrapped in aluminium foil 
to prevent evaporation and photo-degradation, and shaken on an orbital shaker 
(Labline Instrument Inc, III USA).  After 30 minutes the optical density was 
read at 550nm in an automated ELISA plate reader (Anthos htIII, Anthos Labtec 
Instruments, Salzberg, Austria). 
 
Preparation and storage of plasma samples 
Large volumes of liver failure plasma (LFP 1-4) were kindly donated by Fin 
Larsen from the Department of Hepatology, University of Copenhagen, 
Denmark .  This plasma had been collected from patients with acute liver failure 
and grade IV encephalopathy at the onset of therapeutic plasmapheresis as part 
of a clinical trial with consent.   
Heparinised plasma patients acute liver failure due to various aetiologies (Table 
1) and 4 normal controls was acquired with informed consent. Samples from 
patients fulfilling criteria for MARS treatment was collected before and after 
each treatment. 
Briefly blood was collected through a 16 gauge needle into a heparinised blood 
tubes.  The plasma was rapidly separated by centrifugation at 2500g for 
20minutes at 4
o
C.  Plasma was gently aspirated from cellular debris and stored 
at -20ºC until further use. 
Routine biochemical and haematological analysis was sent to the diagnostics 
laboratory. 
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dialysis and after the second dialysis, rapidly separated and kept at – 20ºC until 
used in the apoptosis assay as described above.   
 
Measurement of protein concentration (The Bradford Method (Bradford, 
1976)) 
Coomassie dye binds protein in an acidic medium, an immediate absorbance 
shift occurs from 465nm to 595nm with a simultaneous colour change from 
green/brown to blue.  This reagent gives a characteristic linear response curve 
within a given range (100-1,500µg/ml).  Coomassie Plus-200 Protein assay 
Reagent (Pierce, Rockford, USA); containing the Coomassie G-250 dye, 
methanol, phosphoric acid and solubilising agents in water was stored at 4ºC 
until use.  
Diluted Bovine Serum Albumin (BSA) standards were prepared by diluting the 
2.0mg/ml BSA standard to the following concentrations 0µg/ml, 1µg/ml, 
2µg/ml, 5µg/ml, 10µg/ml, 15µg/ml, 20µg/ml.  Having allowed the Coomassie 
plus reagent to come to room temperature, the reagent was mixed by gently 
inverting the bottle several times.  150µL of each standard or unknown sample 
was placed in wells of a 96 well plate in triplicate.  Three samples of the diluent 
alone were also used as blanks.  150uL of the Coomassie plus reagent was added 
to each well, and the plate mixed well on a plate shaker for 30 seconds.  
Absorbance was measured at 595nm on a plate reader.  The average 595nm 
reading for the blanks was subtracted from each reading or standard.  A standard 
curve was prepared by plotting the average reading for each of the standards 
minus the blank.  Readings from unknown samples were then converted to 
protein concentrations using the standard dilution curve. 
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Silver Staining of protein Gels 
Gels were carefully removed from casting apparatus, wearing gloves to avoid 
protein contamination, and soaked in 300ml of fixer (10% ethanol: 5% glacial 
acetic acid) for 40 minutes, fixer being refreshed every 10 minutes.  Fixer was 
removed by aspiration and replaced with 50% Methanol and washed for 1 hour, 
refreshing the solution every 20 minutes.  The gel was then washed three times 
each for 10 minutes in distilled water.    
As the last wash was finished the stain solution was made up by adding solution A 
(0.8g of silver nitrate dissolved in 4 mls of distilled water) to solution B (21 ml of 
0.36% NaOH (0.18 g in 50 ml water), added to 1.4 ml of 14.8M Ammonium 
hydroxide) drop wise with constant shaking. The solution was added slowly to 
avoid precipitation of silver salts and then made up to 100ml with distilled water. 
The gel was soaked in stain solution for 10 minutes and then rinsed twice with 
distilled water to remove stain solution.  Developer (2.5 ml of 1% citric acid (0.2g 
per 20 ml) and 0.25 ml of 38% formaldehyde ( stock usually 38-40%). Made up to 
500 ml with distilled water) was added to the gel and gently shaken over a light 
box. Bands were seen to appear within minutes.  Once a suitable band intensity 
was reached, the developer was quickly removed and stopper (45% methanol: 10% 
acetic acid) was added and left to soak for one hour. Gels were stored complete in 
polythene containing water to prevent dehydration.   
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Caspase3 Staining of cells with Caspatag™  
The CaspaTag™ Caspase Activity Kit (Serologicals Corporation USA) detects 
active caspases in living cells through the use of a carboxyfluorescein labelled 
caspase inhibitor. The inhibitor irreversibly binds to active caspases, they are 
cell permeable and non-cytotoxic Caspase, positive cells (+) are distinguished by 
fluorescence microscopy.  FAM-DEVD-FMK is a carboxyfluorescein analogue  
of  benzyloxy-carbonylaspartyl-glutamylvalylaspartic acid fluoromethyl ketone 
(zDEVD-FMK), potent inhibitor of caspase-3 and caspase-3 like caspases. 
FAM-DEVD-FMK enters the cell and irreversibly binds to activated caspase-3 > 
caspase-8 >caspase-7 > caspase-10 > caspase-6 in the order of decreasing 
binding affinity. 
The kit was stored at 4ºC until first use.  Lyophilized Peptide-FMK was 
reconstituted with 50 µL DMSO resulting in a150X concentration and the 
contents mixed at room temperature until completely dissolved. Aliquots were 
made and stored frozen at -20ºC until ready to use protected from light and 
moisture to avoid multiple freeze-thaw cycles.  Prior to use 30X Working 
Dilutions of FAM labelled inhibitors in were made by diluting in PBS.  FAM 
labelled inhibitors were protected from light at all times.   
10X Wash Buffer wash incubate at 37ºC for 30 minutes to redissolve 
precipitated protein and buffer salts.  The wash buffer was diluted by adding 10 
mL 10X Wash Buffer to 90 mL deionized H2O and mixed thoroughly. 
Cells having previously been seeded onto sterile collagen coated 8-chamber 
slides were exposed to plasma or test solution for 4 hours.  Test solution was 
gently removed and slides washed three times with complete Williams E 
medium to remove any remaining plasma or debris. 10 µL of 30X Working 
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Dilution FAM-Peptide-FMK was added to 290 µL medium and mixed, 300uL 
was added to each chamber of the eight chamber slide and incubated for 1 hour 
at 37ºC under 5% CO2, protected from light. Nuclei were labelled by the 
addition of 1.5 µL Hoechst Stain per 300 µl medium and incubated for a further 
5 minutes.  The medium was removed and cells and washed cells twice with 0.5 
mL 1X Working Dilution Wash Buffer.  The plastic frame of the chamber slide 
was removed and cells fixed by placing slides in a 1% paraformaldehyde 
solution in PBS) and incubated for 15 minutes at room temperature.   Slides 
were then washed twice with PBS followed by mounting onto a microscope 
slide in anti-fade mounting medium. 
 Cells were observed under a fluorescence microscope using a bandpass filter 
(excitation 490 nm, emission 520 nm) to view green fluorescence of caspase 
positive cells. For viewing Hoechst Stain, a UV filter (excitation 365 nm, 
emission 480 nm) was used. 
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TUNEL staining of cells 
TUNEL staining was performed using ApopTag® Red In Situ Apoptosis 
Detection Kit (Serologicals Corporation USA) using the indirect method (figure 
1. courtesy of Serologicals Corporation USA ) 
 
 
 
The kit was stored at -20ºC until first use, thereafter the TdT Enzyme was 
aliquoted into suitable sized aliquots and stored at -20ºC to avoid multiple freeze 
thaw cycles. the remaining components were stored at 4ºC.  Fluorescent reagents 
were protected from unnecessary exposure to light throughout. 
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Eight-chamber slides having been exposed to test substances were washed three 
times in PBS and the chambers removed.  Cells were fixed in 1% 
Paraformaldeyde in PBS pH7.4 in a Coplin jar for 10 minutes at room 
temperature.  Excess liquid was drained off and slides washed in 2 washes of 
PBS each for 5 minutes 
Cells were permeablised by post-fixing in pre-cooled ethanol:acetic acid 2:1 for 
5 minutes at -20ºC in a Coplin jar, which was then drained and cells washed in 2 
changes of PBS for 5 minutes, each wash. 
Excess liquid was removed and the edge of the slide carefully blotted.  75ul of 
equilibration buffer was applied directly to the specimen and incubated for 10 
seconds at room temperature, excess buffer was removed and 55uL of working 
strength TdT enzyme (66uL TdT enzyme + 154ul of reaction buffer, mixed by 
vortexing, kept on ice) was applied and the slides incubated in a humidified 
chamber at 37C for 1hour.  The reaction was quenched by placing the specimen 
in a Coplin jar containing working strength stop/wash buffer (1ml stock 
stop/wash buffer +34ml ddH2O), agitated for 15 seconds, and incubated for 10 
minutes at room temperature.  An aliquot of antidigoxigenin conjugate sufficient 
to process the desired number of slides was removed from the stock vial and 
warmed to room temperature avoiding exposure to light.  Working strength 
Rhodamine antidigoxigenin conjugate was prepared by adding 68uL of blocking 
solution to 62uL of Ant-digoxigenin Conjugate and vortexing, the solution was 
stored on ice and protected from light.  Excess liquid was removed from slides 
and 65uL of conjugate which had been allowed to warm to room temperature 
was added to each slide.  Slides were incubated in a humidified chamber for 
30minutes at room temperature in the dark.  Specimens were then washed in 3 
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changes of PBS in a Coplin jar for 2 minutes per wash.  Nuclei were 
counterstained by the application of 1.5uL of Hoesch stain in 65uL of PBS and 
incubated at room temperature for 5 minutes in a humidified chamber.  Finally 
slides were washed by 2 further washes in PBS before being mounted in anti-
fade mountant.  Slide edges were sealed with rubber cement and slides stored at 
-20C protected from light.   Slides were viewed with a fluorescence microscopy 
with a filter of wavelength suitable for viewing of Rhodamine (red) 
fluorescence. 
 
TUNEL staining tissue samples 
Liver tissue harvested from experimental animals was snap frozen in liquid 
nitrogen at -80C.  Liver tissue was fixed in formalin overnight and later placed 
in Paraffin blocks.  Paraffin embedded tissue sections were cut by Miss Sherri-
Anne Chalmers, placed on APES coated slides and allowed to dry 
Tissue was deparafinise tissue by washing in 3 changes of xylene for 5 mins 
each wash, followed by 2 changes of absolute ethanol for 5mins each wash.  
Followed by rehydating by washing in 95% ethanol for 3 minutes; followed by 
washing in 70% ethanol for 3 mins; followed by washing in PBS for 5 mins. 
Proteinase k solution used to pre-treat the tissue was reconstituted according to 
manufacturers (R&D) instructions by mixing 1uL Proteinase k solution in 50uL 
dH20.  The solution was place on ice until use.  50uL of Proteinase k solution 
was added onto each sample, covered with a coverslip and incubated at room 
temp for 20 minutes.  Slides were washed twice 2 minutes per wash in water.  
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A positive control was made by adding TACS nuclease 1uL in 50uL TACS 
nuclease buffer to liver tissue and incubating at 37C for 30 mins.  The reaction 
was stopped reaction by washing in PBS.   
Excess liquid was removed by gently tapping off blotting around specimens.  
75uL of equilibration buffer was applied directly onto specimens and incubated 
for 10 secs at room temp.  Working strength TdT enzyme was made up by 
mixing 33uL TdT enzyme with 77uL of reaction buffer and stored on ice .  55uL 
of working strength TdT enzyme was added to each specimen and incubated at 
37C for 2 hours in protected from light. 
Stop/wash buffer was made up by adding 1ml of stop wash buffer to 34ml dH20 
and slides were placed in stop wash buffer, agitated for 15 secs and then 
incubated for 10 mins room temp.  Slides were then treated with 
Antidigoxigenin conjugate and counterstained with Hoescht stain and mounted 
as described in the above method. 
    
Primary human hepatocytes or HepG2 cells were plated onto collagen coated 
glass 8- chamber slides or collagen coated white sided, optical bottomed 96 
well, tissue culture plates.   
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Caspase 3 activation measurement in live cells (Caspse-Glo
tm 
3/7 Assay) 
Apoptosis inducible by liver failure plasma was confirmed by the measurement 
of Caspase 3 activation.  Caspase-Glo
tm
 is a homogeneous luminescent assay 
that measures Caspase 3 activity by providing a proluminescent Caspase 3 
substrate which contains the tetrapeptide sequence DEVD in a substrate which 
lysis cells followed by Caspase cleavage of the substrate and generation of a 
―glow type‖ luminescent signal. 
Hepatocytes were seeded on collagen coated sterile 96 well plates and having 
been allowed to attach for 12 hours and debris washed off as described earlier, 
were exposed to plasma for 4 hours (100uL/well) at 37ºC in a humidified 
incubator.  Identical plates, with no cells added, were prepared for the addition 
of plasma samples for use as blanks. 
Caspase-Glo buffer and lyophilized substrate which had been stored at-20C 
protected from light was allowed to warm to room temperature.  The contents of 
the buffer bottle was poured into the amber bottle containing the Caspase-Glo 
substrate and mixed by swirling to thoroughly dissolve the reagent.  An equal 
volume of mixed reagent was added to medium in a 1:1 ratio (100uL added to 
each well of a 96 well plate) and mixed using a plate shaker at 300-500rpm for 
30 seconds.  Plates were then incubated for 2 hours, having determined this as 
the optimal exposure time.  200uL was aspirated from each well and placed in 
white-sided clear bottomed 96 well luminometer plates. Luminescence was 
recorded and the luminescence of the appropriate blank subtracted.  Each sample 
was prepared in triplicate. 
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Caspase inhibitors – Caspase inhibitors were purchased from R&D Systems 
(Minneapolis, Mn, USA) solubilised in DMSO and a 100x final concentration 
prepared in Williams E medium. Similarly prepared no-inhibitor dilutions were 
used to eliminate possible DMSO effects. Caspase inhibitor or control 
preparations were then diluted 1:100 with plasma, mixed thoroughly and applied 
to cell layers for 4 hours before TUNEL analysis as before. Caspase 3 inhibitor 
Z-VAD-FMK, Caspase 8 inhibitor Z-IETD-FMK, and Caspase 9 inhibitor Z-
LEHD-FMK were all used at final concentrations 20 μMol.  Each experiment 
was repeated on at least three separate occasions each time using hepatocytes 
prepared from a different liver resection. Results shown are representative of all 
experiments.  
 
Caspase inhibitors for animal studies was supplied gratis by Vertex 
Pharmaceuticals, Didcot. 
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Abstract  
Benign recurrent intrahepatic cholestasis is a rare autosomal recessive condition 
characterised by intermittent episodes of pruritis and jaundice that may last days 
to months. Treatment is often ineffective and symptoms, particularly pruritis, 
can be severe. Extracorporeal albumin dialysis (MARS) is a novel treatment 
which removes albumin bound toxins including bilirubin and bile salts.  We 
describe a case of a 34-year-old male with BRIC and secondary renal 
impairment who having failed standard medical therapy was treated with 
MARS.  The treatment immediately improved his symptoms, renal and liver 
function tests and appeared to terminate the episode of cholestasis. 
We conclude that MARS is a safe and effective treatment for BRIC with 
associated renal impairment. 
 
Key words 
Benign recurrent intrahepatic cholestasis (BRIC) 
Extracorporeal albumin dialysis (MARS) 
Acute renal failure 
Cholestasis 
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Introduction 
Benign recurrent intrahepatic cholestasis (BRIC) or Summerskill and Walshe 
syndrome, is a rare autosomal recessive condition.  It is characterised by 
recurrent episodes of acute onset cholestasis separated by periods of complete 
physical and biochemical normality (1;2) .  The precipitants to the episodes of 
cholestasis are unknown, after a virus-like prodromal illness patients develop 
pruritis and jaundice, usually with pale stools and dark urine.  The episodes vary 
in duration lasting from weeks to months. 
The mainstay of pharmacological treatment is corticosteroids and 
cholestyramine (3), with equivocal efficacy (4), which does not improve with 
the addition of phenobarbitone (5).  More recently ursodeoxycholic acid has 
been used to reduce itch and diarrhoea(6) and rifampicin has been shown to 
improve itch and biochemical parameters of cholestasis (7).  In severe or 
protracted disease plasma exchange can be beneficial and it is suggested that its 
use early in the course of the illness may shorten the duration of an attack (8;9). 
Extracorporeal albumin dialysis (MARS) is a new method of removing albumin 
bound toxins.  A special membrane allows transfer of water soluble and albumin 
bound toxins with molecular weight less than 50kDa from blood into a dialysate 
solution containing 20% human albumin (10).  MARS provides potential 
advantages over plasmapheresis since it is less expensive, has less theoretical 
risk of transmission of infection, is less immunogenic and is more selective 
leaving possibly beneficial growth factors and hormones in the circulation (11) 
MARS has been previously used in a single case of BRIC and was shown to 
improve cholestasis, reduce bile salts, change bile salt composition, and improve 
symptoms of diarrhoea and itching (12).  We describe a case of BRIC with an 
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episode of progressively worsening cholestasis and the onset of secondary renal 
insufficiency despite standard pharmacological therapy.  We proposed that a 
short course of treatment with MARS (3 daily treatments) would remove 
albumin bound toxins, including bile salts, and would result in improvement in 
both renal and liver function terminating the episode of cholestasis.   
Patient 
A thirty-four year old man with BRIC was transferred from his local hospital 
after a 2-month episode of cholestasis with increasing bilirubin and deteriorating 
renal function despite treatment.  
 He had first presented aged 15 years with jaundice, itching, lethargy and pale 
stools and dark urine, which was initially diagnosed as ―infective hepatitis‖.  
Subsequently in view of negative viral serology, copper studies, ferritin, alpha-
1-antitrypsin and in the light of his family history and liver biopsy the diagnosis 
was revised as BRIC. 
His sister had previously been diagnosed with BRIC after she presented with 
cholestasis at the age of 6 months and had suffered from frequent episodes of 
cholestasis thereafter.  His parents who were non-consanguineous, and his other 
sibling were well.  His mother had two cousins both of whom had died in 
childhood of liver disease, one at 11 weeks of age, cause of death recorded as 
―?Infective Hepatitis. Obstruction of the bile duct‖ and one at 5 years of age 
cause of death recorded as ―1. Pulmonary Oedema.  2(a).  Hepatic Cirrhosis.  
(b). Erythroblastosis Foetalis‖. 
The patients presenting episode was treated with corticosteroids and 
cholestyramine and he made a rapid and complete recovery.  A year later he had 
acute pancreatitis and was found on ultrasound examination to have gallstones, 
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there was no cholodocholithiasis or duct dilatation on ERCP and he underwent 
cholecystectomy.  Whilst awaiting surgery he had a further attack of cholestasis 
which, unlike his initial episode was slow to resolve, taking 3 months, despite 
treatment with prednisolone and cholestyramine.  He had further episodes aged 
22 and 24 years both of which were of short duration and he remained well with 
no further episodes of cholestasis until he represented on this occasion. 
Two months prior to admission to the Royal Free Hospital he had suffered 
several days of pruritis which resolved spontaneously.  One month later he 
became jaundiced, with pruritis and lethargy.  He was commenced on 
cholestyramine 4g  t.d.s., prednisolone 30mg o.d. multivitamins and calcichew.  
He failed to improve and was admitted to his local hospital where 
ursodeoxycholic acid 500mg b.d. was added to his treatment.  Unfortunately his 
symptoms and liver function continued to deteriorate.  Associated with the very 
high levels of bilirubin and bile salts, and despite appropriate i.v. fluid therapy, 
he developed acute renal impairment with a urea of 8.2 mmol/l and a creatinine 
of 187μmol/l having had previously normal renal function. 
After transfer to this hospital he underwent a liver biopsy, which showed 
extensive severe intracellular and canalicular cholestasis, with some hepatocyte 
ballooning.  Occasional portal tracts contained a mild mixed inflammatory cell 
infiltrate, and a few foci of parenchymal inflammation were also seen.  However 
there was no evidence of portal tract fibrosis or ductopenia.  The appearance was 
identical to those of his original biopsy nineteen years prior and was in keeping 
with the diagnosis of BRIC (figure 1).  His serological screen for HIV, CMV, 
Hepatitis B and C, autoantibodies and immunoglobulins was negative. 
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In view of his failure to respond to standard medical therapy, increasing 
symptoms and onset of renal impairment he was commenced on MARS 
treatment.  He was treated for 6 hours a day (flow rate 200ml/min) on three 
consecutive days via a dual lumen haemodialysis catheter in the right femoral 
vein.  The patient gave informed consent in accordance with local ethics 
committee approval.  
 
Figure 1.  Photomicrograph of the current liver biopsy (x10 objective), 
showing extensive cholestasis.  The portal tracts (top centre and left) show 
no evidence of fibrosis or ductopenia, and there is a minimal portal 
inflammatory cell  infiltrate 
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Results 
After treatment he was visibly less icteric, had less pruritis and lethargy and 
described himself as ―feeling on top of the world‖.  His bile acids fell during 
each six hour treatment from a mean pre-treatment of 136.7µmol/L to a mean 
post-treatment of 75 μmol/L.  His liver and renal function improved dramatically 
and he was discharged home 1 week later. His liver and renal function continued 
to recover and returned to normal 7 weeks later.  He remains well with no 
further episodes of cholestasis. 
Discussion 
The exact mechanism of cholestasis in BRIC and many other cholestatic 
conditions is poorly understood.  The gene responsible FIC1(ATP8B1) is a 
member of a family of P-type ATPases, and it is probably responsible for ATP 
dependent aminophospholipid transport.  It is expressed in liver in the 
cholangiocyte and canalicular membrane (13;14), and is also expressed in the 
small intestine where it is likely to play a role in enterohepatic circulation of bile 
acids (7;15).  Progressive Familial Intrahepatic Cholestasis (PFIC), or ―Bylers‖ 
disease, is a more severe inherited form of cholestasis.  It usually presents in 
infancy and unlike BRIC, causes progressive cholestasis leading to cirrhosis and 
death in childhood.  Some forms of Progressive Familial Intrahepatic 
Cholestasis (PFIC 1)‖ map to the same locus as BRIC (16) and it has been 
suggested that a single gene is at fault in both BRIC and PFIC 1  and that the 
two are allelic diseases.  In some rare cases BRIC may progress to PFIC (17).  
Interestingly, and not previously described, there appears to be both BRIC and 
PFIC phenotypes within the same family in this case. 
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The exact precipitants of the episodes of cholestasis are unknown but there is 
characteristic elevation of bile acids bilirubin and Alkaline Phosphatase (ALP) 
with mild elevation of transaminases, white cell count, erythrocyte 
sedimentation rate (ESR), with relatively normal gamma GT(4;18) 
Unlike other cholestatic liver diseases in BRIC bile acid levels rise before 
bilirubin (19) suggesting a possible role for bile acids in the pathogenesis of this 
condition.  The role of ―toxic bile‖ is further supported by the efficacy of 
external biliary diversion and ursodeoxycholic acid in the treatment of PFIC(20).  
Bile acids are cholestatogenic(21) and pro-apoptotic to hepatocytes (22;23).  
Thus apoptosis and secondary necrosis may be responsible for the mild portal 
inflammation found in up to a third of patients with BRIC (9).  It is therefore a 
reasonable hypothesis that by removing factors, which may perpetuate the 
disease process, that resolution of a cholestatic episode would be accelerated. 
MARS is known to remove a number of cholestatogenic and pro-apoptotic 
agents and appeared to resolve this patient‘s episode of protracted cholestasis, 
which had been resistant to standard medical therapy.  MARS has also been 
shown to improve renal function in patients with hepato-renal syndrome, due to 
both removal of nephrotoxic substances and improved haemodynamics (24).  
MARS treatment also reversed this patients deteriorating renal function. 
We confirm that MARS is a safe and efficacious treatment for BRIC and suggest 
it should be used to terminate episodes of cholestasis particularly when 
associated with secondary renal impairment.  We also suggest that MARS may 
have therapeutic potential in other more common episodic cholestatic conditions 
e.g. cholestasis of pregnancy (25) and drug induced cholestasis, particularly 
when there is developing secondary renal impairment. 
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Abbreviations 
BRIC Benign Recurrent Intrahepatic Cholestasis 
MARS Molecular Adsorbent Recycling System 
ERCP Endoscopic retrograde choledochopancreatography 
PFIC Progressive Familial Intrahepatic Cholestasis 
ALP Alkaline Phosphatase 
ESR Erthrocyte Sedimentation Rate   
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Abstract 
Erythropoietic protoporphyria (EPP) causes photosensitivity, abdominal pain 
and in some patients severe liver dysfunction and confusion.  The mechanism of 
liver injury is unknown but deposition of protoporphyrins in the liver has been 
implicated.   Protoporphyrins are albumin bound and theoretically should be 
removed by extracorporeal albumin dialysis (MARS).  This case study reports 
the effects of MARS therapy on plasma protoporphyrins, liver function and 
confusion in a patient with advanced EPP.  A sixty year old male with EPP 
developed liver failure and a severe organic confusional state which continued to 
deteriorate despite full medical therapy, including plasmapheresis.  He was 
therefore treated with MARS therapy alternating with plasmapheresis.   Plasma 
protoporphyrins decreased by 9.1% per treatment with plasmapheresis (mean 
pre-treatment 4570nmol/L, mean post-treatment 4150nmol/L, P=0.33, normal 
range<200nmol/L), but there was no improvement in mental state.  MARS 
therapy decreased plasma protoporphyrins by 21.4% per treatment (mean pre-
treatment 4710nmol/L, mean post-treatment 3700nmol/L, P<0.01,) and 
dramatically improved liver function and mental state.  Conclusions:  This is the 
first reported use of MARS therapy in porphyria.  It supports a direct toxic role 
for protoporphyrins in EPP associated liver failure and confusion and suggests 
MARS therapy may be useful in the treatment of porphyric disorders.  (Word 
count abstract 195 words) 
Keywords 
Porphyria 
Extracorporeal albumin dialysis 
Plasmapheresis 
 310 
Introduction:  The porphyrias are a group of disorders caused by enzyme 
deficiencies in the heme biosynthetic pathway. Erythropoietic protoporphyria 
(EPP), first described by Professor Magnus in 1961, is caused by a partial 
deficiency of ferrochelatase, the terminal enzyme of heme biosynthesis whose 
substrate is protoporphyrin.  Inherited as an autosomal dominant trait, EPP 
results in the accumulation of protoporphyrin in erythrocytes, liver, plasma and 
faeces (but not in urine as it is poorly water soluble).  In most cases, patients 
present in childhood with cutaneous photosenstitivity.  Characteristically, there 
is an immediate painful, burning or stinging sensation in skin on light exposure 
followed several hours later by erythema and oedema (1).  Hepatic 
manifestations are diverse, with mildly disturbed liver enzymes in 20% and fatal 
hepatic failure in 5%-10% of cases.  Black protoporphyrin can be identified in 
liver biopsy specimens.  Protoporphyrin crystal deposition in hepatocytes, 
canaliculi, bile ductules and macrophages with formation of cytotoxic bile and 
disturbance of redox systems are suggested toxic mechanism.  Abdominal pain, 
haemolysis and neurological dysfunction may complicate end-stage liver disease 
(2;3). 
Treatments include beta-carotene, canthaxanthin, N-acetyl cysteine, 
phototherapy, blood transfusion and antihistamines as well as binding agents, 
charcoal and cholestyramine.  Good evidence for efficacy has been difficult to 
assess due to the subjective nature of symptoms and high placebo response rates.  
Liver transplantation is sometimes required for end-stage liver disease.  
However, because the underlying enzyme defect in EPP is bone marrow derived 
there are high rates of recurrence of liver dysfunction post-transplant usually 
occurring after a number of years (4).  The only curative treatment is bone 
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marrow transplantation.   However, since only a minority of patients develop life 
threatening complications, and these cannot be predicted, selection of patients 
for elective transplantation of liver, bone marrow or both is difficult.  
Conversely patients may present suddenly and deteriorate rapidly making urgent 
transplantation hazardous.   
Plasmapheresis (5) has been used to reduce levels of plasma and erythrocyte 
protoporphyin levels in patients both before liver transplantation (6), and after 
recurrence in the transplanted liver, with improvement in liver histological and 
biochemical abnormalities (7).  Whilst this is suggestive of a directly 
hepatotoxic role for protoporphyrins, plasmapheresis is highly non-selective and 
removal of other humoral substances may be implicated. 
Extracorporeal albumin dialysis with the Molecular Adsorbents Removal 
System (MARS) is a new method of removing albumin bound toxins.  A special 
membrane allows transfer of water soluble and albumin bound toxins with 
molecular weight less than 50kDa from blood into a dialysate solution 
containing 20% human albumin (8).  MARS provides potential advantages over 
plasmapheresis since it is less expensive, has potentially greater clearance of 
albumin bound substances, has less theoretical risk of transmission of infection, 
is less immunogenic and is more selective leaving more, possibly beneficial, 
growth factors and hormones in the circulation (9).  Protoporphyrin is more than 
90% albumin bound in plasma with a high affinity for albumin (KA = 3 X 
10(9)M-1 in phosphate-buffered saline)(10) and should theoretically be removed 
by MARS therapy.   We hypothesised that MARS would efficiently remove 
protoporphyrin resulting in improvement in liver failure associated with EPP 
and would therefore offer therapeutic potential. 
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Case History:  A sixty-year-old man underwent cadaveric liver transplantation 
to treat end stage liver disease due to EPP (figure 1).  He was diagnosed with 
EPP aged 53 years when he first presented with photosensitive skin rash and 
mildly abnormal liver function tests.  After his liver transplant he was entirely 
asymptomatic.  Six months  
 
 
 
 
  
Figure 1.  A formalin fixed slice of the explanted liver.  The liver is almost 
blackened due to protoporphyrin deposition which partly obscures the 
fibrosis and nodularity of the cirrhosis which is also present. 
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after transplantation he became increasingly icteric and photosensitive.  Despite 
treatment with cholestyramine he remained unwell and was admitted after a one 
week history of an acute confusion state and mild abdominal discomfort.  On 
admission he was found to have markedly deranged liver function.  Total 
bilirubin 391μMol/L (NR 5-17), alkaline phosphatase 288 IU/L (NR 35-130), 
aspartate transaminase 380 IU/L (NR 5-40), albumin 35g/dL (NR 35-50), INR 
1.7 (NR 0.9-1.2).  A transjugular liver biopsy taken 10 months after liver 
transplantation showed marked hepatic deposition of protoporphyrins (Figure 2).  
He was treated for three weeks with standard medical therapy including 
plasmapheresis, haemarginate and hypertransfusion.  Unfortunately his 
condition continued to deteriorate with increasing confusion, and the onset of 
visual hallucinations.  He underwent psychiatric assessment and an organic 
confusional state was diagnosed.  In view of his relentless deterioration he was 
commenced on MARS therapy.  In view of the experimental nature of this 
treatment he was also treated with plasmapheresis.  He received two consecutive 
days of plasmapheresis followed by two days of MARS therapy, followed again 
by two days of plasmapheresis finishing with two days of MARS therapy.  
Plasma protoporphyrin levels were measured before and after each daily 
treatment and were analysed in a blinded fashion.  All filters and lines were 
protected from light during treatment. 
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Figure 2a. (Top)  
A low magnification x40 photomicrograph of a liver biopsy taken 10 
months after liver transplantation and before MARS therapy.  There is 
abundant dark brown pigment in hepatocytes, dilated canaliculae, and 
macrophages.   
Figure 2b (bottom). The same biopsy as shown in Fig 2a, viewed with 
polarised light and at high magnification.  The typical red birefringence of 
protoporphyrin is seen. 
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 Results:  After the second day of treatment with MARS therapy the patients‘ 
cognitive function returned to normal, as assessed by independent psychiatric 
assessment and the opinion of relatives.  He had no memory of his confusional 
episode.  His abdominal discomfort and lethargy also resolved and he noted 
return of his appetite and sense of humour.  During treatment it was noted that 
the anion exchange resin in the MARS circuit had become noticeably blackened 
compared to treatment of equally icteric non-porphyric patients, presumably due 
to protoporphyrin deposition.   
Plasma protoporphyrin levels fell by 9.1% per daily treatment with 
plasmapheresis (mean pre-treatment 4570nmol/L, mean post-treatment 
4150nmol/L, P=0.33) and 21.4% per daily treatment with MARS therapy (mean 
pre-treatment 4710nmol/L, mean post-treatment 3700nmol/L, P<0.01, normal 
range for plasma protoporphyrin <200nmol/L).  This demonstrates that MARS 
therapy removes protoporphyrins and may be more efficient in there removal 
than plasmapheresis.  The patient had significant clinical improvement after 
treatment with MARS, his clinical condition having been deteriorating up to that 
point despite full medical treatment including plasmapheresis.  Subsequently the 
patients liver function continued to improve and he was discharged home.  He 
was briefly readmitted two months later again with worsening of his liver 
function and acute confusion that again completely resolved with MARS 
therapy.  MARS therapy was electively continued monthly and four months 
after his original presentation the patients liver function tests were entirely 
normal.     
Discussion:  The normal route of excretion of protoporphyrins, as with many 
poorly water-soluble albumin bound substances, is in the bile after liver 
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metabolism.  We propose that in excess protoporphyrins are directly hepatotoxic 
and cholestatic resulting in decreased liver function and decreased excretion of 
protoporphyrins.  Thus a vicious circle of worsening liver function and 
accumulating protoporphyrin ensues.  The removal of protoporphyrin by MARS 
therapy may allow improvement in liver function such that adequate endogenous 
excretion of porphyrins is re-established thus breaking this chain of events.  
Reducing plasma porphyrins and removing other toxins which are normally 
cleared by the liver may also account for the striking improvement in the mental 
state of this patient after MARS therapy.   We conclude that MARS is an 
effective alternative to plasmapheresis in the treatment of EPP induced liver 
disease and can be used to treat life-threatening episodes of liver failure allowing 
subsequent elective curative treatment to be undertaken.  MARS could also 
potentially be used prophylactically to prevent recurrence of protoporphyrin 
deposition in allograft livers.   Plasmapheresis has been suggested to be of value 
in acute intermittent porphyria and porphyria cutanea tarda (11),(12) and these 
conditions could also potentially benefit from treatment with MARS.  In 
summary MARS represents an exciting new tool in the treatment of porphyric 
disorders. 
Abbreviations 
Erythropoeitic Protoporphyria (EPP) 
Molecular Adsorbents Recirculating System (MARS) 
Acknowledgments 
We would like to thank Prof.T.Cox from Addenbrookes Hospital, Cambridge for 
medical advice.  Dr.M.Badminton from University of Cardiff and Dr.J.Marsden 
from Kings College Hospital London for technical advice and porphyrin 
analysis and Teraklin who supplied medical equipment gratis. 
 317 
 References 
 1.  Sarkany RP. Erythropoietic protoporphyria (EPP) at 40. Where are we 
now?. [Review] [39 refs]. Photodermatology, Photoimmunology & 
Photomedicine 2002;18(3):147-52. 
 2.  Meerman L. Erythropoietic protoporphyria. An overview with emphasis on 
the liver. [Review] [114 refs]. Scandinavian Journal of Gastroenterology - 
Supplement 2000(232):79-85. 
 3.  Gross U, Hoffmann GF, Doss MO. Erythropoietic and hepatic porphyrias. 
[Review] [113 refs]. Journal of Inherited Metabolic Disease 
2000;23(7):641-61. 
 4.  Bloomer JR, Rank JM, Payne WD, Snover DC, Sharp HL, Zwiener RJ et 
al. Follow-up after liver transplantation for protoporphyric liver disease. 
Liver Transplantation & Surgery 1996;2(4):269-75. 
 5.  Jacob CK. Plasmcapheresis--principles and practice. [Review] [8 refs]. 
Journal of the Indian Medical Association 2001;99(7):364-7. 
 6.  Reichheld JH, Katz E, Banner BF, Szymanski IO, Saltzman JR, 
Bonkovsky HL. The value of intravenous heme-albumin and 
plasmapheresis in reducing postoperative complications of orthotopic liver 
transplantation for erythropoietic protoporphyria. Transplantation 
1999;67(6):922-8. 
 7.  Do KD, Banner BF, Katz E, Szymanski IO, Bonkovsky HL. Benefits of 
chronic plasmapheresis and intravenous heme-albumin in erythropoietic 
 318 
protoporphyria after orthotopic liver transplantation. Transplantation 
2002;73(3):469-72. 
 8.  Stange J, Mitzner SR, Risler T, Erley CM, Lauchart W, Goehl H et al. 
Molecular adsorbent recycling system (MARS): clinical results of a new 
membrane-based blood purification system for bioartificial liver support. 
Artificial Organs 1999;23(4):319-30. 
 9.  Hughes RD. Review of methods to remove protein-bound substances in 
liver failure. [Review] [39 refs]. International Journal of Artificial Organs 
2002;25(10):911-7. 
 10.  Lamola AA, Asher I, Muller-Eberhard U, Poh-Fitzpatrick M. Fluorimetric 
study of the binding of protoporphyrin to haemopexin and albumin. 
Biochemical Journal 1981;196(3):693-8. 
 11.  Dupre A, Bonafe JL, Callot JP, Campardou AM, Nabulsi-Kassas M, 
Snapir G et al. [Treatment of a case of porphyria cutanea tarda by 
plasmapheresis]. [French]. Annales de Dermatologie et de Venereologie 
1980;107(7):693-5. 
12.   Miyauchi S, Shiraishi S, Miki Y. Small volume plasmapheresis in the 
management of porphyria cutanea tarda. Archives of Dermatology 
1983;119(9):752-5. 
 319 
 
